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The ovary is a heterogenous structure that produces a variety of sex steroid hormones and 
participates in several feedback loops within the hypothalamic-pituitary-ovary axis.  Further, it is 
the site of storage and maturation of the female gamete: the oocyte.  Females are born with a 
finite number of oocytes in the form of the primordial follicle pool.  Primordial follicles are 
composed of an oocyte surrounded by supporting somatic cells.  Activated primordial follicles 
will grow through the primary, preantral, and antral follicle stages before ovulating.  Proper 
maintenance of this follicular growth, termed folliculogenesis, is imperative for maintenance of 
proper fertility and overall somatic health.  Female fertility relies on a steady stream of maturing 
follicles in addition to the proper maintenance of the cyclical rise and fall of sex steroid and 
peptide hormones.  Further, sex steroid hormones play a role in maintenance of multiple aspects 
of somatic health, including the cardiovascular system, bone density, and neurological health.  
Thus, chemical exposures that target the ovary can lead to disruptions in reproductive and overall 
health. 
 
The phthalate chemical family has several prominent members with endocrine disrupting 
capabilities.  One of the most common phthalates is di(2-ethylhexyl) phthalate (DEHP), with up 
to 100 million pounds produced within the U.S. each year.  DEHP is used as a plasticizer to 
impart strength and flexibility into products.  DEHP can be found in products such as plastic 
food packaging, clothes, shower curtains, upholstery, and medical equipment.  Because DEHP is 
noncovalently bound to products, it can leach out over time and be absorbed via inhalation, 




µg/kg/day, and DEHP metabolites have been found in samples of human blood, urine, semen, 
amniotic fluid, cord blood, and ovarian follicular fluid.  This is concerning because DEHP is a 
known reproductive toxicant and endocrine disrupting chemical.  Although some studies have 
shown that DEHP targets the ovary, very few studies have investigated whether short-term 
exposure to DEHP during adulthood can have long-lasting impacts on the exposed individual. 
 
Some manufacturers have elected to start replacing DEHP with other plasticizers.  Unfortunately, 
these replacements are often understudied, and few studies have investigated the reproductive 
toxicity potential of these compounds.  Diisononyl phthalate (DiNP) is one such understudied 
DEHP substitute.  Few reproductive toxicity studies using DiNP have been conducted, and the 
majority focus on males.  Further, studies that report data on the reproductive toxicity of DiNP in 
females tend to only include data on the effects of DiNP on the weights of reproductive organs.  
Although reproductive organ weights are an important and useful metric for assessing the 
reproductive toxicity for a particular chemical, these data do not provide a complete 
understanding of the potential reproductive toxicity of the chemical.  Further, the present 
literature concerning the effects of DiNP on female reproduction often use doses well above the 
range of environmental relevance.  It is imperative to investigate these chemicals at relevant 
doses because of the non-monotonic dose responses that some endocrine disrupting chemicals 
can elicit.   
 
Together, information is lacking on the effects of DEHP and DiNP on female reproduction, 
especially as it concerns exposure during adulthood.  Therefore, the purpose of my doctoral 




replacement chemical, DiNP, on the reproductive health over the lifetime of the exposed female 
mice at both high and environmentally relevant doses.  Specifically, I investigated the effects of 
short-term exposure to DEHP and DiNP during adulthood on estrous cyclicity, fertility, sex 
steroid hormones, peptide hormones, and ovarian follicle populations at time points including 
immediately post-dosing and 3, 6, 9, 12, 15, and 18 months post-dosing  
 
First, I tested the hypothesis that short-term exposure (10 days) to DEHP and DiNP during 
adulthood in the mouse was sufficient to disrupt estrous cyclicity, fertility, and weights of 
reproductive organs at time points during the prime reproductive age of the mouse, including 
immediately post-dosing and 3 and 9 months post-dosing.  Immediately post-dosing and 3 and 9 
months post-dosing, fertility was assessed via breeding trials and weights of reproductive organs 
were measured.  In addition, estrous cyclicity was monitored at 3 and 9 months post-dosing.  
Assessing estrous cyclicity disruptions and changes in weights of organs can give insight to 
possible avenues through which DEHP and DiNP may disrupt fertility.  I found that 10 days of 
DEHP exposure was enough to significantly reduce the uterine weight immediately post-dosing.  
Additionally, at 3 months post-dosing, females treated with the lowest dose of DEHP and DiNP 
had significant difficulty achieving pregnancy from a mating, resulting in significantly fewer 
females producing offspring in these groups when compared to control.  I also observed that 
several treatment groups had increased male to female ratios of pups  at 9 months post-dosing.  
Further, 10 days of phthalate exposure was enough to significantly affect the estrous cyclicity at 






Next, I tested the hypothesis that short-term exposure (10 days) to DEHP and DiNP during 
adulthood in the mouse was sufficient to alter levels of sex steroid hormones, levels of the 
peptide hormones follicle-stimulating hormone (FSH) and inhibin B, and ovarian follicle 
populations at time points during the prime reproductive life of the mouse, including 
immediately post-dosing and 3, 6, and 9 months post-dosing.  Proper maintenance of ovarian 
follicle maturation is necessary for proper fertility and maximization of the reproductive lifespan.  
Further, changes in circulating hormones can alter cyclicity and behavior and can directly impact 
fertility itself.  I found that transient exposure to DEHP and DiNP during adulthood was 
sufficient to cause disruption of ovarian folliculogenesis by altering numbers of follicle types, 
percentages of follicle types, and percent of unhealthy follicles immediately post-dosing and up 
to 9 months post-dosing.  Further, I found that DEHP and DiNP disrupted several hormones and 
that disruptions were present at all time points tested in this study. 
 
Further, I tested the hypothesis that short-term exposure (10 days) to DEHP and DiNP during 
adulthood in the mouse was sufficient to disrupt fertility and estrous cyclicity and alter levels of 
sex steroid hormones, levels of the peptide hormones follicle-stimulating hormone (FSH) and 
inhibin B, and ovarian follicle populations at time points during late-life in the mouse, including 
12, 15, and 18 months post-dosing.  Maintenance of the finite pool of ovarian follicles is required 
for maximization of the reproductive lifespan in females.  Dysregulation of the ovarian follicular 
pool or hormones could lead to abnormalities in reproductive behavior, fertility complications, 
and shortening of the reproductive lifespan.  I found that DEHP and DiNP increased pregnancy 
loss, reduced fertility, and altered follicular populations and circulating hormone levels in late-




exposure to DEHP and DiNP during adulthood has consequences on a variety of aspects of 
female fertility at time points ranging from immediately post-dosing to 18 months following 
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The proper development of follicles within the ovary is critical for female fertility. Follicular 
development, often referred to as folliculogenesis, begins with maturation of a germ cell into a 
primordial follicle, then to a primary follicle, then a pre-antral, antral, and finally to a 
preovulatory follicle. Development through these stages and subsequent successful ovulation is 
necessary for proper female fertility [1, 2].  Thus, chemicals that cause dysregulation of 
folliculogenesis, or otherwise alter follicular numbers within the ovary, can alter the course of 
the reproductive life of the female in question. Endocrine disrupting chemicals (EDCs) are 
chemicals with the ability to alter aspects of the endocrine system within an organism [3].   
Several EDCs have been found to have significant impacts on the ovary [4, 5].  Phthalates are a 
class of EDCs commonly used as plasticizers and stabilizers in several different kinds of 
consumer products, and they can be absorbed via inhalation, ingestion, and dermal contact [5-
10].  Because of their widespread use, phthalate exposure is ubiquitous, as evidenced by the 
presence of phthalate metabolites in nearly all tested human urine samples [11].  Di(2-
ethylhexyl) phthalate (DEHP), in particular, is a widely used phthalate with several million 
pounds produced annually in the U.S. alone [12].  Due to the mass production of DEHP, DEHP 
metabolites are found in the vast majority of urine samples taken from men, women, and 
children [13] and in a variety of bodily tissues [14].  This ubiquitous exposure to DEHP is of 
concern because DEHP, and its bioactive metabolite, mono(2-ethylhexyl) phthalate (MEHP), are 




a previous study conducted in our laboratory reported that short-term DEHP exposure 
significantly reduced numbers of primordial follicles and total follicle numbers [17], but it is not 
known whether this decrease in ovarian reserve has any impact on female fertility and the 
reproductive lifespan. 
  
Further, possibly due to the increased concern about the presence of DEHP in consumer 
products, there has been a rise in production and use of DEHP replacements such as diisononyl 
phthalate (DiNP) [19, 20].  Although DiNP has not been studied extensively, it has been shown 
to cause histopathological changes in the testes of perinatally exposed rats [21-23] as well as 
disruption of steroidogenesis in fetal rat testes in a similar manner as seen in DEHP exposure 
[23-25].  However, studies investigating the effects of DiNP on female reproduction are 
incredibly sparse, and studies that include data on reproductive toxicity in females consistently 
lack data on the effects of DiNP on reproductive parameters outside of effects on weights of the 
female reproductive organs.  Although it is important to investigate the effects of DiNP on gross 
attributes of the reproductive organs, female fertility is a highly regulated and complex system 
with several interacting aspects.  This results in an urgent need for more studies to investigate the 
effects of DiNP on female reproduction, especially in terms of consequences that occur after 
exposure during adulthood. 
 
Thus, the goal of my doctoral dissertation work was to investigate the effects of short-term 
exposure to DEHP or DiNP during adulthood on female reproductive health at time points 
throughout the rest of the life of the mouse.  Specifically, my doctoral dissertation work tested 




cyclicity, fertility, litter outcomes, ovarian hormones, peptide hormones, and ovarian follicular 
populations at time points throughout the life of the female CD-1 mouse.  To test this hypothesis, 
I completed the following specific aims: 
 
Specific Aim 1:  Determine if short-term exposure to DEHP and/or DiNP during adulthood 
alters estrous cyclicity, fertility, litter outcomes, and reproductive organ weights at time 
points during the prime reproductive life of the female CD-1 mouse. 
 
To complete this aim, I orally dosed adult (age 39-40 days) female CD-1 mice for 10 days with 
either vehicle control (corn oil), DEHP (20 µg/kg/day, 200 µg/kg/day, 20 mg/kg/day, 200 
mg/kg/day), or DiNP (20 µg/kg/day, 100 µg/kg/day, 20 mg/kg/day, 200 mg/kg/day).  I 
investigated the effects of DEHP and DiNP on estrous cyclicity at 3 and 9 months post-dosing.  
Further, I performed breeding trials using untreated male CD-1 mice immediately post-dosing 
and 3 and 9 months post-dosing, wherein I assessed fertility of the dosed females and their litter 
outcomes.  Lastly, separate groups of mice were dosed and cohorts were euthanized immediately 
post-dosing and 3 and 9 months post-dosing to examine changes in weight of reproductive 
organs.  I found that multiple doses of DEHP decreased uterine weights and that DiNP disrupted 
estrous cyclicity at both tested time points, causing greater disruption than DEHP.  Further, I 
found that DEHP and DiNP reduced overall fertility at 3 and 9 months post-dosing and that the 
lowest doses of DEHP and DiNP greatly reduced the ability of females to become pregnant at 3 
months post-dosing.  Treatment affected few litter outcomes, but multiple doses of DEHP and 
DiNP increased the male to female ratio of pups born at the 9 month post-dosing breeding trial.  




damaging effects on multiple aspects of female fertility throughout the prime reproductive life of 
the female CD-1 mouse.  These data are presented in Chapter 3. 
 
Specific Aim 2:  Determine if short-term exposure to DEHP and/or DiNP during adulthood 
alters ovarian follicle populations and circulating hormone levels at time points during the 
prime reproductive life of the female CD-1 mouse. 
 
To complete this aim, I orally dosed adult (age 39-40 days) female CD-1 mice for 10 days with 
either vehicle control (corn oil), DEHP (20 µg/kg/day, 200 µg/kg/day, 20 mg/kg/day, 200 
mg/kg/day), or DiNP (20 µg/kg/day, 100 µg/kg/day, 20 mg/kg/day, 200 mg/kg/day).  Groups of 
mice were euthanized at different time points following completion of dosing, including 
immediately post-dosing and 3, 6, and 9 months post-dosing.  Sera were collected and analyzed 
for levels of estradiol, progesterone, testosterone, FSH, and inhibin B.  Ovaries were collected 
and histologically evaluated to assess numbers of different follicle types, percentages of different 
follicle types, percentages of unhealthy follicles, and the total number of follicles.  I found that 
both DEHP and DiNP disrupted follicle numbers and percentages at multiple time points.  
Further, I found that DEHP and DiNP disrupted a variety of hormones at multiple time points 
and that the most severe effects were seen immediately post-dosing.  Collectively, these data 
show that short-term exposure to DEHP and DiNP during adulthood has negative consequences 
on the ovary and levels of circulating hormones during the prime reproductive life of the female 





Specific Aim 3:  Determine if short-term exposure to DEHP and/or DiNP during adulthood 
alters estrous cyclicity, fertility, litter outcomes, ovarian follicle populations and circulating 
hormone levels at time points in the late-life of the female CD-1 mouse. 
 
To complete this aim, I orally dosed adult (age 39-40 days) female CD-1 mice for 10 days with 
either vehicle control (corn oil), DEHP (20 µg/kg/day, 200 µg/kg/day, 20 mg/kg/day, 200 
mg/kg/day), or DiNP (20 µg/kg/day, 100 µg/kg/day, 20 mg/kg/day, 200 mg/kg/day).  One group 
of mice was monitored for estrous cyclicity followed by a breeding trial at 12 and 15 months 
post-dosing to assess fertility and effects on litter outcomes.  Further, additional groups of mice 
were euthanized at 12, 15, and 18 months post-dosing, and sera and ovaries were collected.  Sera 
were analyzed for levels of estradiol, progesterone, testosterone, FSH, and inhibin B.  Ovaries 
were histologically processed and evaluated to assess numbers of different follicle types, 
percentages of different follicle types, percentages of unhealthy follicles, and the total number of 
follicles.  I found that DEHP disrupted estrous cyclicity at both time points tested.  Further, I 
found that DEHP and DiNP increased pregnancy loss, decreased overall fertility, and decreased 
the percent of female pups born at 12 months post-dosing.  Additionally, both DEHP and DiNP 
altered follicle populations and several hormones at many of the time points tested in this study.  
Collectively, these data show that short-term exposure to DEHP and DiNP during adulthood has 
long-term consequences that persist into late-life in the female CD-1 mouse.  These data are 
presented in Chapter 5. 
 
Taken together, my doctoral dissertation work shows that short-term insults such as exposure to 




reproduction.  Further, my work shows that these effects can persist throughout the prime 
reproductive life of the female and that some effects remain after the transition into reproductive 
senescence and throughout late-life.  Overall, my studies provide insight on the short-term and 
long-term consequences of transient exposure to DEHP and DiNP during adulthood on female 
reproduction. 
 
In summary, Chapter 1 provides on overview of my doctoral dissertation work.  Chapter 2 
provides background information epidemiological evidence showing associations between adult 
exposure to a variety of environmental contaminants and reproductive outcomes in both men and 
women.  Chapter 3 describes the work that tested the hypothesis that short-term exposure to 
DEHP and/or DiNP during adulthood alters estrous cyclicity, fertility, litter outcomes, and 
reproductive organ weights at time points during the prime reproductive life of the female CD-1 
mouse.  Chapter 4 describes the work that tested the hypothesis that short-term exposure to 
DEHP and/or DiNP during adulthood alters ovarian follicle populations and circulating hormone 
levels at time points during the prime reproductive life of the female CD-1 mouse.  Chapter 5 
describes the work that tested the hypothesis that short-term exposure to DEHP and/or DiNP 
during adulthood alters estrous cyclicity, fertility, litter outcomes, ovarian follicle populations 
and circulating hormone levels at time points in the late-life of the female CD-1 mouse.  Lastly, 
Chapter 6 summarizes the findings of the work presented in this dissertation and suggests future 
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Environmental Contaminants affecting Fertility and Somatic Health1 
 
2.1 Abstract 
This review article summarizes the epidemiological findings published between 2011 and 2016 
concerning bisphenol A (BPA), phthalates, dioxins, pesticides, air pollution, fracking chemicals, 
triclosan, and parabens and fertility parameters in men (i.e., semen volume, sperm concentration, 
sperm motility, sperm morphology) as well as fertility parameters in women (i.e., cyclicity, 
fertility treatment outcomes), pregnancy outcomes (i.e., preterm birth, miscarriage), and 
reproductive disorders (i.e., polycystic ovary syndrome, endometriosis, uterine fibroids). Overall, 
this review indicates that several environmental toxicants are significantly associated with 
reduced fertility parameters in men and women as well as several reproductive disorders in 
women. Although many studies report that the selected exposures are associated with adverse 
fertility outcomes, several studies report null associations. Thus, future studies are still needed to 
better elucidate the associations and potential mechanisms between these environmental 






1. Reprinted with permission from Chiang C., Mahalingam S., Flaws J. A., Environmental Contaminants affecting 






Humans are often exposed to a wide variety of chemicals in their everyday environments. This 
review focuses on epidemiological and clinical research conducted between 2011 and 2016 that 
investigates environmental chemicals and their associations with reproductive outcomes in both 
men and women (Figure 2.1 and 2.2).  While the body of my doctoral dissertation work focuses 
on phthalate exposure in females and consequences of exposure during adulthood, humans are 
exposed to a wide variety of environmental chemical contaminants.  Further, both males and 
females are affected by exposure to environmental contaminants.  Thus, a variety of chemicals 
and chemical classes and their effects on both males and females are explored in this review.  We 
chose to investigate bisphenol A (BPA), select phthalates, dioxins, pesticides, and air pollution 
because of the high rate of exposure of humans to these chemicals and their strong presence in 
the environment. We also chose to review fracking chemicals, triclosan, and parabens because of 
emerging literature and interest in the impact of these chemicals on reproductive outcomes. 
Several studies show contrasting results for the association between many environmental 
exposures and reproductive outcomes. Thus, this review summarizes positive, negative, and null 
associations.    
 
2.3 BPA 
BPA is a chemical used in a wide variety of products such as medical equipment, epoxy resins 
lining aluminum cans, polycarbonate plastics, and dental sealants [1-5]. Although BPA can be 
absorbed via inhalation, ingestion, and dermal contact, the most common route of exposure is via 
ingestion of food or beverages contaminated with BPA [1]. After exposure, BPA can be 




fluid, breast milk, urine, semen, blood, and plasma [1, 5-7]. Due to BPA’s ability to interact with 
hormone receptors [2] and the extensive exposure of the general population to BPA, the 
associations between BPA exposure and reproductive outcomes have been widely investigated 
and the results are summarized below. 
 
Associations with Male Reproductive Outcomes 
BPA exposure has been associated with general male infertility [1, 6], but the results are 
equivocal [8-10] (Figure 2.1). High levels of BPA also have been associated with reduced sexual 
desire, increased erectile and ejaculatory difficulties, and increased severity of infertility [1, 6].  
Further, seminal and urinary BPA levels have been negatively correlated with sperm density, 
total count, and concentration [1, 2, 6, 10, 11], motility [2, 6, 10, 12] , and morphology [1, 6, 10, 
11]. However, some studies reported no association between BPA exposure and these semen 
quality parameters [8, 10, 12]. In addition, although studies examining paternal exposure to BPA 
and assisted reproductive technologies (ART) are sparse, one study found that paternal urinary 
BPA levels were not associated with fertilization, embryo quality, implantation, or live birth 
[10]. Further, another study reported no association between paternal urinary BPA levels and 
couples fecundity [13]. 
 
Associations with Female Reproductive Outcomes 
BPA exposure has been associated with fertility outcomes in women (Figure 2.2). Collectively, 
these studies have shown that elevated serum or urinary BPA levels were associated with 
anovulation14, lower antral follicle counts [5, 15], and infertility [5].  Further, BPA exposure has 




contrast, some studies report no association between urinary BPA levels and fecundity, time to 
pregnancy [5, 13], or spontaneous abortions [20].   
As in males, BPA exposure has been associated with poor ART outcomes. Specifically, serum 
BPA levels were negatively associated number of oocytes retrieved, oocyte maturation, 
fertilization rates, as well as embryo quality in women undergoing in vitro fertilization (IVF) 
treatment [2, 5]. Additionally, urinary BPA levels were associated with a decrease in successful 
implantation rate in women undergoing IVF [2, 5]. However, some studies report null 
associations between urinary BPA levels and number of oocytes retrieved, embryo quality, and 
fertilization rates [5]. 
 
Several studies investigated BPA exposure and incidence of reproductive disorders such as 
polycystic ovarian syndrome (PCOS), endometriosis, and fibroids.  The majority of these studies 
showed that women with PCOS had significantly higher levels of BPA in the blood [14, 21], 
serum [21, 22], and follicular fluid [22, 23] compared to women without PCOS. Similarly, 
women with endometriosis had higher levels of BPA than women without endometriosis [2, 24], 
and women with fibroids had higher levels of BPA than women without fibroids [25, 26]. 
However, some studies have found no associations between serum BPA concentrations and 
incidence of PCOS [27], endometriosis [28], or fibroids [29].  
 
2.4 Phthalates 
Phthalates are synthetic chemicals used in cosmetics, medications, plastic toys, and construction 
material. Phthalate exposure can occur via ingestion, inhalation, and dermal contact [3, 4, 30], 




described here include di(2-ethylhexyl) phthalate (DEHP), diethyl phthalate (DEP), dibutyl 
phthalate (DBP), and benzylbutyl phthalate (BBP).  DEHP is commonly found in materials such 
as surgical tubing and gloving as well as plastic food storage containers, roofing, and carpeting 
[31]. DEP and DBP are mostly found in personal care products such as lotions, nail polishes, and 
fragrances, whereas BBP is used in products such as vinyl flooring [32]. The associations 
between exposure to these phthalates and reproductive outcomes in men and women (Figure 2.1 
and 2.2) are summarized below. 
 
2.4.1 Di(2-ethylhexyl) Phthalate (DEHP)  
Associations with Male Reproductive Outcomes 
Several studies, but not all, have found that levels of DEHP or DEHP metabolites were 
associated with reduced fertility in men. Specifically, seminal DEHP levels and urinary levels of 
the DEHP metabolites mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), but not the DEHP 
metabolites mono-(2-ethylhexyl) phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate 
(MEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), or mono-(2-
carboxymethylhexyl) phthalate (MCMHP) have been associated with male infertility [13, 33, 
34].  Further, serum concentrations of the sum of DEHP metabolites or the individual 
metabolites (MEOHP, MEHHP, and MECPP) have been significantly associated with decreased 
semen volume and sperm count [11, 35-38], sperm concentration [37, 39, 40], sperm motility 
[11, 36, 39-42], percent of morphologically normal sperm [36, 43], and acrosin activity [42]. In 
contrast, several studies report no associations between DEHP exposure and risk of subfertility 





Associations with Female Reproductive Outcomes 
Several studies have examined DEHP exposure and fertility in women. Overall, these studies 
have shown that urinary DEHP metabolites were significantly associated with decreased 
gestation length [19, 46] as well as increased gestational length [46], increased risk of preterm 
birth [30, 47, 48], and intra-uterine growth restriction [49]. Further, urinary DEHP metabolites 
were associated with reduced antral follicle counts, a potential indicator of subfertility [50]. 
However, some studies reported null associations when examining urinary levels of DEHP 
metabolites and fertility parameters such as time to pregnancy [51], infertility [34, 45], and 
fecundity [13, 34]. 
 
Similar to studies on BPA, DEHP exposure has been associated with ART outcomes. In women 
undergoing IVF, urinary levels of the sum of DEHP metabolites were significantly associated 
with reduced total oocyte yield and a reduced probability of achieving pregnancy and live birth 
[52]. In contrast, a Chinese study found no association between urinary MEHP levels and clinical 
pregnancy loss [53]. 
 
Additionally, some studies on DEHP have shown that urinary metabolites of DEHP were 
associated with reproductive disorders such as PCOS, endometriosis, and fibroids [2, 27, 46, 54]. 
In contrast, one study found that urinary levels of MEHP were inversely associated with 
endometriosis risk [55], and one study reported urinary levels of MEHP, MEHHP, or MEOHP 
were not associated with endometriosis [56]. Further, one study found that urinary levels of 





2.4.2 Diethyl Phthalate (DEP) 
Associations with Male Reproductive Outcomes 
A few studies have examined the associations between DEP exposure and fertility in men. 
Specifically, seminal levels of DEP and urinary levels of its metabolite monoethyl phthalate 
(MEP) have been significantly associated with male infertility [33, 45], reduced sperm count and 
concentration [37, 45], reduced sperm motility [37], and reduced numbers of morphologically 
normal sperm [36, 37, 45]. However, a few studies have found no associations between urinary 
levels of MEP and subfertility in men [9, 13], sperm count and concentration, sperm motility, 
sperm viability, and abnormal sperm morphology [9, 37, 43-45]. 
 
Associations with Female Reproductive Outcomes 
Studies investigating DEP exposure and indicators of general fertility in women are scarce, but 
some studies have indicated that urinary MEP levels were significantly higher in females from 
infertile couples than females from fertile couples [45] and that urinary MEP levels were 
significantly associated with clinical pregnancy loss [53] and preterm delivery [57]. However, 
some studies have found no associations between urinary MEP concentrations and time to 
pregnancy [13, 51], clinical pregnancy loss [46], and preterm birth [46, 48]. Further, urinary 
levels of MEP were not associated with the probability of pregnancy or odds of live birth in 
women undergoing IVF or intra-cytoplasmic sperm injection (ICSI) [52]. 
 
Recent epidemiological studies investigating the associations between DEP exposure and 
reproductive disorders are limited in number, but one study reported that urinary concentrations 




studies report no associations between urinary MEP concentrations and endometriosis [46, 55] or 
uterine fibroids [25, 46]. 
 
2.4.3 Dibutyl Phthalate (DBP) 
Associations with Male Reproductive Outcomes 
A handful of studies have investigated the potential associations between DBP exposure and 
indicators of general fertility in men. These studies indicated that seminal levels of DBP [33] and 
urinary levels of one of its metabolites, mono-n-butyl phthalate (MnBP) [45], were significantly 
higher in infertile men when compared to fertile men. Further, urinary levels of MnBP, DBP, or 
another metabolite, monobutyl phthalate (MBP), were associated with lowered sperm 
concentration [37, 43-45, 58], reduced total sperm count [43], reduced sperm motility [37, 41, 
44, 45, 58], reduced proportions of morphologically normal sperm [36, 42], and reduced acrosin 
activity [42]. Additionally, paternal urinary concentrations of MBP have been significantly 
associated with an increased time to pregnancy in couples [13]. Interestingly, some studies 
reported that urinary MnBP was significantly associated with increased semen volume and sperm 
concentration [45, 59]. In contrast, some studies show urinary MnBP was not associated with 
risk of subfertility [9] and that DBP exposure was not associated with sperm count, 
concentration, motility, or morphology [9, 37, 40-43, 45]. 
 
Associations with Female Reproductive Outcomes 
Studies investigating the associations between DBP exposure and general indicators of female 
fertility are scarce. However, urinary MnBP levels were significantly higher in women from 




pregnant mothers were significantly associated with clinical pregnancy loss [53]. Further, urinary 
MBP levels as well as cord blood concentrations of DBP were significantly associated with odds 
of preterm birth [30, 47, 48, 57]. Contrarily, some studies have found urinary MBP levels were 
not significantly associated with time to pregnancy [13, 51], gestational age [46], and pregnancy 
loss [46]. Similarly, one study reported no significant associations between urinary levels of 
MBP and probability of pregnancy or live birth in women undergoing IVF and live births 
resulting from ICSI [52]. 
 
Few studies have examined associations between exposure to DBP and PCOS, endometriosis, 
and fibroids. Interestingly, women with PCOS were more likely to have lower levels of urinary 
MBP than those without PCOS [27]. Further, urinary MBP levels were significantly associated 
with nearly a two-fold increase in odds of an endometriosis diagnosis [2], and urinary MnBP 
levels as well as plasma DBP levels were significantly associated endometriosis [46]. However, 
several studies report null associations between urinary MBP [46] and MnBP [46, 54, 55] and 
endometriosis. Similarly, studies consistently report no association between urinary MBP [46] or 
MnBP [25, 46] and uterine fibroids. 
 
2.4.4 Benzylbutyl Phthalate (BBP) 
Associations with Male Reproductive Outcomes 
Few studies have examined the associations between exposure to BBP and fertility in men. 
These studies show that seminal levels of BBP were significantly higher in a group of infertile 
men when compared to a group of fertile men [33] and that paternal urinary levels of the 




pregnancy [13], decreased sperm count and concentration [36, 42, 44], and reduced numbers of 
morphologically normal sperm [36, 42]. Interestingly, some studies reported that urinary MBzP 
levels were associated with higher semen volume [43, 59] as well as increased sperm 
concentration [45]. However, some studies reported no association between urinary MBzP and 
risk of subfertility [9, 45], semen volume, or sperm count, concentration, morphology, or 
motility [9, 37, 42-45]. 
 
Associations with Female Reproductive Outcomes 
Very few recent studies have investigated the associations between BBP exposure and general 
indicators of female fertility. Although one study indicated that BBP exposure is associated with 
preterm birth [48, 57], some studies reported no association between urinary MBzP 
concentrations and risk of infertility [45], time to pregnancy [13, 51], and gestational age [46]. 
Further, urinary levels of MBzP were not associated with odds of pregnancy or live birth in 
women undergoing IVF or live births in women undergoing ICSI [52]. Finally, urinary MBzP 
levels were inversely associated with an increased odds of PCOS [27], but not with 
endometriosis [46, 54, 55] or uterine fibroids [25, 46]. 
 
2.5 Air Pollutants 
Air pollution has significant harmful effects on environmental and human health worldwide. 
Inhalation exposure to air pollutants such as particulate matter (PM), ozone (O3), sulfur dioxide 
(SO2), nitrogen oxides (NOx), carbon monoxide (CO), polycyclic aromatic hydrocarbons 
(PAHs), and volatile organic compounds (VOCs) have been associated with various health 




Associations with Male Reproductive Outcomes 
Several cross-sectional, longitudinal, and ecological studies have found that air pollution was 
significantly negatively associated with sperm quality, which may contribute to male-mediated 
infertility (Figure 2.1). For example, exposure to particulate matter 10 µM or less in size (PM10) 
was associated with increased sperm aneuploidy, DNA fragmentation, abnormal chromatin and 
sperm morphology, and decreased sperm motility [61]. Exposure to fine particulate matter less 
than 2.5 µM (PM2.5) was associated with sperm aneuploidy and decreased sperm motility, with 
a 2-3 month lag. Ambient O3 levels were significantly associated with low average sperm 
concentrations at all biologically relevant time points during spermatogenesis. Other gaseous 
pollutants such as SO2, NOx, and CO were associated with reduced sperm motility and kinetics 
and increased morphological abnormalities [61]. Further, traffic police and tollgate workers 
exposed to motor vehicle exhaust had an increased proportion of sperm with damaged chromatin 
and fragmented DNA compared to unexposed healthy men [62]. In contrast, one study found no 
associations between exposure to O3 or PM2.5 at levels below the current National Ambient Air 
Quality Standards and sperm quality parameters [61]. Similarly, although a few studies indicate 
that occupational exposure to the major components present in motor vehicle exhaust, including 
CO, NOx, O3, PM, VOCs and PAHs is associated with reduced sperm counts, total motility, 
progressive motility, and sperm kinetics, one study found that exposure to CO, NO2, and PM10 
was not associated with sperm quality [62].  
 
Associations with Female Reproductive Outcomes 
Although limited information is available on air pollutants and female reproductive outcomes 




an index of air pollution exposure) and preeclampsia, premature rupture of membrane, and 
preterm birth, but not gestational diabetes mellitus, placenta abruption, placenta previa, or 
preterm labor [63]. Similarly, exposure to ambient PM2.5 increased the risk of preterm birth, 
particularly if exposure occurred during early or mid-pregnancy [64]. Further, maternal exposure 
to emissions from municipal solid-waste incinerators throughout pregnancy was associated with 
preterm birth [65]. Ambient air pollution was also correlated spontaneous abortion [66] as well 
as decreased fecundability[67]. 
 
2.6 Dioxins 
Dioxins and dioxin-like compounds (referred to from here on as dioxins) are a group of 
chemicals with similar structural and biological properties and include polychlorinated dibenzo-
p-dioxins, polychlorinated dibenzofurans, and certain polychlorinated biphenyls. They are 
released into the environment as by-products of combustion (e.g., municipal and commercial 
waste incineration, burning of fuels, and forest fires), chemical manufacture (e.g., pesticide and 
herbicide production, and chlorine bleaching of paper and pulp), and metal industry operations. 
These compounds are highly stable, persistent pollutants in the environment that bioaccumulate 
in the food chain. Consumption of contaminated food and water is the major source of human 
exposure. Dioxins are a public health threat worldwide and have been associated with serious 
health issues, including reproductive problems [3, 68]. 
 
Associations with Male Reproductive Outcomes 
Dioxin exposure has been associated with adverse male reproductive outcomes (Figure 2.1).  




tetrachlorodibenzo-p-dioxin (TCDD) content in semen was associated with abnormal 
spermograms (characterized by teratozoospermia, oligospermia, and asthenospermia)[69]. 
However, not all studies find associations between dioxin exposure and semen quality 
parameters or risk of subfertility in men [9]. 
 
Associations with Female Reproductive Outcomes 
As in males, dioxin exposure in females has been associated with adverse reproductive outcomes 
(Figure 2.2). Maternal exposure to dioxins was associated with reduced fetal growth at intakes 
below the tolerable weekly intake of 14 picograms toxic equivalents/kilogram body weight/week 
[70]. However, the Seveso Women's Health Study, a retrospective cohort of TCDD exposure and 
reproductive health that assessed pregnancy outcomes over 30 years following a chemical 
explosion resulting in the highest known residential exposure to TCDD, found no significant 
associations between maternal exposure and spontaneous abortion, fetal growth, gestational 
length, or endometriosis [71]. Similarly, a Japanese study found no significant association 




Pesticides, which include herbicides, insecticides, and fungicides play a major role in agriculture, 
horticulture, livestock production, and disease control. Their use has been associated with 
adverse effects on human and environmental health worldwide. Certain pesticides such as 
organochlorines are persistent pollutants in the environment and show bioaccumulation in the 




contaminated food, water, and soil, inhalation, as well as dermal and ocular contact. Pesticides 
are thought to act as endocrine disruptors and may be associated with reproductive problems 
[74]. 
 
Associations with Male Reproductive Outcomes 
Collectively, studies show that various pesticide exposures have been associated with reduced 
sperm numbers, motility, or volume (Figure 2.1). Specifically, agricultural pesticide exposure 
was associated with a decline in semen quality, decreased sperm count, decreased sperm 
motility, and increased teratospermia [75]. Similarly, organophosphate pesticides were 
associated with reduced sperm motility, seminal volume, and increased sperm morphological 
abnormalities [75]. Further, occupational exposure to the herbicide 2,4-dichlorophenoxyacetic 
acid was associated with asthenospermia, necrospermia, and teratospermia [75]. Occupational 
exposure to the carbamate insecticide carbaryl was associated with low sperm counts and 
abnormal sperm morphology, and occupational exposure to dibromochloropropane was 
associated with male subfertility, oligospermia, and genetic alterations in sperm [74]. Exposure 
to organophosphate pesticides (dimethylphosphate, dimethylthiophosphate, 
dimethyldithiophosphate) was negatively associated with sperm concentration, total sperm count, 
and percentage of motile sperm [76]. Exposure to pyrethroid pesticides was positively associated 
with the percentage of medium sperm DNA fragmentation index and high sperm DNA 
fragmentation index [77] as well as abnormal sperm morphology and low sperm concentration 
[78]. Increased serum levels of oxychlordane (a metabolite of the organochlorine pesticide, 
chloradane) were associated with an increased risk of subfertility and decreased sperm 




(DDE) and lindane were negatively associated with sperm motility [79], and DDE exposure was 
associated with increased sperm sex-chromosome disomy [80]. Finally, high plasma abamectin 
levels were associated with decreased sperm motility and sperm maturity [81]. 
 
Associations with Female Reproductive Outcomes 
Similar to men, organochlorine pesticide exposures have been associated with adverse 
reproductive outcomes such as low fecundability, miscarriage, preeclampsia, intrauterine growth 
restriction, poor weight gain during fetal development, and preterm birth [73, 82](Figure 2.2). 
Further, organochlorine pesticide exposure has been associated with an increased risk of 
PCOS22, endometriosis [83], and fibroids [84]. Interestingly, exposure to organochlorine 
pesticides was associated with shorter menstrual cycles, whereas exposure to non-organochlorine 
pesticides was associated with longer menstrual cycles or absence of cycles [14]. Similarly, 
exposure to the commonly used herbicide atrazine via drinking water was associated with 
menstrual cycle irregularity and longer follicular phases [85]. Finally, exposure to pyrethroids in 
women living in rural South Africa was negatively associated with plasma levels of anti-
Müllerian hormone, a marker of ovarian reserve [86]. However, one study reported no 
association between glyphosate, another commonly used herbicide, and adverse reproductive 
effects at environmentally relevant concentrations [87]. 
 
2.8 Fracking Chemicals 
Fracking chemicals are used and produced during the process of drilling and hydraulic fracturing 
for oil and gas manufacture. Fracking chemicals from oil and gas extraction, processing, 




inhalation, and dermal exposure to these chemicals can occur through residential proximity or 
occupational exposure. Several fracking chemicals have been associated with endocrine 
disrupting activities and adverse reproductive outcomes [88, 89]. 
 
Associations with Male Reproductive Outcomes 
A few studies reported that occupational exposure to fracking operations was associated with 
decreased sperm concentration and motility, and increased DNA damage [88](Figure 2.1). 
Further, exposures to fracking chemicals such as benzene, toluene, ethylbenzene, and xylene 
were associated with low sperm count, motility, and viability, abnormal sperm morphology, and 
abnormal semen viscosity [90]. 
 
Associations with Female Reproductive Outcomes 
Several studies have reported a significant association between maternal exposure to fracking 
operations and preterm birth as well as miscarriage, but not the incidence of stillbirths 
[88](Figure 2.2). Further, the fracking chemical toluene was associated with reduced fecundity, 




Triclosan is a phenolic compound with antimicrobial activity that is commonly used in products 
like soaps, disinfectants, and toothpaste [8]. Exposure to triclosan occurs via oral, inhalation, and 
dermal routes [18]. Research on triclosan is sparse and epidemiological data regarding its 




Associations with Male Reproductive Outcomes 
A case control study which examined whether exposure to various endocrine disrupting 
chemicals was associated with subfertility in men found no associations between triclosan and 
semen quality parameters or risk of subfertility [9]. Another case control study which examined 
the relationship between exposure to phenols and idiopathic male infertility found that urinary 
triclosan concentrations were not significantly associated with idiopathic male infertility [8]. 
 
Associations with Female Reproductive Outcomes 
Little information is available about the relationship between triclosan and female fertility. 
However, a retrospective time to pregnancy study in women recruited from the Maternal-Infant 
Research on Environmental Chemicals (MIREC) Study suggested that elevated urinary triclosan 
levels may be associated with decreased fecundity [51]. 
 
2.10 Parabens 
Parabens are a group p-hydroxybenzoic acid esters that are commonly found in cosmetics as 
preservatives. They can also be found in foods where they are used as antimicrobials to help 
preserve foods and increase shelf life. Humans are most commonly exposed to parabens via 
dermal contact or ingestion [91].  Studies investigating the potential associations between 
parabens and fertility outcomes in men and women are sparse (Figure 2.1 and 2.2). 
 
Associations with Male Reproductive Outcomes 
Although limited information exists on parabens and male reproductive outcomes, one study 




live birth after intra-uterine insemination (IUI) [92]. In contrast, paternal urinary concentrations 
of methyl-, propyl- or butylparaben were not associated with fertilization rate, embryo quality, or 
odds of implantation in couples who underwent IVF [92]. Similarly urinary concentrations of 
methyl-, propyl-, and butylparaben were not associated with sperm concentration or motility 
[93]. 
 
Associations with Female Reproductive Outcomes 
Few epidemiological studies have investigated parabens and female reproductive health. One 
such study found no significant associations between urinary concentrations of methyl-, propyl-, 
or butylparaben with total and mature oocyte yields, embryo quality, fertilization rates, 
implantation, clinical pregnancy, or live birth rates in women undergoing IVF [94]. 
 
2.11 Conclusions 
The average person is exposed to environmental endocrine disruptors daily due to their 
ubiquitous presence in the general environment as well as their use in a wide variety of consumer 
products. Many of the studies published during the past five years demonstrate significant 
negative associations between exposure to the selected chemicals and reproductive outcomes in 
both men and women. In general, BPA exposure was associated with several negative 
reproductive factors in men and women with relative consistency. Similarly, dioxins and 
pesticides were significantly associated with reduced fertility parameters in men and women. 
However, not all studies reported significant associations between chemical exposures and 
reproductive outcomes in humans. These conflicting results could be due to the high variability 




reproductive outcomes measured between studies. Thus, further studies are needed to clarify 
associations between exposures to these chemicals as well as further define the possible 
























2.12 Figures and Legends 
Figure 2.1 Associations with male reproductive outcomes  
 
A brief summation of epidemiological research investigating endocrine disruptors and their 











Figure 2.2 Associations with female reproductive outcomes 
 
A brief summation of epidemiological research investigating endocrine disruptors and their 












1. Manfo, F.P., R. Jubendradass, E.A. Nantia, P.F. Moundipa, and P.P. Mathur, Adverse 
effects of bisphenol A on male reproductive function. Rev Environ Contam Toxicol, 
2014. 228: 57-82 
2. Peretz, J., L. Vrooman, W.A. Ricke, et al., Bisphenol a and reproductive health: update of 
experimental and human evidence, 2007-2013. Environ Health Perspect, 2014. 122(8): 
775-86 
3. Jenardhanan, P., M. Panneerselvam, and P.P. Mathur, Effect of environmental 
contaminants on spermatogenesis. Semin Cell Dev Biol, 2016.  
4. Patel, S., C. Zhou, S. Rattan, and J.A. Flaws, Effects of Endocrine-Disrupting Chemicals 
on the Ovary. Biol Reprod, 2015. 93(1): 20 
5. Ziv-Gal, A. and J.A. Flaws, Evidence for bisphenol A-induced female infertility: a 
review (2007-2016). Fertil Steril, 2016. 106(4): 827-56 
6. Vitku, J., J. Heracek, L. Sosvorova, et al., Associations of bisphenol A and 
polychlorinated biphenyls with spermatogenesis and steroidogenesis in two biological 
fluids from men attending an infertility clinic. Environ Int, 2016. 89–90: 166-173 
7. Cantonwine, D.E., R. Hauser, and J.D. Meeker, Bisphenol A and Human Reproductive 
Health. Expert Rev Obstet Gynecol, 2013. 8(4) 
8. Chen, M., R. Tang, G. Fu, et al., Association of exposure to phenols and idiopathic male 
infertility. J Hazard Mater, 2013. 250–251: 115-121 
9. Den Hond, E., H. Tournaye, P. De Sutter, et al., Human exposure to endocrine disrupting 
chemicals and fertility: A case-control study in male subfertility patients. Environ Int, 




10. Minguez-Alarcon, L., R. Hauser, and A.J. Gaskins, Effects of bisphenol A on male and 
couple reproductive health: a review. Fertil Steril, 2016. 106(4): 864-70 
11. Lagos-Cabre, R. and R.D. Moreno, Contribution of environmental pollutants to male 
infertily: a working model of germ cell apoptosis induced by plasticizers. Biol Res, 2012. 
45(1): 5-14 
12. Lassen, T.H., H. Frederiksen, T.K. Jensen, et al., Urinary bisphenol A levels in young 
men: association with reproductive hormones and semen quality. Environ Health 
Perspect, 2014. 122(5): 478-84 
13. Buck Louis, G.M., R. Sundaram, A.M. Sweeney, E.F. Schisterman, J. Maisog, and K. 
Kannan, Urinary bisphenol A, phthalates, and couple fecundity: the Longitudinal 
Investigation of Fertility and the Environment (LIFE) Study. Fertil Steril, 2014. 101(5): 
1359-66 
14. Costa, E.M., P.M. Spritzer, A. Hohl, and T.A. Bachega, Effects of endocrine disruptors in 
the development of the female reproductive tract. Arq Bras Endocrinol Metabol, 2014. 
58(2): 153-61 
15. Souter, I., K.W. Smith, I. Dimitriadis, et al., The association of bisphenol-A urinary 
concentrations with antral follicle counts and other measures of ovarian reserve in women 
undergoing infertility treatments. Reprod Toxicol, 2013. 42: 224-31 
16. Lathi, R.B., C.A. Liebert, K.F. Brookfield, et al., Conjugated bisphenol A in maternal 
serum in relation to miscarriage risk. Fertil Steril, 2014. 102(1): 123-8 
17. Shen, Y., Y. Zheng, J. Jiang, et al., Higher urinary bisphenol A concentration is 
associated with unexplained recurrent miscarriage risk: evidence from a case-control 




18. Yuan, M., M.Z. Bai, X.F. Huang, et al., Preimplantation Exposure to Bisphenol A and 
Triclosan May Lead to Implantation Failure in Humans. Biomed Res Int, 2015. 2015: 
184845 
19. Weinberger, B., A.M. Vetrano, F.E. Archer, et al., Effects of maternal exposure to 
phthalates and bisphenol A during pregnancy on gestational age. J Matern Fetal Neonatal 
Med, 2014. 27(4): 323-7 
20. Chen, X., M. Chen, B. Xu, et al., Parental phenols exposure and spontaneous abortion in 
Chinese population residing in the middle and lower reaches of the Yangtze River. 
Chemosphere, 2013. 93(2): 217-22 
21. Palioura, E. and E. Diamanti-Kandarakis, Polycystic ovary syndrome (PCOS) and 
endocrine disrupting chemicals (EDCs). Rev Endocr Metab Disord, 2015. 16(4): 365-71 
22. Rutkowska, A.Z. and E. Diamanti-Kandarakis, Polycystic ovary syndrome and 
environmental toxins. Fertil Steril, 2016. 106(4): 948-58 
23. Wang, Y., Q. Zhu, X. Dang, Y. He, X. Li, and Y. Sun, Local effect of bisphenol A on the 
estradiol synthesis of ovarian granulosa cells from PCOS. Gynecol Endocrinol, 2016. 1-5 
24. Simonelli, A., R. Guadagni, P. De Franciscis, N. Colacurci, and M. Pieri, Environmental 
and occupational exposure to bisphenol A and endometriosis: urinary and peritoneal fluid 
concentration levels. 2016.  
25. Pollack, A.Z., G.M. Buck Louis, Z. Chen, et al., Bisphenol A, benzophenone-type 





26. Shen, Y., Q. Xu, M. Ren, X. Feng, Y. Cai, and Y. Gao, Measurement of phenolic 
environmental estrogens in women with uterine leiomyoma. PLoS One, 2013. 8(11): 
e79838 
27. Vagi, S.J., E. Azziz-Baumgartner, A. Sjodin, et al., Exploring the potential association 
between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine 
pesticides, perfluorinated compounds, phthalates, and bisphenol A in polycystic ovary 
syndrome: a case-control study. BMC Endocr Disord, 2014. 14: 86 
28. Upson, K., S. Sathyanarayana, A.J. De Roos, H.M. Koch, D. Scholes, and V.L. Holt, A 
population-based case-control study of urinary bisphenol A concentrations and risk of 
endometriosis. Hum Reprod, 2014. 29(11): 2457-64 
29. Shen, Y., Y.M. Dong, Q. Lu, et al., Phenolic environmental estrogens in urine and blood 
plasma from women with uterine leiomyoma: Epidemiological survey. J Obstet Gynaecol 
Res, 2016. 42(4): 440-5 
30. Ferguson, K.K., M.S. O'Neill, and J.D. Meeker, Environmental contaminant exposures 
and preterm birth: a comprehensive review. J Toxicol Environ Health B Crit Rev, 2013. 
16(2): 69-113 
31. Hannon, P.R. and J.A. Flaws, The effects of phthalates on the ovary. Front Endocrinol 
(Lausanne), 2015. 6: 8 
32. Johns, L.E., G.S. Cooper, A. Galizia, and J.D. Meeker, Exposure assessment issues in 
epidemiology studies of phthalates. Environ Int, 2015. 85: 27-39 
33. Wang, S.Y., Y. Wang, F.Q. Xie, et al., Analysis of PAEs in semen of infertile men. Int J 




34. Specht, I.O., J.P. Bonde, G. Toft, C.H. Lindh, B.A. Jonsson, and K.T. Jorgensen, Serum 
phthalate levels and time to pregnancy in couples from Greenland, Poland and Ukraine. 
PLoS One, 2015. 10(3): e0120070 
35. Specht, I.O., G. Toft, K.S. Hougaard, et al., Associations between serum phthalates and 
biomarkers of reproductive function in 589 adult men. Environ Int, 2014. 66: 146-56 
36. Bloom, M.S., B.W. Whitcomb, Z. Chen, A. Ye, K. Kannan, and G.M. Buck Louis, 
Associations between urinary phthalate concentrations and semen quality parameters in a 
general population. Hum Reprod, 2015. 30(11): 2645-57 
37. Jurewicz, J. and W. Hanke, Exposure to phthalates: reproductive outcome and children 
health. A review of epidemiological studies. Int J Occup Med Environ Health, 2011. 
24(2): 115-41 
38. Lenters, V., L. Portengen, and L.A. Smit, Phthalates, perfluoroalkyl acids, metals and 
organochlorines and reproductive function: a multipollutant assessment in Greenlandic, 
Polish and Ukrainian men. 2015. 72(6): 385-93 
39. Huang, L.P., C.C. Lee, J.P. Fan, P.H. Kuo, T.S. Shih, and P.C. Hsu, Urinary metabolites 
of di(2-ethylhexyl) phthalate relation to sperm motility, reactive oxygen species 
generation, and apoptosis in polyvinyl chloride workers. Int Arch Occup Environ Health, 
2014. 87(6): 635-46 
40. Pant, N., G. Kumar, A.D. Upadhyay, D.K. Patel, Y.K. Gupta, and P.K. Chaturvedi, 
Reproductive toxicity of lead, cadmium, and phthalate exposure in men. Environ Sci 




41. Axelsson, J., L. Rylander, A. Rignell-Hydbom, B.A. Jonsson, C.H. Lindh, and A. 
Giwercman, Phthalate exposure and reproductive parameters in young men from the 
general Swedish population. Environ Int, 2015. 85: 54-60 
42. Pan, Y., J. Jing, F. Dong, et al., Association between phthalate metabolites and 
biomarkers of reproductive function in 1066 Chinese men of reproductive age. J Hazard 
Mater, 2015. 300: 729-36 
43. Wang, Y.X., L. You, Q. Zeng, et al., Phthalate exposure and human semen quality: 
Results from an infertility clinic in China. Environ Res, 2015. 142: 1-9 
44. Cai, H., W. Zheng, P. Zheng, et al., Human urinary/seminal phthalates or their metabolite 
levels and semen quality: A meta-analysis. Environ Res, 2015. 142: 486-94 
45. Kay, V.R., M.S. Bloom, and W.G. Foster, Reproductive and developmental effects of 
phthalate diesters in males. Crit Rev Toxicol, 2014. 44(6): 467-98 
46. Kay, V.R., C. Chambers, and W.G. Foster, Reproductive and developmental effects of 
phthalate diesters in females. Crit Rev Toxicol, 2013. 43(3): 200-19 
47. Ferguson, K.K., T.F. McElrath, and J.D. Meeker, Environmental phthalate exposure and 
preterm birth. JAMA Pediatr, 2014. 168(1): 61-7 
48. Ferguson, K.K., T.F. McElrath, Y.A. Ko, B. Mukherjee, and J.D. Meeker, Variability in 
urinary phthalate metabolite levels across pregnancy and sensitive windows of exposure 
for the risk of preterm birth. Environ Int, 2014. 70: 118-24 
49. Zhao, Y., L. Chen, L.X. Li, et al., Gender-specific relationship between prenatal exposure 
to phthalates and intrauterine growth restriction. Pediatr Res, 2014. 76(4): 401-8 
50. Messerlian, C., I. Souter, A.J. Gaskins, et al., Urinary phthalate metabolites and ovarian 




51. Velez, M.P., T.E. Arbuckle, and W.D. Fraser, Female exposure to phenols and phthalates 
and time to pregnancy: the Maternal-Infant Research on Environmental Chemicals 
(MIREC) Study. Fertil Steril, 2015. 103(4): 1011-1020.e2 
52. Hauser, R., A.J. Gaskins, I. Souter, et al., Urinary Phthalate Metabolite Concentrations 
and Reproductive Outcomes among Women Undergoing in Vitro Fertilization: Results 
from the EARTH Study. Environ Health Perspect, 2016. 124(6): 831-9 
53. Mu, D., F. Gao, Z. Fan, H. Shen, H. Peng, and J. Hu, Levels of Phthalate Metabolites in 
Urine of Pregnant Women and Risk of Clinical Pregnancy Loss. Environ Sci Technol, 
2015. 49(17): 10651-7 
54. Kim, S.H., S. Cho, H.J. Ihm, et al., Possible Role of Phthalate in the Pathogenesis of 
Endometriosis: In Vitro, Animal, and Human Data. J Clin Endocrinol Metab, 2015. 
100(12): E1502-11 
55. Upson, K., S. Sathyanarayana, A.J. De Roos, et al., Phthalates and risk of endometriosis. 
Environ Res, 2013. 126: 91-7 
56. Itoh, H., M. Iwasaki, T. Hanaoka, H. Sasaki, T. Tanaka, and S. Tsugane, Urinary 
phthalate monoesters and endometriosis in infertile Japanese women. Sci Total Environ, 
2009. 408(1): 37-42 
57. Huang, Y., J. Li, J.M. Garcia, et al., Phthalate levels in cord blood are associated with 
preterm delivery and fetal growth parameters in Chinese women. PLoS One, 2014. 9(2): 
e87430 
58. Knez, J., Endocrine-disrupting chemicals and male reproductive health. Reprod Biomed 




59. Toshima, H., Y. Suzuki, K. Imai, et al., Endocrine disrupting chemicals in urine of 
Japanese male partners of subfertile couples: a pilot study on exposure and semen quality. 
Int J Hyg Environ Health, 2012. 215(5): 502-6 
60. Giudice, L.C., Environmental toxicants: hidden players on the reproductive stage. Fertil 
Steril, 2016. 106(4): 791-4 
61. Deng, Z., F. Chen, M. Zhang, et al., Association between air pollution and sperm quality: 
A systematic review and meta-analysis. Environ Pollut, 2016. 208(Pt B): 663-9 
62. Rengaraj, D., W.S. Kwon, and M.G. Pang, Effects of motor vehicle exhaust on male 
reproductive function and associated proteins. J Proteome Res, 2015. 14(1): 22-37 
63. Yorifuji, T., H. Naruse, S. Kashima, T. Murakoshi, and H. Doi, Residential proximity to 
major roads and obstetrical complications. Sci Total Environ, 2015. 508: 188-92 
64. Chang, H.H., J.L. Warren, L.A. Darrow, B.J. Reich, and L.A. Waller, Assessment of 
critical exposure and outcome windows in time-to-event analysis with application to air 
pollution and preterm birth study. Biostatistics, 2015. 16(3): 509-21 
65. Candela, S., A. Ranzi, L. Bonvicini, et al., Air pollution from incinerators and 
reproductive outcomes: a multisite study. Epidemiology, 2013. 24(6): 863-70 
66. Enkhmaa, D., N. Warburton, B. Javzandulam, et al., Seasonal ambient air pollution 
correlates strongly with spontaneous abortion in Mongolia. BMC Pregnancy Childbirth, 
2014. 14: 146 
67. Slama, R., S. Bottagisi, I. Solansky, J. Lepeule, L. Giorgis-Allemand, and R. Sram, 





68. U.S.EPA, An inventory of sources and environmental releases of dioxin-like compounds 
in the United States for the years 1987, 1995, and 2000 (EPA/600/P-03/002F). 2006: 
National Center for Environmental Assessment, Washington, DC. 
69. Galimova, E.F., Z.K. Amirova, and N. Galimov Sh, Dioxins in the semen of men with 
infertility. Environ Sci Pollut Res Int, 2015. 22(19): 14566-9 
70. Papadopoulou, E., I.H. Caspersen, H.E. Kvalem, et al., Maternal dietary intake of dioxins 
and polychlorinated biphenyls and birth size in the Norwegian Mother and Child Cohort 
Study (MoBa). Environ Int, 2013. 60: 209-16 
71. Wesselink, A., M. Warner, S. Samuels, et al., Maternal dioxin exposure and pregnancy 
outcomes over 30 years of follow-up in Seveso. Environ Int, 2014. 63: 143-8 
72. Soave, I., D. Caserta, J.M. Wenger, S. Dessole, A. Perino, and R. Marci, Environment 
and Endometriosis: a toxic relationship. Eur Rev Med Pharmacol Sci, 2015. 19(11): 
1964-72 
73. Annamalai, J. and V. Namasivayam, Endocrine disrupting chemicals in the atmosphere: 
Their effects on humans and wildlife. Environ Int, 2015. 76: 78-97 
74. Sengupta, P. and R. Banerjee, Environmental toxins: alarming impacts of pesticides on 
male fertility. Hum Exp Toxicol, 2014. 33(10): 1017-39 
75. Mehrpour, O., P. Karrari, N. Zamani, A.M. Tsatsakis, and M. Abdollahi, Occupational 
exposure to pesticides and consequences on male semen and fertility: a review. Toxicol 
Lett, 2014. 230(2): 146-56 
76. Melgarejo, M., J. Mendiola, H.M. Koch, M. Monino-Garcia, J.A. Noguera-Velasco, and 




metabolite levels and reproductive parameters in men from an infertility clinic. Environ 
Res, 2015. 137: 292-8 
77. Jurewicz, J., M. Radwan, B. Wielgomas, et al., The effect of environmental exposure to 
pyrethroids and DNA damage in human sperm. Syst Biol Reprod Med, 2015. 61(1): 37-
43 
78. Radwan, M., J. Jurewicz, B. Wielgomas, et al., Semen quality and the level of 
reproductive hormones after environmental exposure to pyrethroids. J Occup Environ 
Med, 2014. 56(11): 1113-9 
79. Pant, N., M. Shukla, A.D. Upadhyay, P.K. Chaturvedi, D.K. Saxena, and Y.K. Gupta, 
Association between environmental exposure to p, p'-DDE and lindane and semen 
quality. Environ Sci Pollut Res Int, 2014. 21(18): 11009-16 
80. McAuliffe, M.E., P.L. Williams, S.A. Korrick, L.M. Altshul, and M.J. Perry, 
Environmental exposure to polychlorinated biphenyls and p,p'-DDE and sperm sex-
chromosome disomy. Environ Health Perspect, 2012. 120(4): 535-40 
81. Celik-Ozenci, C., A. Tasatargil, M. Tekcan, et al., Effect of abamectin exposure on 
semen parameters indicative of reduced sperm maturity: a study on farmworkers in 
Antalya (Turkey). Andrologia, 2012. 44(6): 388-95 
82. Chevrier, C., C. Warembourg, E. Gaudreau, et al., Organochlorine pesticides, 
polychlorinated biphenyls, seafood consumption, and time-to-pregnancy. Epidemiology, 
2013. 24(2): 251-60 
83. Upson, K., A.J. De Roos, M.L. Thompson, et al., Organochlorine pesticides and risk of 
endometriosis: findings from a population-based case-control study. Environ Health 




84. Trabert, B., Z. Chen, K. Kannan, et al., Persistent organic pollutants (POPs) and fibroids: 
results from the ENDO study. J Expo Sci Environ Epidemiol, 2015. 25(3): 278-85 
85. Cragin, L.A., J.S. Kesner, A.M. Bachand, et al., Menstrual cycle characteristics and 
reproductive hormone levels in women exposed to atrazine in drinking water. Environ 
Res, 2011. 111(8): 1293-301 
86. Whitworth, K.W., D.D. Baird, A.Z. Steiner, et al., Anti-Mullerian hormone and lifestyle, 
reproductive, and environmental factors among women in rural South Africa. 
Epidemiology, 2015. 26(3): 429-35 
87. Williams, A.L., R.E. Watson, and J.M. DeSesso, Developmental and reproductive 
outcomes in humans and animals after glyphosate exposure: a critical analysis. J Toxicol 
Environ Health B Crit Rev, 2012. 15(1): 39-96 
88. Balise, V.D., C.X. Meng, J.N. Cornelius-Green, C.D. Kassotis, R. Kennedy, and S.C. 
Nagel, Systematic review of the association between oil and natural gas extraction 
processes and human reproduction. Fertil Steril, 2016. 106(4): 795-819 
89. Elliott, E.G., A.S. Ettinger, B.P. Leaderer, M.B. Bracken, and N.C. Deziel, A systematic 
evaluation of chemicals in hydraulic-fracturing fluids and wastewater for reproductive 
and developmental toxicity. J Expo Sci Environ Epidemiol, 2016.  
90. Webb, E., S. Bushkin-Bedient, A. Cheng, C.D. Kassotis, V. Balise, and S.C. Nagel, 
Developmental and reproductive effects of chemicals associated with unconventional oil 
and natural gas operations. Rev Environ Health, 2014. 29(4): 307-18 
91. Andersen, A., Final amended report on the safety assessment of Methylparaben, 
Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and 




92. Dodge, L.E., P.L. Williams, M.A. Williams, et al., Paternal Urinary Concentrations of 
Parabens and Other Phenols in Relation to Reproductive Outcomes among Couples from 
a Fertility Clinic. Environ Health Perspect, 2015. 123(7): 665-71 
93. Meeker, J.D., T. Yang, X. Ye, A.M. Calafat, and R. Hauser, Urinary concentrations of 
parabens and serum hormone levels, semen quality parameters, and sperm DNA damage. 
Environ Health Perspect, 2011. 119(2): 252-7 
94. Minguez-Alarcon, L., Y.H. Chiu, C. Messerlian, et al., Urinary paraben concentrations 
and in vitro fertilization outcomes among women from a fertility clinic. Fertil Steril, 




















Subchronic Exposure to Di(2-ethylhexyl) Phthalate and Diisononyl Phthalate During 
Adulthood Has Immediate and Long-Term Reproductive Consequences in Female Mice2 
 
3.1 Abstract 
Di(2-ethylhexyl) phthalate (DEHP) is a plasticizer used in a wide variety of consumer products.  
This is concerning because DEHP is an endocrine disruptor and ovarian toxicant.  Diisononyl 
phthalate (DiNP) is a DEHP replacement that is a rising human toxicant due to its increased use 
as a DEHP substitute.  However, little is known about the effects of DEHP or DiNP exposure 
during adulthood on female reproduction.  Thus, this study tested the hypothesis that DEHP or 
DiNP exposure during adulthood has long-term consequences for female reproduction in mice.  
Adult female CD-1 mice (39-40 days) were orally dosed with vehicle control (corn oil), DEHP 
(20 µg/kg/day - 200 mg/kg/day), or DiNP (20 µg/kg/day - 200 mg/kg/day) for 10 days.  Females 
were paired with untreated male mice for breeding trials immediately post-dosing and again at 
three and nine months post-dosing.  Immediately post-dosing, DEHP and DiNP did not affect 
fertility.  At three months post-dosing, DiNP (20 and 100 µg/kg/day and 200 mg/kg/day) 
significantly disrupted estrous cyclicity, and DiNP and DEHP (20 µg/kg/day) significantly 
reduced the ability of females to get pregnant.  At nine months post-dosing, DiNP significantly 
disrupted estrous cyclicity (100 µg/kg/day), reduced time to mating (100 µg/kg/day – 200 
mg/kg/day), and borderline reduced percent of females who produced offspring (20 mg/kg/day).  
At nine months post-dosing, DEHP (200 µg/kg/day and 200 mg/kg/day) and DiNP (100 
2. Reprinted with permission from Chiang C., Flaws J. A., Subchronic Exposure to Di(2-ethylhexyl) Phthalate and 
Diisononyl Phthalate During Adulthood Has Immediate and Long-Term Reproductive Consequences in Female 





µg/kg/day and 20 and 200 mg/kg/day) increased numbers of male-biased litters.  These data 
show that DEHP and DiNP exposure has long-term consequences for female reproduction, even 
long after cessation of exposure. 
 
3.2 Introduction 
Phthalates are chemicals commonly used as plasticizers and stabilizers in a wide variety of 
consumer products.  One of the most common phthalates is di(2-ethylhexyl) phthalate (DEHP), 
with up to 100 million pounds produced within the U.S. each year [1, 2].  DEHP can be found in 
products such as surgical tubing, blood bags, building materials, clothes, and baby toys [1].  
Because DEHP is noncovalently bound to the products it is used in, it can leach out over time 
and be absorbed via inhalation, ingestion, and dermal contact [1, 3, 4].  Due to the ubiquitous 
nature of DEHP environmental contamination, the estimated average daily intake of DEHP is 3-
30 µg/kg/day [1].   
 
Widespread and daily exposure of humans to DEHP is concerning because DEHP is a known 
reproductive toxicant and endocrine disrupting chemical [5-8].  DEHP exposure has been shown 
to reduce testosterone levels and decrease sperm quantity and quality in mice [9, 10] and it is 
associated with decreased sperm concentration and motility in humans [11, 12].  Further, DEHP 
exposure disrupts ovarian folliculogenesis and steroidogenesis in female mice [13, 14] and it is 
associated with preterm delivery in women and premature thelarche in girls [15, 16].   
 
Possibly due to increased public awareness of the endocrine disrupting effects of DEHP, some 




manufacturers replacing DEHP, the general population is still exposed to DEHP daily, and some 
populations are exposed to even higher levels due to occupation or medical treatment [17-20].  
However, few studies have examined how DEHP affects female reproductive parameters 
overtime.  Thus, it is critical to fill this gap in knowledge. 
 
Although the movement to replace DEHP with a less toxic plasticizer is a step in the right 
direction, often these substitute chemicals have not been rigorously tested for toxicity, especially 
in regards to endocrine disruption.  Diisononyl phthalate (DiNP) is one such understudied DEHP 
substitute.  Few reproductive studies using DiNP have been conducted, but some studies have 
found that perinatal exposure to DiNP causes histopathological changes in the testes, and 
prenatal exposure to DiNP disrupts steroidogenesis in the testes in a similar manner to DEHP in 
rats [21-26].  In men, DiNP exposure has been associated with reduced testicular volume, semen 
volume, and testosterone levels [27-29].   
 
Even fewer studies have been conducted on the effects of DiNP on female reproduction.  One 
study found that DiNP reduced corpora lutea number and ovarian and uterine weight at puberty 
in rats [21].  Although these studies have shed some light on the effects of DiNP on 
reproduction, they often use doses well above the levels of human exposure.  It is imperative to 
use environmentally relevant doses because effects may not be seen at these higher doses due to 
endocrine disrupting chemicals sometimes exhibiting non-monotonic dose response curves [30].   
 
In this study, we aim to fill the gaps in knowledge concerning the short-term and long-term 




previous study in our laboratory has shown that 10 days of exposure to DEHP during adulthood 
is sufficient to alter folliculogenesis in female mice [31].  Thus, this study tested the hypothesis 
that 10 days of exposure to DEHP or DiNP during adulthood can significantly affect female 
fertility at time points immediately post-dosing, three months post-dosing, and nine months post-
dosing. 
 
3.3 Materials and Methods 
Chemicals 
DEHP and DiNP were purchased from Sigma-Aldrich (St. Louis, MO).  Corn oil (vehicle 
control) was purchased from MP Biomedicals (Solon, OH).  Dosing solutions were created by 
using the highest concentration dose of stock solution (200 mg/kg/day for both DEHP and DiNP) 
in serial dilutions to make lower dose stock solutions (20 µg/kg/day, 200 µg/kg/day, and 20 
mg/kg/day DEHP and 20 µg/kg/day, 100 µg/kg/day, and 20 mg/kg/day DiNP).  Stock solutions 
for DEHP doses were prepared at concentrations of 133.33, 13.33, 0.13, and 0.013 mg/mL from 
the highest to lowest dose.  Stock solutions for DiNP doses were prepared at concentrations of 
133.33, 13.33, 0.067, and 0.013 mg/mL from the highest to lowest dose. 
 
These doses for DEHP were chosen because 20 µg/kg/day is the EPA reference dose and also 
falls within the range of estimated daily exposure to DEHP (3-30 µg/kg/day) [32, 33].  The 200 
µg/kg/day DEHP dose falls within the estimated range for occupational exposure (143-286 
µg/kg/day) [34].  The 20 and 200 mg/kg/day doses of DEHP were chosen because they were 
used in previous studies and provide a wide range to aid in observation of dose response effects 




occupational exposure to DiNP (up to 26 µg/kg/day) [36].  The 100 µg/kg/day dose was chosen 
because it falls within the range of estimated daily exposure for infants chewing on plastic toys 
(up to 260 µg/kg/day) [37].  The 20 and 200 mg/kg/day doses were chosen because they allow 
for direct comparison of toxicity to DEHP throughout the study. 
 
Animals and Dosing 
Adult CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA) and were 
allowed to acclimate to the facility prior to the beginning of their dosing at age 39-40 days.  Mice 
were given ad libitum access to reverse osmosis treated water and Teklad Rodent Diet (8604).  
Facilities were maintained at 21.1 ± 2.2˚C with humidity at 50 ± 20% and 12 hour light-dark 
cycles to provide a consistent and controlled housing environment.  All animal handling and 
procedures used in this study were approved by the University of Illinois at Urbana-Champaign 
Institutional Animal Care and Use Committee (Protocol No.: 17079).  
 
Mice were orally dosed with the vehicle control (corn oil), DEHP (20 µg/kg/day, 200 µg/kg/day, 
20 mg/kg/day, or 200 mg/kg/day), or DiNP (20 µg/kg/day, 100 µg/kg/day, 20 µg/kg/day, 20 
mg/kg/day, or 200 mg/kg/day) daily for 10 consecutive days every morning (two hours following 
the start of the light cycle).  Volume of dose was determined using a spreadsheet to find the 
corresponding volume given the weight of the mouse immediately before dosing each day.  Mice 
were group housed three to a cage during the dosing period, with every mouse in a single cage 
receiving the same treatment.  A single cohort of mice was designated for breeding trials and 
estrous cyclicity monitoring and this cohort was used continuously throughout the study at every 




DEHP and DiNP for every time point unless data were missing for any mouse/mice.  For tissue 
collection, each time point used a separate cohort of mice.  The sample size for these cohorts of 
mice designated for tissue collection was 12 mice in control and 6 mice for every dose of DEHP 
and DiNP for every time point unless data were missing for any mouse/mice. 
 
Estrous Cyclicity Monitoring 
Mice were group housed (three/cage) and vaginally lavaged with 1X phosphate-buffered saline 
daily (two hours following the start of the light cycle) for 14 days prior to each breeding trial 
occurring at three and nine months post-dosing (n = 12-24 mice/group per time point unless data 
were unavailable for any mouse/mice).  The stage of the estrous cycle was determined by 
examining the lavage sample under a light microscope.  The type, amount, and condition of the 
cells present was used to determine if the mouse was in estrus, metestrus, diestrus, or proestrus 
as previously defined [38].  Metestrus and diestrus were combined in the analyses because of 
their similarity in behavioral and hormonal profiles.  Percent time spent in each stage of the cycle 
was determined by taking the number of days in each stage (proestrus, estrus, and 
metestrus/diestrus) divided by 14 and multiplied by 100.   
 
Breeding Trials and Fertility Indices 
Females were paired with an untreated CD-1 male mouse (age seven weeks) in a harem fashion, 
with two females plus a male in a new, clean cage.  Females were checked in the morning and 
afternoon for the presence of copulatory plugs.  If a copulatory plug was observed, the female 
was removed and placed in a new, clean cage.  Females were group housed until 3-7 days before 




maximum of 14 days had passed.  If a plug was found the morning immediately following the 
day of male introduction, the time to mating was calculated as one day.  From the time of pairing 
until birth, females were weighed twice a week to monitor weight gain due to pregnancy.  If a 
weight gain of four grams was observed, the female was considered pregnant.  Females were 
checked morning and afternoon for birth.  To calculate the length of gestation, the first day the 
copulatory plug was observed was considered day 0.5 of the pregnancy.  The fertility index was 
calculated by dividing the number of pregnant females by the number of females who presented 
with a copulatory plug and multiplying by 100.  The gestational index was calculated by dividing 
the number of females who gave birth to pups by the number of pregnant females and 
multiplying by 100.  The index for females who gave birth was calculated by dividing the 
number of females who gave birth to pups by the number of total females in each treatment 
group and multiplying by 100.  If a female gave birth, the first day pups were observed was 
considered to be postnatal day (PND) 0, and total pup number, number of females and males, 
number of dead pups, and average weight of all live pups was recorded.  Male to female ratio of 
pups was calculated by dividing the number of male pups by the number of female pups.  Pup 
mortality was calculated by dividing the number of pups who died by the total number of pups in 
the litter and multiplying by 100.  Average live weight was measured by collectively weighing 
all live pups on PND 0 and dividing the total weight by the number of live pups.  If the number 
of total pups or the number of males or females could not be determined due to cannibalism, the 








Mice were group housed (three/cage) until each cohort was collected immediately following 
dosing, three months following dosing, and nine months following dosing.  Mice were 
euthanized via CO2 asphyxiation in the diestrous stage of the estrous cycle.  Ovaries were 
collected and the gonadal fat was trimmed away before weighing.  The uteri were collected with 
the oviducts and the cervix attached and fat was trimmed away before weighing.  The livers were 
collected and weighed for each animal. 
 
Statistical Analysis 
Data were analyzed using SPSS statistical software (SPSS Inc., Chicago, IL).  Data were 
presented as means ± standard error or as percentages.  If data were normally distributed and met 
the assumption of homogeneity of variances, means were compared using a one-way analysis of 
variance (ANOVA) followed by Dunnett’s T test post hoc.  If the data did not meet the statistical 
assumptions required for ANOVA, they were analyzed via Kruskal-Wallis one-way analysis of 
variance followed by Mann-Whitney U tests.  Nominal data were analyzed using a 1-sided 
Fisher’s exact test.  Statistical significance was assigned at p ≤ 0.05. 
 
3.4 Results 
Effects of DEHP and DiNP on body weight and organ weights 
Immediately post-dosing, 200 µg/kg/day and 20 mg/kg/day DEHP significantly decreased 
uterine weight compared to control (Table 3.1, n = 6-12 mice/group, p ≤ 0.05).  Additionally, 
200 mg/kg/day DEHP borderline decreased uterine weight (Table 3.1, n = 6-12 mice/group, p = 




weight at this time point.  Additionally, no doses of DEHP or DiNP affected body weight, 
ovarian weight, uterine weight, or liver weight at three (Table 3.1, n = 5-12 mice/group) or nine 
months post-dosing (Table 3.1, n = 5-12 mice/group). 
 
Effects of DEHP and DiNP on estrous cyclicity 
At three months post-dosing, DEHP did not significantly affect the time spent in any stage of the 
estrous cycle.  However, the 200 mg/kg/day dose of DEHP borderline decreased the time spent 
in proestrus compared to control (Fig. 3.1A, n = 12-22 mice/group, p = 0.09).  In contrast, 20 
µg/kg/day and 200 mg/kg/day DiNP significantly decreased the time spent in proestrus, and 100 
µg/kg/day and 200 mg/kg/day DiNP significantly increased the time spent in metestrus and 
diestrus compared to control (Fig. 3.1A, n = 12-22 mice/group, p ≤ 0.05).   At nine months post-
dosing, DEHP did not significantly affect the time spent in any stage of the estrous cycle (Fig. 
3.1B, n = 11-22 mice/group), but 100 µg/kg/day DiNP significantly increased the time spent in 
metestrus and diestrus compared to control (Fig. 3.1B, n = 11-22 mice/group, p ≤ 0.05). 
 
Effects of DEHP and DiNP on time to mating 
DEHP and DiNP did not significantly affect the time to mating following introduction of the 
male into the cage for breeding trials immediately post-dosing (Fig. 3.2A, n = 7-21 mice/group) 
or three months post-dosing compared to control (Fig. 3.2B, n = 7-18 mice/group).  However, at 
nine months post-dosing, 200 mg/kg/day DiNP significantly decreased time to mating (p ≤ 0.05) 
and 100 µg/kg/day and 20 mg/kg/day DiNP borderline decreased time to mating compared to 





Effects of DEHP and DiNP on fertility index 
DEHP and DiNP did not significantly affect the ability of females to become pregnant after a 
successful mating immediately post-dosing (Fig. 3.3A, n = 12-23 mice/group) or at nine months 
post-dosing compared to control (Fig. 3.3C, n = 10-22 mice/group).  At three months post-
dosing, however, the lowest doses of DEHP (20 µg/kg/day) and DiNP (20 µg/kg/day) 
significantly reduced the ability of females to become pregnant compared to control (Fig. 3.3B, n 
= 11-22 mice/group, p ≤ 0.05).  Approximately half of successfully mated females treated with 
20 µg/kg/day DEHP and one third of females treated with 20 µg/kg/day DiNP were unable to 
achieve pregnancy, whereas 95% of females achieved pregnancy in the control group (Fig. 3.3B, 
n = 11-22 mice/group). 
 
Effects of DEHP and DiNP on gestational index 
Treatment did not affect the gestational index.  Specifically, DEHP and DiNP did not 
significantly affect the ability of females to carry their pregnancy to term immediately post-
dosing (Fig. 3.4A, n = 11-23 mice/group), three months post-dosing (Fig. 3.4B, n = 6-21 
mice/group), or nine months post-dosing compared to control (Fig. 3.4C, n = 6-18 mice/group). 
 
Effects of DEHP and DiNP on gestation length 
Immediately post-dosing, 200 mg/kg/day DiNP borderline increased length of gestation 
compared to control (Fig. 3.5A, n = 8-20 mice/group, p = 0.07).  DEHP and DiNP did not 
significantly affect length of gestation at three months post-dosing (Fig. 3.5B, n = 3-17 





Effects on DEHP and DiNP on the ability of females to produce pups 
Immediately post-dosing, DEHP and DiNP did not significantly affect the overall ability of 
females to produce offspring compared to control (Fig. 3.6A, n = 11-23 mice/group).  Strikingly, 
after three months post-dosing, females in the lowest treatment groups (20 µg/kg/day) for DEHP 
and DiNP had a significantly impaired ability to give birth to pups compared to control (Fig. 
3.6B, n = 11-22 mice/group, p ≤ 0.05).  Additionally, at nine months post-dosing, females in the 
20 mg/kg/day DiNP group had a borderline impaired ability to produce offspring compared to 
control (Fig. 3.6C, n = 11-22 mice/group, p = 0.07). 
 
Effects of DEHP and DiNP on litter size and average live pup weight 
DEHP and DiNP did not significantly affect litter size immediately post-dosing (Fig. 3.7A, n = 
8-19 mice/group), three months post-dosing (Fig. 3.7B, n = 5-18 mice/group), or nine months 
post-dosing compared to control (Fig. 3.7C, n = 4-14 mice/group).  Immediately post-dosing, the 
average live weight of pups on PND 0 was significantly increased by treatment with 20 
mg/kg/day DEHP compared to control (Fig. 3.7D, n = 8-19 mice/group, p ≤ 0.05).  At nine 
months post-dosing, treatment with 20 mg/kg/day DiNP borderline increased average live weight 
of pups on PND 0 compared to control (Fig. 3.7F, n = 4-15 mice/group, p = 0.06).  DEHP and 
DiNP did not significantly affect the average live weight of pups on PND 0 at three months post-
dosing compared to control (Fig. 3.7E, n = 5-16 mice/group). 
 
Effects of DEHP and DiNP on pup mortality and sex ratio 
DEHP and DiNP did not significantly affect pup mortality immediately post-dosing (Fig. 3.8A, n 




post-dosing compared to control (Fig. 3.8C, n = 3-13 mice/group).  Additionally, DEHP and 
DiNP did not significantly affect the male to female ratio of pups immediately post-dosing (Fig. 
8D, n = 9-18 mice/group) or at three months post-dosing compared to control (Fig. 3.8E, n = 4-
14 mice/group).  However, at nine months post-dosing, treatment with 20 and 200 mg/kg/day 
DEHP and 100 µg/kg/day DiNP significantly increased the male to female ratio of pups 
compared to control (Fig. 3.8F, n = 4-11 mice/group, p ≤ 0.05).  Further, treatment with 20 and 
200 mg/kg/day DiNP borderline significantly increased the ratio of male to female pups at nine 
months post-dosing compared to control (Fig. 3.8F, n = 4-11 mice/group, 0.05 < p ≤ 0.10). 
 
3.5 Discussion 
In this study, we investigated how sub-chronic exposure to DEHP or DiNP during adulthood 
affected female fertility.  Previously, our research group showed that an acute exposure to DEHP 
(10 days) was sufficient to accelerate ovarian folliculogenesis immediately post-dosing and 
disrupt estrous cyclicity and steroidogenesis up to nine months post-dosing [31, 35].  The present 
study builds upon this knowledge by examining fertility at additional time points and testing the 
reproductive toxicity of a common DEHP replacement, DiNP.  This study shows that exposure to 
DEHP and DiNP has negative impacts on female reproductive parameters several months after 
exposure has stopped.  These negative impacts include changes in reproductive organ weights, 
disruption of estrous cyclicity, reduction in fertility, changes in mating behavior, and changes in 
litter outcomes. 
 
Immediately post-dosing, 20 mg/kg/day DEHP significantly increased the average live weight of 




obesogenic [39]. Thus, it is possible that DEHP exposure increases adiposity and subsequently, 
birth weight of pups.  Our finding contrasts with epidemiological data that find associations 
between phthalate exposure and low birth weight [40, 41].  The differences between the current 
study and epidemiological data may be due to different exposure times and species differences.   
 
Immediately post-dosing, some doses of DEHP, but not DiNP, significantly decreased uterine 
weight.  In a previous study in our laboratory, we did not observe any effects of DEHP exposure 
for 10 days on uterine weight [35].  This discrepancy may be due to animals being housed in 
groups for the current experiment and singly in the previous study.  Group housing is known to 
suppress estrus in rodents, which may cause lower estradiol and subsequently, lower uterine 
weight [42, 43].  Additionally, DEHP has been shown to disrupt ovarian steroidogenesis in vivo 
and in vitro; thus, the observed decrease in uterine weight in this study may also be mediated by 
DEHP-induced decrease of estradiol [7].  Therefore, it is possible that the DEHP-induced 
reduction in uterine weight in this study was only statistically detectable once animals were 
group housed, causing them to be in a lower estrogen state than in the previous study. 
 
Three months post-dosing, some doses of DiNP significantly disrupted estrous cyclicity 
compared to controls.  At one dose, these effects persisted for as long as nine months following 
dosing.  It is possible that DiNP may be affecting levels of sex steroid hormones which dictate 
the estrous cycle in the mouse [44].  DiNP has been shown to disrupt steroid hormone production 
in porcine granulosa cell cultures, indicating that DiNP maybe be targeting ovarian 
steroidogenesis and subsequently disrupting estrous cyclicity [45].  Other studies have found that 




The difference in estrous cyclicity outcomes between these previous studies and the present 
study may be due to the use of different animal models as well as exposure windows.  Previous 
studies assessed cyclicity at postnatal week (PNW) 8-11 or at PNW 8-9 and again at 19-20, 
whereas the mice in the present study were first monitored at approximately 19 weeks of age and 
again at approximately 44 weeks of age.   
 
At three months post-dosing, we observed that treatment with 20 µg/kg/day of DEHP or DiNP, 
the lowest dose used in this study, significantly reduced the fertility index of females compared 
to control.  A reduction in the fertility index indicates a reduction in the ability of females to 
become pregnant from a confirmed mating.  Additionally, this significant reduction in the 
fertility index led to a significant reduction in the percent of females who produced pups.  
Because the affected females had complete infertility as opposed to reduced fertility (e.g. smaller 
litter sizes), it is possible that the underlying mechanism involves disruption of global uterine 
receptivity to implantation.  Proper regulation of sex steroid hormones is necessary for the 
opening of the “implantation window,” the narrow time frame during which the uterus is 
receptive to embryo implantation [47].  In fact, DEHP has been shown to decrease implantation 
rates in mice by decreasing endometrial receptivity to the embryo [48].  However, one study 
found that rats exposed to DiNP via the diet prior to mating and during mating had no difficulty 
achieving pregnancy and producing pups [49].  The differences observed between this past study 






At nine months post-dosing, 200 mg/kg/day DiNP significantly reduced time to mating and 100 
µg/kg/day and 20 mg/kg/day DiNP borderline reduced time to mating.  The effects of DiNP on 
time to mating reported in the current study appear to be novel, as most studies investigate 
developmental exposure windows and do not measure time to mating as a fertility parameter.  
Sex steroid hormones are necessary for maintenance of proper reproductive behavior; thus, it is 
possible that DiNP disrupts circulating hormones, particularly estradiol and progesterone, in a 
manner that increases female sexual receptivity to males [50].  Although treatment did not affect 
the fertility index or gestational index of females at nine months post-dosing, 20 mg/kg/day 
DiNP borderline decreased the percent of females who gave birth.  It is hard to specifically 
assign the cause of the DiNP-induced reduction in overall fertility to a reduction in ability to 
achieve pregnancy or ability to carry a pregnancy to term because neither the fertility index nor 
gestational index were statistically different from controls.  It is likely that 20 mg/kg/day DiNP 
reduced both of these indices enough to cause a cumulative effect that can be seen in the 
reduction of percent of females who gave birth, but not enough to be statistically detectable for 
either of the individual fertility indices.  It is possible that this overall reduction in fertility could 
be the beginning of the onset of reproductive senescence in these mice.  Previous studies have 
shown that phthalate exposure has been associated with premature menopause in women as well 
as increased markers of reproductive aging in female mice [13, 31, 51].   
 
At nine months post-dosing, 200 µg/kg/day and 200 mg/kg/day DEHP and 100 µg/kg/day DiNP 
significantly increased the male to female ratio of pups, and 20 and 200 mg/kg/day borderline 
increased the male to female ratio of pups.  We find this result particularly interesting because it 




heterogametic sex in mice.  However, the present study is not the first to find that treatment of 
females can result in altered offspring sex ratio.  Multiple animal-based studies have found that 
females fed diets supplemented with fats produce male-biased litters [52, 53].  One hypothesis 
that has existed for decades is that hormonal milieu affects offspring sex ratio in humans [54].  
Supporting this hypothesis, one study found that women with fat deposition patterns indicative of 
higher testosterone were significantly more likely to produce male offspring than their 
counterparts with fat deposition patterns indicative of lower testosterone levels [55].  We 
speculate that the observed sex selection occurs at the level of the sperm and vaginal mucosa 
because of evidence that Y-bearing sperm are smaller and more motile and are subsequently able 
to navigate through cervical mucus faster than their X-bearing counterparts [56].  Because 
hormones are known to have a significant impact on mucus production and viscosity within the 
female reproductive tract, it is possible that DEHP and DiNP may be disrupting hormone levels, 
leading to a change in the mucosal environment of the female reproductive tract that selects 
favorably for Y-bearing sperm [57].  Further, we do not think the sex selection occurs at the level 
of the embryo because we did not observe any changes in litter size that would suggest altered 
resorption of embryos. 
 
In conclusion, this study found that DEHP and DiNP disrupt several aspects of female fertility at 
time points up to nine months after cessation of exposure.  Many of the results observed in this 
study may be due to disruption of the hormonal milieu due to treatment with DEHP or DiNP.  
Thus, future studies should investigate the effects of DEHP and DiNP on sex steroid hormones 
and gonadotropins.  Additionally, future studies should investigate fertility at time points even 




reproductive senescence and elucidate any effects of these phthalates on the reproductive 
lifespan.  Collectively, these findings suggest that phthalates, which are ubiquitous 
environmental contaminants that humans are exposed to daily, may have long lasting 























3.6 Table, Figures, and Legends 
Table 3.1 Effects of DEHP and DiNP on body weight and organ weights 
 
Time Point Treatment Body Weight (g) Ovary Weight (g) Uterine Weight (g) Liver Weight (g) 
Immediately Post-Dosing 
Control 24.17 ± 0.55 0.0088 ± 0.0003 0.1050 ± 0.0065 1.3223 ± 0.0399 
   20 µg/kg/day DEHP 24.06 ± 0.64 0.0095 ± 0.0008 0.0871 ± 0.0101 1.2810 ± 0.0726 
200 µg/kg/day DEHP 24.38 ± 0.69 0.0082 ± 0.0007    0.0767 ± 0.0036 * 1.2295 ± 0.0676 
 20 mg/kg/day DEHP 23.67 ± 0.62 0.0082 ± 0.0007    0.0722 ± 0.0054 * 1.2490 ± 0.0422 
200 mg/kg/day DEHP 23.63 ± 0.65 0.0084 ± 0.0003    0.0814 ± 0.0079 ^ 1.3291 ± 0.0826 
  20 µg/kg/day DiNP 24.63 ± 0.79 0.0082 ± 0.0014 0.1034 ± 0.0111 1.3205 ± 0.0376 
100 µg/kg/day DiNP 23.25 ± 0.46 0.0073 ± 0.0014 0.1050 ± 0.0072 1.2145 ± 0.0549 
 20 mg/kg/day DiNP 23.02 ± 0.35 0.0088 ± 0.0003 0.0938 ± 0.0099 1.1924 ± 0.0160 
200 mg/kg/day DiNP 23.67 ± 0.51 0.0085 ± 0.0006 0.0920 ± 0.0052 1.3561 ± 0.0657 
3 Months Post-Dosing 
Control 30.95 ± 0.48 0.0212 ± 0.0002 0.1228 ± 0.0086 1.4679 ± 0.0401 
  20 µg/kg/day DEHP 31.47 ± 0.66 0.0241 ± 0.0020 0.1254 ± 0.0039 1.5827 ± 0.0514 
200 µg/kg/day DEHP 30.29 ± 0.62 0.0199 ± 0.0018 0.1363 ± 0.0129 1.3443 ± 0.0592 
  20 mg/kg/day DEHP 31.82 ± 1.76 0.0183 ± 0.0007 0.1467 ± 0.0183 1.5889 ± 0.1343 
200 mg/kg/day DEHP 30.97 ± 1.37 0.0161 ± 0.0009 0.1383 ± 0.0195 1.4389 ± 0.1071 
  20 µg/kg/day DiNP 31.09 ± 0.68 0.0199 ± 0.0016 0.1207 ± 0.0092 1.3353 ± 0.0368 
100 µg/kg/day DiNP 30.75 ± 1.42 0.0215 ± 0.0023 0.1534 ± 0.0141 1.3968 ± 0.0615 
  20 mg/kg/day DiNP 32.56 ± 0.97 0.0218 ± 0.0022 0.1512 ± 0.0317 1.5541 ± 0.0564 
200 mg/kg/day DiNP 30.06 ± 0.79 0.0210 ± 0.0017 0.1492 ± 0.0185 1.3395 ± 0.0299 
9 Months Post-Dosing 
Control 48.78 ± 1.71 0.0290 ± 0.0004 0.2102 ± 0.0202 2.0953 ± 0.0656 
   20 µg/kg/day DEHP 42.38 ± 2.07 0.0280 ± 0.0044 0.1818 ± 0.0142 1.8339 ± 0.1252 
 200 µg/kg/day DEHP 44.50 ± 3.11 0.0244 ± 0.0042 0.2083 ± 0.0317 1.8429 ± 0.1250 
  20 mg/kg/day DEHP 48.07 ± 2.99 0.0277 ± 0.0043 0.1663 ± 0.0165 2.0197 ± 0.0931 
200 mg/kg/day DEHP 44.78 ± 2.80 0.0224 ± 0.0038 0.2068 ± 0.0256 1.9930 ± 0.0844 
   20 µg/kg/day DiNP 45.63 ± 3.36 0.0294 ± 0.0027 0.2036 ± 0.0382 1.7889 ± 0.0613 
 100 µg/kg/day DiNP 46.14 ± 3.81 0.0343 ± 0.0091 0.2190 ± 0.0385 1.9513 ± 0.0497 
  20 mg/kg/day DiNP 45.86 ± 5.14 0.0197 ± 0.0020 0.1759 ± 0.0234 2.0728 ± 0.2606 
200 mg/kg/day DiNP 47.75 ± 4.93 0.0236 ± 0.0048 0.2060 ± 0.0406 1.8549 ± 0.1936 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were euthanized in diestrus either immediately post-dosing (n = 6-12 mice/group), 3 months 
post-dosing (n = 5-12 mice/group), or 9 months post-dosing (n = 4-12 mice/group) and body 
weight and organ weights were measured.  Data are represented as means ± standard error.  
Statistically significant difference when compared to control (p ≤ 0.05) is denoted with an 





Figure 3.1 Effects of DEHP and DiNP on estrous cyclicity 
 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were vaginally lavaged daily for two weeks to assess estrous cyclicity three months post-dosing 
(n = 12-22 mice/group) and again nine months post-dosing (n = 11-22 mice/group).  Data are 
represented as means ± standard error.  Statistically significant difference when compared to 
control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 




Figure 3.2  Effects of DEHP and DiNP on time to mating 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day). Females 
were mated with untreated male mice for breeding trials immediately post-dosing (Panel A, n = 
7-21 mice/group), three months post-dosing (Panel B, n = 7-18 mice/group), and nine months 
post-dosing (Panel C, n = 10-20 mice/group) and checked every morning and afternoon until a 
copulatory plug was observed or until 14 days had elapsed.  Time to mating was calculated as the 
days between male introduction and observation of a copulatory plug.  Data are represented as 
means ± standard error.  Statistically significant difference when compared to control (p ≤ 0.05) 
is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 0.10) is denoted 






Figure 3.3 Effects of DEHP and DiNP on fertility index 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing (Panel A, n = 
12-23 mice/group), three months post-dosing (Panel B, n = 11-22 mice/group), and nine months 
post-dosing (Panel C, n = 10-22 mice/group).  The fertility index was calculated by dividing the 
number of females who successfully achieved pregnancy by the number of females who 
presented with a copulatory plug and multiplying by 100. Data are represented as percentages.  
Statistically significant difference when compared to control (p ≤ 0.05) is denoted with an 







Figure 3.4 Effects of DEHP and DiNP on gestational index 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing (Panel A, n = 
11-23 mice/group), three months post-dosing (Panel B, n = 6-21 mice/group), and nine months 
post-dosing (Panel C, n = 6-18 mice/group).    The gestational index was calculated by dividing 
the number of females who gave birth to pups by the number of females who successfully 









Figure 3.5 Effects of DEHP and DiNP on gestation length 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing (Panel A, n = 
8-20 mice/group), three months post-dosing (Panel B, n = 3-17 mice/group), and nine months 
post-dosing (Panel C, n = 6-14 mice/group).    Gestation length was calculated by using the day a 
copulatory plug was observed as day 0.5 of pregnancy.  Data are represented as means ± 









Figure 3.6 Effects on DEHP and DiNP on the ability of females to produce pups 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing (Panel A, n = 
11-23 mice/group), three months post-dosing (Panel B, n = 11-22 mice/group), and nine months 
post-dosing (Panel C, n = 11-22 mice/group).  The percent of females who gave birth was 
calculated by dividing the number of females who produced pups by the total number of females 
in that treatment group and multiplying by 100. Data are represented as percentages.  Statistically 
significant difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  







Figure 3.7 Effects of DEHP and DiNP on litter size and average live pup weight 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing, three months 
post-dosing, and nine months post-dosing.  Live and dead pups were counted to determine the 
litter size on PND 0 (Panels A, B, and C, n = 8-19 mice/group, n = 5-18 mice/group, and n = 4-
14 mice/group, respectively).  Live pups were weighed collectively and an average was taken on 
PND 0 to determine the average live weight (Panels D, E, and F, n = 8-19 mice/group, n = 5-16 
mice/group, and n = 4-15 mice/group, respectively). Data are represented as means ± standard 
error.  Statistically significant difference when compared to control (p ≤ 0.05) is denoted with an 





Figure 3.8 Effects of DEHP and DiNP on pup mortality and sex ratio 
 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day – 200 mg/kg/day), or DiNP (20 µg/kg/day – 200 mg/kg/day).  Females 
were mated with untreated male mice for breeding trials immediately post-dosing, three months 
post-dosing, and nine months post-dosing.  Pup mortality was calculated by dividing the number 
of dead pups by the total number of pups within the litter and multiplying by 100 (Panels A, B, 
and C, n = 9-19 mice/group, n = 5-20 mice/group, and n = 3-13 mice/group, respectively).  The 
male to female ratio was calculated by dividing the number of male pups by the number of 
female pups for each litter and multiplying by 100 (Panels D, E, and F, n = 9-18 mice/group, n = 
4-14 mice/group, and n = 4-11 mice/group, respectively). Data are represented as means ± 
standard error.  Statistically significant difference when compared to control (p ≤ 0.05) is 
denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 0.10) is denoted with 
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Exposure to Di(2-ethylhexyl) Phthalate and Diisononyl Phthalate During Adulthood 
Disrupts Hormones and Ovarian Folliculogenesis Throughout the Prime Reproductive Life 
of the Mouse 
4.1 Abstract 
Di(2-ethylhexyl) phthalate (DEHP) is a phthalate commonly used for its plasticizing capabilities. 
Because of the wide production and use of DEHP, humans are exposed to DEHP on a daily 
basis.  Diisononyl phthalate (DiNP) is often used as a DEHP replacement chemical, and because 
of the increased use of DiNP, humans are increasingly exposed to DiNP over time.  Of concern 
is that DEHP and DiNP both exhibit endocrine disrupting capabilities, and little is known about 
how short-term exposure to either of these phthalates affects aspects of female reproduction.  
Thus, this study tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood has long-lasting consequences on ovarian follicles and hormones in female mice.  
Female CD-1 mice aged 39-40 days were orally dosed with either vehicle control (corn oil), 
DEHP (20 µg/kg/day–200 mg/kg/day), or DiNP (20 µg/kg/day–200 mg/kg/day) for 10 days.  
Ovarian follicle populations, estradiol, testosterone, progesterone, follicle stimulating hormone 
(FSH), and inhibin B were analyzed at time points immediately post-dosing and 3, 6, and 9 
months post-dosing.  The results indicate that 10 days of exposure to DEHP and DiNP changed 
the distribution of ovarian follicle populations, quality of follicles, and sex steroid hormones at 
multiple time points, including the last time point, 9 months post-dosing.  Further, FSH was 
increased at multiple doses up to 6 months post-dosing.  Inhibin B was not affected by treatment. 
These data show that short-term exposure to either DEHP or DiNP has long-term consequences 





Maintenance of female fertility is a carefully controlled event with multiple inputs and feedback 
loops.  Namely, female fertility is maintained by the cyclical rise and fall of a variety of 
hormones at key time points throughout the cycle.  In females, the hypothalamus releases 
gonadotropin releasing hormone (GnRH), which travels to the pituitary via the hypophyseal 
portal system.  Once GnRH arrives in the pituitary, it stimulates specialized cells called 
gonadotropes to release the gonadotropins, follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) [1].  FSH and LH are key components in proper development of the ovarian 
follicles, and LH initiates ovulation, which releases the mature oocyte for fertilization [2].  The 
follicle is also a major player in the maintenance of female fertility.  The follicle is the primary 
site of production of sex steroid hormones, including estradiol, testosterone, and progesterone.  
These hormones also contribute to the cyclic nature of female fertility, and they can exert both 
positive and negative feedback at the level of the hypothalamus, pituitary, or even at the level of 
the ovary by acting on neighboring follicles [1, 3].  Additionally, they play roles in mating 
behavior as well as receptivity of the endometrial lining to an implanting embryo [4, 5].  Thus, 
disruption of the hormonal profiles may lead to disruption of follicular development and vice 
versa.  In addition to disruption of fertility, altering levels of sex steroid hormones can elicit 
negative effects on somatic health.  Disruption of the hormonal milieu in females has been linked 
to several negative health outcomes including cardiovascular disease, stroke, osteoporosis, and 
increased mortality [6-10], thus making reproductive health important for the overall health of 





Concerningly, a variety of environmental contaminants have been designated as endocrine 
disrupting chemicals that can impact the reproductive and overall health of exposed individuals.  
One such class of environmental endocrine disruptors is phthalates.  Di(2-ethylhexyl) phthalate 
(DEHP) is a prominent member of the phthalate family and is commonly found in consumer 
products such as shower curtains, furniture and car upholstery, baby toys, medical tubing, and 
blood storage bags [12].  Because of the use of DEHP in a variety of consumer products, humans 
are ubiquitously exposed to DEHP on a daily basis at an estimated daily intake of 3-30 
µg/kg/day for a 70kg adult [12].  This is concerning because DEHP is an endocrine disruptor.  
Multiple studies have found that DEHP is associated with reduced anogenital distance, a marker 
of fetal androgens, at birth in humans [13], and DEHP has been shown to transgenerationally 
disrupt female reproductive parameters in animal studies [14, 15].  Further, DEHP is associated 
with reproductive disorders in women [11, 16].  One study found that women diagnosed with 
endometriosis had higher serum levels of DEHP than women without endometriosis [17], and 
another study found that urinary DEHP metabolites were associated with increased uterine 
volume, which is used as a proxy for burden of uterine fibroids in women [18]. 
 
Diisononyl phthalate (DiNP) is another member of the phthalate family.  Although a less 
prominent member of this family, DiNP production has been rising over the past several years 
[19], and subsequently, humans are being exposed to greater levels of DiNP as evidenced by 
rapidly increasing levels of DiNP metabolites in human urine samples [20].  Because DiNP is 
commonly used as a substitute for DEHP, it can be found in many of the same products [19, 21].  
However, few studies have been conducted that explore the reproductive consequences of 




is present indicates that DiNP has endocrine disrupting capabilities.  For example, DiNP has 
been associated with reduced semen quality parameters and reduced testosterone in men in 
epidemiological studies [13].  Additionally, one animal study found that in utero exposure to 
DiNP reduces intratesticular testosterone in fetal rats [22], and previous studies have suggested 
the anti-androgenic effects of DiNP act through similar mechanisms of action as DEHP [23].  
DiNP has also been shown to have negative effects in females.  A study investigating 
reproductive outcomes in couples found that women with higher levels of serum DiNP had 
increased time to pregnancy [24].  Additionally, an animal study found that rats exposed through 
the maternal diet during gestation had reduced corpora lutea in the ovary at postnatal week 11 
when compared to controls [25].  Although these aforementioned studies have investigated the 
effects of DiNP on both male and female reproduction, a significant lack of studies that utilize 
environmentally relevant doses exists, and few studies have investigated the effects of DiNP 
exposure on follicle populations within the ovary or hormone levels in exposed females.  
 
This study was designed to fill the gap in knowledge concerning the effects of short-term 
exposure to DEHP and DiNP during adulthood on major reproductive hormones and follicle 
populations within the ovary in female mice.  Previously, our laboratory has shown that short-
term exposure to both DEHP and DiNP affects cyclicity and fertility for up to nine months 
following completion of dosing [26, 27].  However, it is still unknown if short-term exposure to 
DEHP or DiNP during adulthood affects follicle populations and hormones, including sex steroid 
hormones and peptide hormones.  Thus, this study tested the hypothesis that short-term exposure 





4.3 Materials and Methods 
Chemicals 
DEHP and DiNP were purchased from Sigma-Aldrich (St. Louis, MO).  Corn oil (vehicle 
control) was purchased from MP Biomedicals (Solon, OH).  Dosing stock solutions were created 
by serially diluting from the highest dose down to the lowest dose.  Batches of stock solutions 
were stored at room temperature away from light for up to a month. 
 
Animals and Dosing 
Female CD-1 mice were purchased from Charles River (Wilmington, MA) and housed in the 
College of Veterinary Medicine Animal Facility at the University of Illinois at Urbana-
Champaign (Urbana, IL).  Mice were allowed to acclimate to facilities for a minimum of 5 days 
before the dosing period started.  Ambient temperature was maintained at 21.1 ± 2.2˚C with 
humidity at 50 ± 20%.  Mice were given ad libitum access to reverse osmosis-treated water and 
Teklad Rodent Diet (8604).  Mice were kept on 12 hour light-dark cycles.  All procedures 
involving animal handling were approved by the University of Illinois at Urbana-Champaign 
Institutional Animal Care and Use Committee (Protocol No.: 17079).   
 
Mice were dosed orally via pipette at age 39-40 days with either vehicle control (corn oil), 
DEHP (20 µg/kg/day, 200 µg/kg/day, 20 mg/kg/day, 200 mg/kg/day), or DiNP (20 µg/kg/day, 
100 µg/kg/day, 20 mg/kg/day, 200 mg/kg/day) for 10 consecutive days every morning at 2 hours 
following the start of the light cycle.  Mice were weighed daily prior to dosing to determine the 




were group housed 3 to a cage, and all 3 mice within a single cage were assigned to the same 
treatment group. 
 
The doses above were chosen because the 20 µg/kg/day DEHP dose is within the estimated 
range for average daily exposure for a 70kg adult (3-30 µg/kg/day) [12].  The 200 µg/kg/day 
DEHP dose falls within the range for those that are occupationally exposed (143-286 µg/kg/day) 
[28]. The 20 and 200 mg/kg/day DEHP doses were chosen because they have been used in 
previous toxicological studies and also allow us to investigate a wide range of doses [15, 29, 30].  
The doses for DiNP were chosen for similar reasons.  The 20 µg/kg/day DiNP dose falls within 
the estimated range for occupational exposure (up to 26 µg/kg/day) [31].  The 100 µg/kg/day 
DiNP dose is within the estimated range of exposure for infants who are chewing on plastic toys 
(up to 260 µg/kg/day) [32].  Lastly, the 20 and 200 mg/kg/day DiNP doses were chosen because 
we wanted to directly compare the toxicity of DiNP to DEHP by using similar doses when 
possible. 
 
Experimental Design  
Groups of animals were euthanized via CO2 asphyxiation at different periods following 
completion of dosing; immediately post-dosing, 3 months post-dosing, 6 months post-dosing, 
and 9 months post-dosing.  All animals were euthanized in the diestrous stage of the estrous 







Enzyme-Linked Immunosorbent Assays 
Blood was collected in a heparinized needle and allowed to clot at room temperature for a 
minimum of 15 minutes, followed by a minimum of 15 minutes in ice.  Blood samples were then 
centrifuged at 4 °C at 14,000 RPM for 15 minutes.  Sera that were separated out were collected 
and stored at -80 °C until use.  Testosterone, progesterone, and estradiol ELISA kits were 
purchased from DRG®.  Lypocheck® from Bio-Rad Laboratories was used as a control with 
known values for all DRG® ELISA kits.  The limit of detection (LOD) for testosterone, 
progesterone, and estradiol was 0.083 ng/mL, 0.045 ng/mL, and 10.60 pg/mL, respectively.  The 
inter- and intra-assay %CVs were ≤ 9.94 and ≤ 4.16, ≤ 9.96 and ≤ 6.99, and ≤ 14.91 and ≤ 9.23 
for testosterone, progesterone, and estradiol, respectively.  Remaining serum samples were 
aliquoted and sent to the University of Virginia Center for Research in Reproduction Ligand 
Assay and Analysis Core for analysis of levels of FSH and inhibin B.  The LODs for FSH and 
inhibin B were 1.6 ng/mL and 35 pg/mL, respectively.  Intra- and inter-assay %CVs for FSH 
were 7.2 and 8.5, respectively, and intra- and inter-assay %CVs for inhibin B were 1.8 and 6.6, 
respectively (https://med.virginia.edu/research-in-reproduction/wp-
content/uploads/sites/311/2019/04/2019-INTRA-INTER-ASSAY-CVs__030419.pdf).  Samples 
below the LOD were analyzed using the LOD value specific to the assay divided by the square 
root of 2. 
 
Histological Evaluation of Ovarian Tissues  
Ovaries were dissected out of mice, cleaned of gonadal fat, and fixed in Dietrich’s solution.  
Tissues remained in the fixative overnight at minimum and then were transferred to 70% ethanol 




microscope slides and stained with hematoxylin and eosin.  Every 10th serial section was used to 
assess follicle populations using previously defined criteria [33, 34]. Primordial follicles were 
designated as oocytes with a single layer of squamous granulosa cells, primary follicles were 
designated as oocytes surrounded by a single layer of cuboidal granulosa cells, preantral follicles 
were designated as oocytes surrounded by more than one layer of cuboidal granulosa cells, and 
antral follicles were designated as oocytes surrounded by multiple layers of cuboidal granulosa 
cells with a distinct fluid filled antrum [15, 27].  Atretic follicles were follicles that had apoptotic 
bodies composing 10% or more of the area of the antral follicle.  Only follicles with 
multinucleated oocytes, multiple oocytes, or fragmented oocytes were counted as abnormal.  
Nuclei must have been present in all abnormal follicle types and preantral and antral follicles to 
be counted to assure that one follicle was not counted twice across sections.  Presence of the 
nucleus was not required for counting primordial or primary follicles because the follicles are too 
small to span multiple sections at this stage.  Each ovary was assigned a unique ID with no 
information about treatment group to blind counters to treatment and prevent bias.  Data were 
analyzed as raw counts, which give a perspective on total follicles in each category, and as 
percentages, which allows analysis of the rate of maturation of follicles.  Percentages were 
achieved by taking the raw number of a particular follicle type, dividing by the total number of 
follicles and multiplying by 100.  All follicle types, including unhealthy, were summed together 
to determine the total number of follicles. Ovarian follicle population data for the DEHP 
treatment groups in the immediately post-dosing time point are not included herein because a 
study conducted by our research group previously published data on the immediate consequences 






Outliers for normally distributed data were identified and removed from analysis via Grubb’s 
Test.  If data met the assumptions of normality and homogeneity of variance, then a one-way 
analysis of variance (ANOVA) was used and followed by Dunnett T 2-sided tests.  If data were 
non-parametric, not normally distributed, or lacked homogeneity of variance, then the Mann-
Whitney U test was used to compare treatment to control.  Significance was assigned at p ≤ 0.05. 
 
4.4 Results and Discussion 
This study tested the hypothesis that short-term exposure to DEHP and DiNP alters ovarian 
follicle populations and levels of circulating hormones.  Previously, we have shown that short-
term exposure to DEHP during adulthood disrupts estrous cyclicity up to 9 months following 
completion of dosing [27].  Additionally, a previous study from our research group showed that 
short-term exposure to DiNP can negatively impact female reproduction as long as 9 months 
following completion of dosing [26].  The current study builds upon this previous knowledge by 
assessing the effects of short-term exposure to DEHP and DiNP on ovarian follicle populations 
and hormone levels at time points where fertility has been disrupted in previous studies.  Further, 
this study fills a gap in knowledge concerning the effects of DiNP on female reproduction.   
 
4.4.1 Effects of DEHP and DiNP on ovarian follicle populations 
Immediately Post-Dosing 
A previous study in our lab found that 10 days of exposure to DEHP immediately disrupted 
folliculogenesis [29].  In the present study, we investigated the immediate effects of 10 days of 




raw numbers of primordial follicles (Fig. 4.1A, n = 5-11 mice/group, p ≤ 0.05) and borderline 
decreased the number of antral follicles when compared to control (Fig. 4.1A, n = 5-11 
mice/group, p = 0.08).  Analysis of follicles by percentages revealed that 20 µg/kg/day of DiNP 
borderline increased the percent of antral follicles when compared to control (Fig. 4.1B, n = 5-12 
mice/group, p = 0.08).  Additionally, 20 mg/kg/day of DiNP increased percent of abnormal 
follicle types when compared to control (Fig. 4.1C, n = 6-11 mice/group, p ≤ 0.05).  DiNP did 
not affect total follicle numbers when compared to control (data not shown).   
 
Female fertility is maintained by a steady stream of growing follicles, thus, disruption of 
folliculogenesis can alter female fertility.  It is possible that DiNP is accelerating the rate at 
which preantral follicles are developing into antral follicles, leading to an abnormally high 
percent of antral follicles.  Further, the decrease in primordial follicles caused by DiNP is 
concerning because females are born with a finite number of primordial follicles.  Thus, targeting 
of the primordial follicle population can shorten the reproductive life of the affected individual.  
We find the differences between DiNP in the current study and DEHP in the previous study 
interesting [29].  The current findings suggest DEHP and DiNP target different follicles and/or 
different aspects of folliculogenesis, even when administered for the same time and at the same 
doses. 
 
3 Months Post-Dosing 
At 3 months post-dosing, DEHP and DiNP did not affect raw numbers of healthy follicle types 
compared to control (Fig. 4.2A, n = 4-11 mice/group).  Interestingly, when follicle numbers were 




and increased the percent of primary follicles when compared to control (Fig. 4.2B, n = 4-11 
mice/group, p ≤ 0.05).  Treatment with 200 µg/kg/day of DEHP decreased percentage of 
abnormal follicle types (Fig. 4.2C, n = 4-11 mice/group, p = 0.06), and 20 µg/kg/day of DEHP 
similarly decreased percent of atretic follicles when compared to control (Fig. 4.2C, n = 4-11 
mice/group, p = 0.08).  Treatment with DEHP and DiNP did not affect total follicle numbers 
when compared to control (data not shown).    
 
The alteration of follicle population proportions induced by DiNP is characteristic of accelerated 
folliculogenesis, an event in which follicles mature at faster rates than is normal and may result 
in early entry into reproductive senescence.  This is concerning because of the myriad of 
negative health that are outcomes associated with premature ovarian failure [6-9].  The reduction 
in abnormal and atretic follicles in some DEHP treatment groups contrasts with some literature 
that reported increased follicular atresia due to in vitro and lactational DEHP exposure [35, 36].  
However, a previous study in our laboratory found that antral follicles treated with an 
environmentally relevant mixture of phthalates exhibited reduced atresia, possibly due to 
treatment-induced cell cycle arrest [37].  Thus, it is possible that DEHP may be acting on genes 
involved in cell cycle regulation and subsequently decreasing rates of atresia. It is also possible 
that DEHP may have upregulated metabolic enzymes and increased clearance of unhealthy 
and/or dying oocytes, thus giving the appearance of fewer unhealthy follicles, but in actuality 
only upregulating clearance. The discrepancies seen between the two chemicals further suggests 
that they may have different potencies or act through different mechanisms to alter 
folliculogenesis and follicular health.  In a previous study, we found that treatment with 20 




post-dosing.  The lack of effects seen in those treatment groups on follicular populations and 
health at this time point suggests that the mechanism through which DEHP and DiNP disrupted 
female fertility in the previous study likely does not lie in alteration of follicle populations, 
follicular health, or folliculogenesis [26]. 
 
6 Months Post-Dosing 
At 6 months post-dosing, 200 µg/kg/day DEHP and 100 µg/kg/day and 20 mg/kg/day DiNP 
increased numbers of primary follicles when compared to control (Fig. 4.3A, n = 5-11 
mice/group, p ≤ 0.05).  Effects were slightly different when follicles were analyzed as 
percentages.  The 200 mg/kg/day dose of DiNP increased the percent of primary follicles (Fig. 
4.3B, n = 4-11 mice/group, p ≤ 0.05) and borderline decreased the percent of preantral follicles 
when compared to control (Fig. 4.3B, n = 5-11 mice/group, p = 0.10).  Further, 20 µg/kg/day 
DiNP (Fig. 4.3B, n = 5-11 mice/group, p ≤ 0.05) and 100 µg/kg/day DiNP (Fig. 4.3B, n = 5-11 
mice/group, p ≤ 0.05) treatment groups had decreased percentages of antral follicles when 
compared to control.  Additionally, 20 µg/kg/day DEHP (Fig. 4.3C, n = 5-11 mice/group, p = 
0.08) and 200 mg/kg/day DiNP (Fig. 4.3C, n = 5-11 mice/group, p = 0.06) increased the percent 
of abnormal follicles in the ovary when compared to control.  No effects were observed on total 
follicle numbers due to treatment (data not shown).   
 
The observed increases in raw and percent of primary follicles suggest that some disruption of 
folliculogenesis still persists at 6 months post-dosing.  It is possible that more primordial follicles 
are being recruited to grow into primary follicles and fewer primary follicles are being signaled 




advancement of follicles past the primary stage could also explain the decrease in the percent of 
preantral and antral follicles observed in some of the DiNP treatment groups.   
 
The sudden reappearance of an increase in abnormal follicle types due to treatment was 
unexpected in light of the absence of effects on the percent of abnormal follicles at the 3 month 
post-dosing time point.  It is possible that follicles that were exposed during the treatment period 
had continued to grow and began to display increasing rates of abnormalities as time elapsed, 
leading to an increase in abnormal follicles.  Finding that DiNP elicited more effects at this time 
point than DEHP was surprising because DiNP has been purported to be less reproductively 
toxic when compared to DEHP [38].  Future studies should investigate potential alterations of 
expression of genes involved in folliculogenesis and maintenance of oocyte heath to help 
elucidate the mechanism through which DEHP and DiNP are acting. 
 
9 Months Post-Dosing 
At 9 months post-dosing, 20 and 200 mg/kg/day of DEHP significantly increased the number of 
preantral follicles in treated mice when compared to control (Fig. 4.4A, n = 5-12 mice/group, p ≤ 
0.05).  No other effects due to treatment were seen on raw follicle numbers for other follicle 
types or total follicles.  However, percent of follicles by type was affected by treatment at the 9 
months post-dosing time point.  Mice treated with 20 µg/kg/day of DiNP had significantly 
decreased percentages of primary follicles when compared to control (Fig. 4.4B, n = 5-12 
mice/group, p ≤ 0.05).  Further, 200 µg/kg/day (Fig. 4.4B, n = 5-12 mice/group, p = 0.10) and 20 
and 200 mg/kg/day of DEHP (Fig. 4.4B, n = 5-12 mice/group, p ≤ 0.05) increased the percent of 




DEHP borderline decreased the percent of antral follicles when compared to control (Fig. 4.4B, n 
= 5-12 mice/group, p = 0.07).  DEHP and DiNP did not affect percent of unhealthy follicles (Fig. 
4.4C, n = 5-12 mice/group) total follicle numbers when compared to control (data not shown). 
 
These results suggest that DEHP disrupts folliculogenesis and is altering the rate of advancement 
through the stages of follicular growth.  Several genes are involved in the transition from the 
preantral to antral stage of the follicle, and during this transition, the follicles convert from FSH-
independent growth to FSH-dependent growth.  Thus, it is possible some genes involved in 
follicle development are affected by treatment in addition to potential disruption of the follicle’s 
ability to respond to FSH.  Further studies should investigate the effects of DEHP and DiNP on 
the expression of genes involved in the transition of follicles through stages of growth. 
 
4.4.2 Effects of DEHP and DiNP on hormone levels 
Immediately Post-Dosing 
Immediately following completion of dosing, DEHP and DiNP both altered the levels of several 
different hormones at multiple doses.  Treatment with 20 and 100 µg/kg/day and 200 mg/kg/day 
of DiNP significantly reduced testosterone levels when compared to control (Fig. 4.5A, n = 6-12 
mice/group, p ≤ 0.05).  Treatment with 200 mg/kg/day of DEHP (Fig. 4.5B, n = 5-11 
mice/group, p ≤ 0.05) and 20 mg/kg/day DiNP (Fig. 4.5B, n = 5-11 mice/group, p = 0.10) 
increased progesterone levels when compared to control.  Additionally, DEHP (20 mg/kg/day) 
and DiNP (100 µg/kg/day and 200 mg/kg/day) significantly decreased levels of estradiol when 
compared to control (Fig. 4.5C, n = 5-12 mice/group, p ≤ 0.05), and 20 µg/kg/day of DiNP 




p = 0.10).  Further, 20 µg/kg/day and 20 mg/kg/day of DEHP increased levels of FSH (Fig. 4.6A, 
n = 4-11 mice/group, p ≤ 0.05), and treatment with 100 µg/kg/day of DiNP borderline increased 
levels of FSH when compared to control (Fig. 4.6A, n = 4-11 mice/group, p = 0.09).  No 
differences due to treatment were detected for inhibin B at this time point, although some 
treatment groups lacked adequate number of samples to statistically analyze due to insufficient 
volume of serum samples from some mice (Fig. 4.6B, n = 1 for 20 and 100 µg/kg/day DiNP 
treatment groups, all other groups n = 3-9 mice/group). 
 
Although DEHP and DiNP tended to illicit similar effects, we found the differences in how these 
chemicals affected testosterone interesting. Previous studies conducted in our research group 
using in utero and in vitro exposure paradigms have shown that DEHP decreases levels of 
testosterone when compared to control [15, 36]. However, another study that orally dosed 
pregnant mice found an increase in maternal testosterone when compared to control [39].  Thus, 
the discrepancies observed between the present study and previous studies conducted in our 
laboratory are likely due to differences in timing of exposure.  In addition, a study using a short-
term exposure to DEHP during adulthood paradigm, but in dairy cattle, found that DEHP 
reduced levels of estradiol, further highlighting the different impacts exposure duration and 
timing can have on outcome [40].  In terms of DiNP, epidemiological literature agrees with the 
findings in this study that DiNP has anti-androgenic properties and is associated with lower 
testosterone in men [13].  A proposed mechanism of action of DEHP is that the primary 
bioactive metabolite of DEHP, mono(2-ethylhexyl) phthalate (MEHP), activates peroxisome 
proliferator-activated receptors (PPARs) α and γ, which both downregulate expression of 




testosterone to estradiol [41].  Thus, it is possible that these phthalates may be acting through 
altering steroidogenic enzyme expression within the ovary.  Interestingly, although we observed 
wide disruption of sex steroid hormones at this time point, in a previous study, we did not 
observe any effects on fertility endpoints in mice bred immediately post-dosing, suggesting that 
disrupting hormones alone is not sufficient to disrupt female fertility at this time point [26].  
 
In terms of FSH, a  previous study in our laboratory found that transgenerational exposure to 
DEHP affected FSH differently in different generations in mice that were one year of age [14].  
Further, a study investigating the associations between urinary DEHP and DiNP metabolites and 
FSH in healthy Danish men found contrasting results and reported that both DEHP and DiNP 
metabolites were associated with reductions in FSH [42].  However, DEHP-induced increases in 
FSH were also observed in a study conducted in male mice orally dosed during adulthood, a 
paradigm that strongly resembles the one in the current study [43].  Although lack of serum 
volume prevented statistical analysis of inhibin B levels for some treatment groups, the lack of 
effects seen with inhibin B by treatment was not surprising due to the lack of dramatic effects 
seen on the follicle populations responsible for inhibin B production.  Further, the previously 
mentioned study in Danish men also found no associations between urinary DEHP and DiNP 
metabolites and inhibin B [42]. Interestingly, DEHP and DiNP seem to follow similar trends in 
their effects, and they tend to have effects in similar directions when compared to control.   
 
3 Months Post-Dosing 
After 3 months following completion of dosing, there were fewer effects observed on the sex 




µg/kg/day dose of DiNP significantly decreased levels of testosterone and progesterone when 
compared to control (Fig. 4.7A, n = 5-12 mice/group, p ≤ 0.05).  Further, 20 µg/kg/day of DiNP 
borderline decreased levels of progesterone (Fig. 4.7B, n = 5-12 mice/group, p = 0.08), and 200 
mg/kg/day of DiNP borderline increased levels of estradiol when compared to control (Fig. 4.7C, 
n = 5-12 mice/group, p = 0.08).  Additionally, the 20 mg/kg/day dose of DiNP borderline 
increased levels of FSH when compared to control (Fig. 4.8A, n = 5-12 mice/group, p = 0.08), 
and no effects due to treatment were seen on levels of inhibin B (Fig. 4.8B, n = 4-11 
mice/group). 
 
Fewer overall effects on hormone levels were observed at 3 months post-dosing when compared 
to immediately post-dosing time point.  However, the 100 µg/kg/day DiNP treatment group had 
persistently reduced testosterone, while other treatment groups had recovered.  Interestingly, we 
also observed an inversion of the effects of treatment on progesterone and estradiol, and at this 
time point DiNP decreased levels of progesterone and increased levels of estradiol.  A previous 
study using porcine granulosa cells in culture found that DEHP and DiNP did not affect basal 
levels of progesterone or estradiol, but did find that DiNP decreased FSH-induced estradiol when 
compared to control [44]. These results contrast with our study and highlight the different effects 
that can be elicited by different exposure paradigms and also suggest that DiNP may be affecting 
metabolism of these enzymes and not solely the ability of the granulosa cells to produce these 
hormones.  Further, it is possible that species differences, along with differences in exposure 
paradigms, may attribute to the discrepancies observed between this study and the present study.  
The inversion of the effects of DiNP on estradiol (decreased immediately post-dosing and 




production was upregulated at the 3 month post-dosing time point to compensate for the 
reduction seen at the immediately post-dosing time point and that levels had yet to return to 
baseline.   
 
At 3 months post-dosing, FSH was modestly increased in the 20 mg/kg/day DiNP treatment 
group, but otherwise was unaffected by treatment.  We find the greater propensity of DiNP to 
increase FSH for a longer time than DEHP interesting because DiNP is thought to be less potent 
than DEHP [38].  In terms of inhibin B, results at 3 months post-dosing are similar to the 
immediately post-dosing time point, and inhibin B remained unaffected by treatment with either 
DEHP or DiNP.   
 
6 Months Post-Dosing 
Following 6 months after completion of dosing, 100 µg/kg/day of DiNP significantly reduced 
levels of testosterone in mice when compared to control, an effect seen at all previous time 
points (Fig. 4.9A, n = 6-12 mice/group, p ≤ 0.05).  Additionally, 200 µg/kg/day of DEHP 
significantly increased circulating levels of estradiol when compared to control (Fig. 4.9C, n = 5-
12 mice/group, p ≤ 0.05).  However, no effects of DEHP and DiNP were seen on progesterone at 
any dose when compared to control (Fig. 4.9B, n = 6-12 mice/group).  The 20 and 200 
mg/kg/day doses of DEHP both significantly increased levels of FSH when compared to control 
(Fig. 4.10A, n = 4-12 mice/group, p ≤ 0.05).  In contrast, inhibin B continued to be unaffected by 





The DEHP-induced increase in estradiol contrasts with previous in vitro studies conducted by 
our research group [36, 45], but agrees with in vivo studies from our research group that have 
investigated the transgenerational effects of DEHP exposure [14, 15] as well as in vivo studies 
from other laboratories [46, 47].  In terms of DiNP, previous epidemiological studies have found 
that DiNP is associated with reduced testosterone [13], but we find this result particularly 
interesting because of its persistence and consistency in this treatment group.   
 
We found the sudden and drastic reappearance of DEHP-induced increases in FSH surprising, 
especially in light of the lack of effects of DEHP on FSH observed at the previous time point.  
Because DEHP and DiNP are purported to act through similar mechanisms, the difference in 
effects between DEHP and DiNP was also surprising.  This drastic increase in FSH was not 
accompanied by concurrent alterations of follicles nor sex steroid hormones, suggesting that the 
follicles may not be responding to FSH signals correctly.  It is important for future studies to 
investigate the effects of phthalate exposure on expression of key female reproductive hormones 
and their receptors to better understand the mechanisms through which DEHP and DiNP may be 
acting. 
 
9 Months Post-Dosing 
At 9 months post-dosing, the only effect seen was a borderline increase in testosterone in the 200 
µg/kg/day of DEHP treatment group when compared to control (Fig. 4.11A, n = 5-12 
mice/group, p = 0.09).  Progesterone, estradiol, FSH, and inhibin B were not affected by 




Interestingly, the observed  effect deviates from all previous time points where, if an effect was 
observed, testosterone was decreased with treatment.  Although a DEHP-induced increase in 
testosterone conflicts with previous transgenerational in vivo studies in our laboratory using a 
prenatal exposure window [14, 15], other studies have found that DEHP’s metabolite, MEHP, 
can increase levels of testosterone in culture [48, 49], further highlighting the different effects 
that can be elicited from exposure during different windows and through different routes.  In 
terms of DiNP, we no longer observed the reduced testosterone levels in the 100 µg/kg/day 
DiNP group that had persisted until this time point, further suggesting that some effects can be 
recovered from given enough recovery time.  
 
At 9 months post-dosing, neither FSH nor inhibin B were affected by treatment.  This suggests 
recovery is possible given enough time passage from the exposure period.  However, we were 
surprised inhibin B was not affected because we observed increases in preantral follicles, which 
are responsible for production of inhibin B.  It is possible that the observed increase in preantral 
follicles in some treatment groups is not drastic enough to elicit detectable changes in inhibin B.  
Conversely, it is possible that treatment may be affecting the ability of these follicles to produce 
inhibin B.  Future studies should investigate how DEHP may affect inhibin B production by 
small, growing follicles. 
 
4.4.3 Correlations between follicle numbers and hormones 
Interestingly, the hormone and follicle count data did not always correlate.  This was surprising 
because antral follicles are the primary source of sex steroid hormones in females [3], and 




decreased, increased, or did not affect antral follicle numbers.  These data suggest that the 
mechanism through which DEHP and DiNP affect hormone levels is not solely through 
manipulation of antral follicle numbers, and that it may involve changing the expression or 
activity of enzymes responsible for the synthesis and/or breakdown of hormones.  However, 
immediately post-dosing, the effects of DEHP and DiNP on sex steroid hormones and FSH are 
much more correlative. Treatment groups with reduced estradiol also tended to have increased 
levels of FSH, suggesting that the negative feedback on FSH production exerted by estradiol 
may be alleviated, resulting in increased FSH levels.  Conversely, it is possible these phthalates 
may be interfering with the ability of FSH to stimulate production of estradiol.  Previous studies 
have shown that MEHP in culture with rat granulosa cells decreased the levels of FSH-induced 
estradiol [41].  Thus, it is possible that the increased FSH observed in some treatment groups is 
compensatory and upregulated due to the lack of FSH-induced estradiol production by granulosa 
cells.  Interestingly, the treatment groups that displayed increased progesterone were not the 
same ones that displayed an increase in FSH, indicating the treatment-induced levels of 
progesterone were likely not due to FSH-mediated mechanisms.   
 
Similar to the immediately post-dosing time point, we again observed little correlation between 
our follicle population data and hormones at 3 months post-dosing.  This further suggests that the 
mechanism through which these phthalates alter sex steroid hormones is not solely by altering 
the number of antral follicles in the ovary, and the answer likely lies in alteration of expression 
of key steroidogenic enzymes, metabolic enzymes, or the overall function of the steroidogenic 
cells.  Further, neither the follicle population data nor the hormone data fully explain the 




identical dosing and exposure paradigm [26].  Thus, DEHP and DiNP must be affecting an 
aspect other than the follicles and hormones to reduce fertility.  One study conducted in equine 
oocytes found that acute in vitro exposure to DEHP inhibits oocyte maturation [50], and another 
utilizing acute exposure during adulthood in dairy cattle reported that DEHP decreased 
developmental competence of oocytes [40].  Thus, it is possible that DEHP and DiNP may be 
affecting oocyte quality in a manner that is undetectable via histological evaluation. 
 
At 6 months post-dosing, we observed increases in raw number and percent of primary follicles 
and decreases in percent of antral follicles.  These changes in follicular populations did not 
always correlate with hormonal changes, except in the case of the 100 µg/kg/day DiNP treatment 
group that had both decreased antral follicles and decreased testosterone.  In some DEHP groups, 
we observed an increase in FSH that did not coincide with a decrease in estradiol as was seen at 
the immediately post-dosing time point, suggesting that the elevation in FSH may be directly due 
to treatment as opposed to induced by lower levels of estradiol.  However, increased FSH should 
instigate increased synthesis of both estradiol and progesterone, which was not observed in the 
treatment groups with elevated FSH.  Subsequently, we suspect that treatment affected the ability 
of the follicles to respond to FSH, potentially through manipulation of expression of the receptor 
for FSH (FSHR).  Although few studies have investigated this, some have found that DEHP 
decreases expression of FSHR [51, 52].  Further, one proposed mechanism of action of DEHP is 
that its metabolite, MEHP, may interfere with FSH binding to FSHR [41].  Thus, it is possible 
that the observed increases in FSH are compensatory and due to a lack of response of the follicle 




because treatment did not dramatically affect the follicles responsible for inhibin B production at 
this time point. 
 
At 9 months post-dosing, the most striking effects were treatment-induced increases in preantral 
follicle populations.  Interestingly, the follicle population effects were not reflected in sex steroid 
or peptide hormone levels, which was unexpected.  This further suggests that the mechanisms 
through which DEHP and DiNP act to disrupt hormones and follicle populations are multi-
faceted and merit further investigation.  Further, the observation of any effects at 9 months post-
dosing, our latest time point, was surprising in itself.  This is evidence that short term exposure 
during an adult exposure window has the ability to impart long-lasting effects on the exposed 
individual, and caution should be taken for exposure not only within developmental windows, 
but outside developmental windows as well. 
 
4.5 Conclusion 
Collectively, our data show that short-term exposure to both DEHP and DiNP have negative 
impacts on ovarian function and folliculogenesis throughout the reproductive life of the mouse.  
Interestingly, throughout our study we observed changes in and sometimes inversions of effects 
from timepoint to timepoint, indicating the mechanism or mechanisms through which these 
phthalates are acting are complex.  Although the antral follicle is the primary source of sex 
steroid hormones in females, we did not always find that antral follicle changes correlated with 
hormone changes, suggesting that the mechanism of action does not solely involve changes to 
the antral follicle population.  Some studies have found that phthalates can change steroidogenic 




change how the ovary responds to other endocrine signals [41, 51, 52].  Further, DEHP has been 
shown to be capable of causing oxidative stress in the ovary and affecting oocyte development 
and competency [40, 50, 55].  Thus, there could be a combination of multiple pathways that may 
be contributing to the variety of effects seen in this study and the fertility effects seen in a 
previous study from our laboratory [26].  Future studies should investigate the mechanisms 





















4.6 Figures and Legends 
Figure 4.1 Effects of DiNP on ovarian follicle populations immediately post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle immediately following dosing and the ovaries were collected and processed for 
histological evaluation of the number healthy follicle types (n = 5-11 mice/group) (A), percent of 
healthy follicle types (n = 5-12 mice/group) (B), and percent of unhealthy follicle types (n = 6-11 
mice/group) (C). Data are represented as means ± standard error.  Statistically significant 
difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline 





Figure 4.2 Effects of DEHP and DiNP on ovarian follicle populations at 3 months post-
dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle 3 months post-dosing and the ovaries were collected and processed for histological 
evaluation of the number healthy follicle types (n = 4-11 mice/group) (A), percent of healthy 
follicle types (n = 4-11 mice/group) (B), and percent of unhealthy follicle types (n = 4-11 
mice/group) (C). Data are represented as means ± standard error.  Statistically significant 
difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline 





Figure 4.3 Effects of DEHP and DiNP on ovarian follicle populations at 6 months post-
dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle 3 months post-dosing and the ovaries were collected and processed for histological 
evaluation of the number healthy follicle types (n = 5-11 mice/group) (A), percent of healthy 
follicle types (n = 4-11 mice/group) (B), and percent of unhealthy follicle types (n = 5-11 
mice/group) (C). Data are represented as means ± standard error.  Statistically significant 
difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline 





Figure 4.4 Effects of DEHP and DiNP on ovarian follicle populations at 9 months post-
dosing  
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle 3 months post-dosing and the ovaries were collected and processed for histological 
evaluation of the number healthy follicle types (n = 5-12 mice/group) (A), percent of healthy 
follicle types (n = 5-12 mice/group) (B), and percent of unhealthy follicle types (n = 5-12 
mice/group) (C). Data are represented as means ± standard error.  Statistically significant 
difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline 




Figure 4.5 Effects of DEHP and DiNP on sex steroid hormones immediately post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of testosterone (n = 6-12 mice/group) (A), 
progesterone (n = 5-11 mice/group) (B), and estradiol (n = 5-12 mice/group) (C). Data are 
represented as means ± standard error.  Statistically significant difference when compared to 
control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 







Figure 4.6 Effects of DEHP and DiNP on FSH and inhibin B immediately post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of FSH (n = 4-11 mice/group) (A) and inhibin 
B (n = 1-9 mice/group) (B). Data are represented as means ± standard error.  Statistically 
significant difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  













Figure 4.7 Effects of DEHP and DiNP on sex steroid hormones at 3 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of testosterone (n = 5-12 mice/group) (A), 
progesterone (n = 5-12 mice/group) (B), and estradiol (n = 5-12 mice/group) (C). Data are 
represented as means ± standard error.  Statistically significant difference when compared to 
control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 







Figure 4.8 Effects of DEHP and DiNP on FSH and inhibin B at 3 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of FSH (n = 5-12 mice/group) (A) and inhibin 
B (n = 4-11 mice/group) (B). Data are represented as means ± standard error.  Statistically 
significant difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  













Figure 4.9 Effects of DEHP and DiNP on sex steroid hormones at 6 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of testosterone (n = 6-12 mice/group) (A), 
progesterone (n = 6-12 mice/group) (B), and estradiol (n = 5-12 mice/group) (C). Data are 
represented as means ± standard error.  Statistically significant difference when compared to 
control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 







Figure 4.10 Effects of DEHP and DiNP on FSH and inhibin B at 6 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of FSH (n = 4-11 mice/group) (A) and inhibin 
B (n = 3-11 mice/group) (B). Data are represented as means ± standard error.  Statistically 
significant difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  













Figure 4.11 Effects of DEHP and DiNP on sex steroid hormones at 9 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of testosterone (n = 5-12 mice/group) (A), 
progesterone (n = 5-12 mice/group) (B), and estradiol (n = 5-12 mice/group) (C). Data are 
represented as means ± standard error.  Statistically significant difference when compared to 
control (p ≤ 0.05) is denoted with an asterisk (*).  Borderline statistical significance (0.05 < p ≤ 







Figure 4.12 Effects of DEHP and DiNP on FSH and inhibin B at 9 months post-dosing 
Adult female CD-1 mice were orally dosed for 10 days with either vehicle control (corn oil) or 
DiNP (20 µg/kg/day – 200 mg/kg/day).  Mice were euthanized in the diestrous stage of the 
estrous cycle and sera were collected for analysis of FSH (n = 5-12 mice/group) (A) and inhibin 
B (n = 4-12 mice/group) (B). Data are represented as means ± standard error.  Statistically 
significant difference when compared to control (p ≤ 0.05) is denoted with an asterisk (*).  
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Late-Life Consequences of Short-Term Exposure to Di(2-ethylhexyl) Phthalate and 
Diisononyl Phthalate During Adulthood in Female Mice 
 
5.1 Abstract 
Di(2-ethylhexyl) phthalate (DEHP) is a ubiquitous environmental contaminant that has been 
shown to accelerate recruitment of primordial follicles from the resting follicle pool.  In addition, 
diisononyl phthalate (DiNP) is a common DEHP replacement chemical. However, little is known 
about late-life consequences due to DEHP or DiNP exposure during adulthood.   Thus, the 
current study tested the hypothesis that adult exposure to DEHP or DiNP negatively affects 
female reproductive parameters including cyclicity, ovarian follicle populations, fertility, and 
hormone concentrations during late-life in female mice.  Female CD-1 mice aged 39-40 days 
were orally dosed with either vehicle control (corn oil), DEHP (20 µg/kg/day–200 mg/kg/day), 
or DiNP (20 µg/kg/day–200 mg/kg/day) for 10 days.  Mice were aged with no additional 
phthalate exposure and cyclicity monitoring periods and breeding trials were conducted at 12 and 
15 months post-dosing.  Further, ovaries and sera were collected at 12, 15, and 18 months post-
dosing for analysis of ovarian follicle populations and concentrations of estradiol, progesterone, 
testosterone, inhibin B, and follicle stimulating hormone.  DEHP and DiNP disrupted estrous 
cyclicity, increased pregnancy loss, decreased overall fertility, and altered the sex ratio of pups.  
Further, DEHP and DiNP altered ovarian follicle populations and hormone levels at all time 
points.  Taken together, these data show that short-term exposure to DEHP or DiNP during 





Female mammals are born with a finite number of oocytes to use throughout their reproductive 
lives [1].  Once this reserve of oocytes has been depleted, the female enters reproductive 
senescence.  During years of fertility, females undergo reproductive cycles in which species-
specific numbers of oocytes are ovulated for fertilization in coordination with a consistent and 
predictable fluctuation in hormones.  The primary hormones that take on a cyclic nature within 
females are the sex steroid hormones estradiol, progesterone, and testosterone as well as peptide 
hormones such as follicle stimulating hormone (FSH), luteinizing hormone (LH), and inhibin A 
and B [2, 3].  Because the sex steroid hormones are primarily produced by structures only 
present in actively cycling females, namely the antral follicle and the corpus luteum (CL), high 
levels of sex steroid hormones are characteristic of fertile and actively cycling females.  
Additionally, some sex steroid hormones share antagonistic relationships with the peptide 
hormones [3].  Thus, as antral follicles, corpora lutea, and subsequently, sex steroid hormones 
decline with age, levels of some peptide hormones such as FSH increase as the negative 
feedback exerted by the sex steroid hormones is alleviated [4].  Additionally, inhibin B levels 
decline as the number of small growing follicles that are responsible for its production drop.  
Thus, the hormone profile of a normal, cycling female will have higher levels of sex steroid 
hormones and inhibin B and lower levels of FSH, and inverse characteristics will be present for 
acyclic females who have entered reproductive senescence.  Taken together, data on levels of 
multiple hormones can be used as a metric for assessing female reproductive health and 





To prevent early entry into reproductive senescence, proper regulation of the activation and use 
of the ovarian reserve is imperative. Aberrant regulation can lead to early depletion of the 
ovarian reserve and, subsequently, early reproductive senescence [4].  In women, early 
menopause is associated with an increased risk of osteoporosis, stroke, cardiovascular disease, 
and increased mortality [5-9].  Concerningly, some studies have found that some environmental 
contaminants can lead to dysregulation of the ovarian reserve, and some studies have found 
markers of reproductive aging are altered by these chemicals as well [10-12].  One class of 
chemicals that has been shown to have endocrine disrupting capabilities is phthalates [13, 14]. 
 
Phthalates are a family of chemicals used widely for their plasticizing and stabilizing properties.  
Lower molecular weight phthalates can commonly be found in personal care products because 
they are used to maintain and stabilize fragrances and colors [15, 16].  Higher molecular weight 
phthalates are more often used for their plasticizing capabilities, resulting in their high use in 
plastic products such as polyvinyl chloride (PVC) goods and other consumer goods such as 
clothing and food packaging [16] .   
 
Di(2-ethylhexyl) phthalate (DEHP) is a high molecular weight phthalate and is often found in 
products such as plastic children’s toys, upholstery, construction materials such as floor tiles, and 
medical equipment such as blood bags and tubing [17].  Millions of pounds of DEHP are 
produced every year within the U.S., and this vast production and use has led to DEHP becoming 
a top environmental contaminant that humans are exposed to daily [17, 18].  The average person 
is estimated to be exposed to between 3-30 µg/kg/day [17], and some populations can experience 




DEHP is a widespread contaminant that humans are exposed to on a daily basis, and some 
populations are vulnerable to even higher levels of exposure.  This is a concern because DEHP 
has endocrine disrupting capabilities and has been associated with a variety of reproductive 
disorders in women in addition to affecting oocyte development, ovulation, and steroidogenesis 
[13, 14].  However, few studies have investigated how exposure to DEHP during adulthood 
affects reproductive aging in females. 
 
Another phthalate of concern is diisononyl phthalate (DiNP), a phthalate often used as a DEHP 
replacement because it is thought to be less anti-androgenic than DEHP.  Because of the 
increased use of DiNP as a DEHP replacement chemical, a steep increase in the levels of DiNP 
metabolites has been detected in human urine samples from the National Health and Nutrition 
Examination Survey (NHANES) [21].  This is concerning because of a paucity of information on 
the effects of DiNP on reproductive aging in females, especially in the context of exposure 
during adulthood.  Further, studies from our own research group have found similar reproductive 
toxicity when comparing DEHP to DiNP [22].  Subsequently, this begs the question of whether 
DiNP is an adequate replacement for DEHP if the goal of substitution is decreased toxicity and 
increased safety for the consumer. 
 
This study aims to fill the gap in knowledge concerning the effects of DEHP and DiNP exposure 
during adulthood on reproductive aging in the female mouse.  Previously, our laboratory has 
shown that 10 days of exposure during adulthood to DEHP and DiNP is adequate to disrupt 
aspects of female fertility up to 9 months following completion of dosing [11, 22].  However, 




Thus, this study tested the hypothesis that short-term exposure to DEHP and/or DiNP during 
adulthood alters markers of reproductive aging, including cyclicity, ovarian hormone 
populations, overall fertility, and circulating hormone levels. 
 
5.3 Materials and Methods 
Chemicals 
DEHP and DiNP were purchased from Sigma-Aldrich (St. Louis, MO).  Corn oil (vehicle 
control) was purchased from MP Biomedicals (Solon, OH).  Dosing stock solutions were made 
via serial dilutions from the highest concentration dose.  Stock solutions were stored at room 
temperature away from exposure to direct light for up to a month.  If a month elapsed from the 
time the stock solutions were made, then a new batch of stock solutions was made. 
 
Animals and Dosing 
Female CD-1 mice were purchased from Charles River (Wilmington, MA) and housed in the 
animal facility at the College of Veterinary Medicine at the University of Illinois at Urbana-
Champaign (Urbana, IL).  Animals were allowed to acclimate to the facilities for a minimum of 
5 days before the dosing period began.  Facility temperature was maintained at 21.1 ± 2.2˚C and 
humidity was maintained at 50 ± 20%.  Mice were given ad libitum access to chow (Teklad 
Rodent Diet 8604) and reverse osmosis-treated water.  Light-dark cycles were 12 hours light and 
12 hours dark.  All animal handling procedures were approved by the University of Illinois at 





Mice were dosed at age 39-40 days orally via insertion of a pipette tip into the mouth.  
Treatments consisted of vehicle control (corn oil), DEHP (20 µg/kg/day, 200 µg/kg/day, 20 
mg/kg/day, 200 mg/kg/day), or DiNP (20 µg/kg/day, 100 µg/kg/day, 20 mg/kg/day, 200 
mg/kg/day) for 10 days.  To determine dose volume, mice were weighed daily immediately 
before dosing.  Mice were housed 3 to a cage with all mice within one cage receiving the same 
dose to minimize contamination. 
 
Experimental Design 
To determine how DEHP and DiNP affect fertility parameters, hormones, and ovarian follicle 
populations in late-life, groups of animals were dosed and data were taken at pre-determined 
time points.  One group of mice was designated for cyclicity monitoring and breeding, and 
cyclicity was monitored at time points 12 and 15 months post-dosing.  Breeding trials for this 
same group of mice commenced following completion of the cyclicity monitoring period.  These 
mice were euthanized at 18 months post-dosing, and blood and ovaries were collected.   
 
Additional groups of mice that were not used for cyclicity monitoring or breeding were dosed 
and euthanized in the same fashion at 12 months post-dosing and 15 months post-dosing, and 
blood and ovaries were collected.  Collectively, this generated breeding and cyclicity data for 12 
and 15 months post-dosing as well as hormone data and ovarian follicle population data for 12, 







Estrous Cyclicity Monitoring 
At time points 12 and 15 months post-dosing, mice were vaginally lavaged with 1X phosphate-
buffered saline for 14 consecutive days, and the lavage samples were analyzed under a light 
microscope to assess stage of the estrous cycle using previously defined criteria [23].  Lavaging 
was conducted at 2 hours after the beginning of the light cycle.  Lavage samples were analyzed 
no later than 3 days following collection, and samples were kept at 4 ˚C until analysis.  Mice 
were housed in groups of 3 animals per cage.  For statistical analysis, the metestrous and 
diestrous stages were combined into a single category because they are similar in mice [23].  
Percent times spent in proestrus, estrus, and metestrus/diestrus were calculated by dividing the 
number of days spent in each stage of the cycle by 14 and multiplying by 100. 
 
Histological Evaluation of Ovarian Tissues 
Following euthanasia, ovaries were removed and fixed overnight in Dietrich’s solution.  
Following fixation, ovaries were transferred to 70% ethanol and then embedded in paraffin wax.  
Ovaries were sectioned serially on a microtome at 8 µm in width and mounted onto microscope 
slides.  Slides were baked overnight at 50 °C and were stained the following day with 
hematoxylin and eosin.  Every tenth section of the ovary was used to assess follicle populations 
as described previously [10].  In addition to normal follicle types, the percent of unhealthy 
follicle types, including abnormal and atretic follicles were assessed.  Abnormal follicles were 
designated as follicles with either a fragmented oocyte, a multinucleated oocyte, or multiple 
oocytes.  The nucleus must have been present in all follicle types to be counted to avoid double 
counting between sections, except for primordial and primary follicles which are too small to 




given a unique histological ID with no relation to treatment group.  Data that are reported as 
follicle numbers represent unaltered, raw number of follicles in each category.  Data that are 
reported as percent of follicles were determined by dividing the raw number of follicles in each 
category by the total number of follicles within the ovary and multiplying by 100 to achieve a 
percentage.  The total number of follicles was determined by summing all follicle types together, 
including unhealthy follicles. 
 
Breeding and Fertility Indices 
Following completion of the cyclicity monitoring periods, females were paired with an untreated 
CD-1 male mouse (age 7 weeks) in a new cage.  Breeding pairs were kept in a harem fashion 
with 2 females and a single male.  Following introduction of the male, females were checked 
every morning and afternoon for the presence of a copulatory plug, which indicated successful 
mating with the male.  Females remained housed with the male until a copulatory plug was 
observed or if 14 days had passed.  If a copulatory plug was noted or the female had been with 
the male for 14 days, the female was removed and single-housed in a new cage.  To calculate 
time to mating, day one was considered the morning immediately after the introduction of the 
male.  To calculate gestation length, the day the copulatory plug was noted was designated 
gestational day 0.5. Females were weighed twice a week starting from the introduction of the 
male until the litter was born.  If a female gained 4 g or more in weight, she was considered 
pregnant.  Around the time of litter bearing, females were checked in the morning and afternoon 
for presence of pups.  Live pups on postnatal day (PND) 0 were weighed together and the 
weights were averaged, and live and deceased pups were counted and sexed, if possible.   




of pups within the litter and multiplying by 100.  If sex or number of pups could not be 
determined due to cannibalism by the dam, those data were not used in the statistical analysis.   
 
Breeding trial indices were used to assess fertility success at multiple stages of the breeding trial.  
The fertility index measured the percent of females who successfully achieved pregnancy from a 
single, confirmed mating by dividing the number of pregnant females by the number of females 
with a copulatory plug and multiplying by 100.  The gestational index measured the percent of 
females who carried their pregnancy to term and gave birth to pups by dividing the number of 
females who gave birth by the number of females that achieved pregnancy and multiplying by 
100.  The percent of females who gave birth was calculated by dividing the number of females 
who gave birth to pups by the total number of females within the treatment group and 
multiplying by 100. 
 
Steroid and Peptide Hormone Assays 
Groups of animals were euthanized via CO2 asphyxiation at different periods following 
completion of dosing; 12 months post-dosing, 15 months post-dosing, and 18 months post-
dosing.  All animals were euthanized in the diestrous stage of the estrous cycle.  Immediately 
after euthanasia, blood was collected in a heparinized needle and allowed to clot in an 
Eppendorf®  tube at room temperature for at least 15 minutes.  Blood samples were then put on 
ice for at least 15 minutes.  Following 15 minutes on ice, samples were centrifuged in a 4 °C 
room at 14,000 RPM for 15 minutes.  Sera were collected and stored at -80 °C until use in 
enzyme-linked immunosorbent assays (ELISAs) or radioimmunoassays.  ELISA kits for 




(LODs) for testosterone, progesterone, and estradiol were 0.083 ng/mL, 0.045 ng/mL, and 10.60 
pg/mL, respectively.  The inter- and intra-assay %CVs were ≤ 9.94 and ≤ 4.16, ≤ 9.96 and ≤ 
6.99, and ≤ 14.91 and ≤ 9.23 for testosterone, progesterone, and estradiol, respectively.  
Lypocheck® from Bio-Rad Laboratories was used as a control with known values in all ELISAs 
in this study.  Aliquots of sera were shipped to the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core.  The facility used radioimmunoassays to 
measure levels of FSH and inhibin B.  The LODs for FSH and inhibin B were 1.6 ng/mL and 35 
pg/mL, respectively.  Intra- and inter-assay %CVs for FSH were 7.2 and 8.5, respectively, and 
intra- and inter-assay %CVs for inhibin B were 1.8 and 6.6, respectively 
(https://med.virginia.edu/research-in-reproduction/wp-content/uploads/sites/311/2019/04/2019-
INTRA-INTER-ASSAY-CVs__030419.pdf).  Samples with values below the limit of detection 
(LOD) were statistically analyzed using the LOD value specific for each assay divided by the 
square root of 2.   
 
Statistical Analysis 
Data that were normally distributed were assessed for outliers using Grubb’s Test.  If outliers 
were detected, they were not used in the following analysis.  Data that were normally distributed 
and met the assumption of homogeneity of variance were analyzed via one-way analysis of 
variance (ANOVA).  Dunnett’s 2-sided test was used post hoc.  If data did not meet the 
assumption of normality and/or the assumption of homogeneity of variance or were non-







5.4.1 Effects of DEHP and DiNP on estrous cyclicity 
12 months post-dosing 
At 12 months post-dosing, 20 µg/kg/day DEHP-treated mice spent significantly more time in 
estrus (Fig. 1A, n = 9-22 mice/group, p ≤ 0.05) and borderline decreased time in 
metestrus/diestrus (Fig. 1A, n = 9-22 mice/group, p = 0.09) when compared to control.  Females 
treated with 20 µg/kg/day of DiNP had borderline increased time spent in estrus when compared 
to control (Fig. 1A, n = 9-22 mice/group, p = 0.06). 
 
15 months post-dosing 
Following 15 months after dosing, females in the 20 µg/kg/day DEHP treatment group spent 
significantly more time in estrus (Fig. 1B, n = 8-20 mice/group, p ≤ 0.05) and borderline 
decreased time in metestrus/diestrus (Fig. 1B, n = 8-20 mice/group, p = 0.09) when compared to 
control.  No other treatments affected estrous cyclicity when compared to control. 
 
5.4.2 Effects of DEHP and DiNP on ovarian follicle populations 
12 months post-dosing 
At 12 months post-dosing, treatment with 20 and 200 mg/kg/day DiNP decreased numbers of 
primordial follicles when compared to control (Fig. 2A, n = 3-12 mice/group, p ≤ 0.05).  Further, 
20 mg/kg/day of DEHP significantly decreased numbers of primary follicles (Fig. 2A, n = 3-12 
mice/group, p ≤ 0.05) and borderline decreased numbers of preantral follicles when compared to 




decreased the total number of follicles within the ovary when compared to control (Fig. 2D, n = 
3-12 mice/group, p = 0.06). 
 
When follicle populations were analyzed as percentages, treatment with 20 and 200 mg/kg/day 
of DiNP significantly decreased the percent of primordial follicles when compared to control 
(Fig. 2B, n = 3-12 mice/group, p ≤ 0.05).  Further, treatment with 200 mg/kg/day of DEHP (Fig. 
2B, n = 3-12 mice/group, p = 0.07) and 20 µg/kg/day of DiNP  (Fig. 2B, n = 3-12 mice/group, p 
≤ 0.05) decreased the percent of primary follicles when compared to control.  Additionally, 200 
mg/kg/day of DiNP borderline increased the percent of preantral follicles when compared to 
control (Fig. 2B, n = 3-12 mice/group, p = 0.08), and 20 mg/kg/day of DiNP significantly 
increased the percent of antral follicles when compared to control (Fig. 2B, n = 3-12 mice/group, 
p ≤ 0.05).   
 
Interestingly, we observed various effects on the percent of unhealthy follicles.  Treatment with 
200 mg/kg/day of DEHP (Fig. 2C, n = 3-12 mice/group, p ≤ 0.05), 100 µg/kg/day DiNP (Fig. 
2C, n = 3-12 mice/group, p = 0.10), and 200 mg/kg/day DiNP (Fig. 2C, n = 3-12 mice/group, p ≤ 
0.05) decreased percent of unhealthy follicles when compared to control.  In contrast, 20 
µg/kg/day of DiNP increased the percent of unhealthy follicles when compared to control (Fig. 
2C, n = 3-12 mice/group, p = 0.10). 
 
15 months post-dosing 
At 15 months post-dosing, 200 µg/kg/day of DEHP and 100 µg/kg/day of DiNP both increased 




0.05).  Additionally, 20 µg/kg/day and 200 mg/kg/day of DEHP decreased the number of antral 
follicles when compared to control (Fig. 3A, n = 4-11 mice/group, p ≤ 0.05).  Conversely, no 
doses of DEHP or DiNP affected the total number of follicles when compared to control (Fig. 
3D, n = 4-11 mice/group). 
 
When follicles were analyzed as percentages, 200 µg/kg/day of DEHP borderline increased the 
percent of primary follicles when compared to control (Fig. 3B, n = 4-11 mice/group, p = 0.10) 
and borderline decreased the percent of antral follicles when compared to control (Fig. 3B, n = 4-
11 mice/group, p = 0.10).  Similarly, 20 mg/kg/day of DEHP and 100 µg/kg/day of DiNP 
significantly decreased the percent of antral follicles when compared to control (Fig. 3B, n = 4-
11 mice/group, p ≤ 0.05).  No doses of DEHP or DiNP affected the percent of unhealthy follicles 
when compared to control (Fig. 3C, n = 4-11 mice/group). 
 
18 months post-dosing 
At 18 months post-dosing, treatment with 100 µg/kg/day and 200mg/kg/day of DiNP 
significantly increased the number of primordial follicles when compared to control (Fig. 4A, n = 
4-12 mice/group, p ≤ 0.05).  Further, 20 µg/kg/day of DiNP significantly decreased the number 
of antral follicles (Fig. 4A, n = 4-12 mice/group, p ≤ 0.05), and in contrast, 100 µg/kg/day of 
DiNP borderline increased the number of antral follicles (Fig. 4A, n – 4-12 mice/group, p = 
0.10).  However, no doses of DEHP or DiNP affected total follicle numbers when compared to 





When follicle populations were analyzed as percentages, 100 µg/kg/day of DiNP borderline 
increased the percent of primordial follicles when compared to control (Fig. 4B, n = 4-12 
mice/group, p = 0.06).  Further, both 20 µg/kg/day of DiNP (Fig. 4B, n = 4-12 mice/group, p = 
0.08) and 200 mg/kg/day of DiNP (Fig. 4B, n = 4-12 mice/group, p = 0.10) decreased the percent 
of antral follicles when compared to control.  In contrast, DEHP and DiNP did not affect the 
percent of unhealthy follicles when compared to control (Fig. 4C, n = 4-12 mice/group). 
 
5.4.3 Effects of DEHP and DiNP on fertility 
12 months post-dosing 
Treatment with 20 µg/kg/day of DiNP resulted in borderline decreased time to mating when 
compared to control (Fig. 5A, n = 9-19 mice/group, p = 0.06).  Treatment with 100 µg/kg/day of 
DiNP (Fig. 5B, n = 4-13 mice/group, p ≤ 0.05) and 200 mg/kg/day of DiNP (Fig. 5B, n = 4-13 
mice/group, p = 0.06) increased the length of gestation when compared to control.  DEHP and 
DiNP did not affect the mating index (Fig. 6A, n = 9-21 mice/group) or the fertility index (Fig. 
6B, n = 8-20 mice/group) at 12 months post-dosing, indicating that treated females were able to 
mate and conceive pregnancies at rates comparable to control.  However, treatment with 20 
µg/kg/day (Fig. 6C, n = 6-16 mice/group, p = 0.07) and 200 mg/kg/day of DEHP (Fig. 6C, n = 6-
16 mice/group, p = 0.10) borderline decreased the gestational index of females in these groups 
when compared to control.  Additionally, females in the 20 mg/kg/day treatment group of DiNP 
had a significantly reduced gestational index when compared to control (Fig. 6C, n = 6-16 
mice/group, p ≤ 0.05), indicating these females were less able to carry their pregnancy to term 
and give birth to pups when compared to control.  Further, the overall ability of females to 




reduced in the 20 µg/kg/day treatment group for both DEHP (Fig. 6D, n = 8-21 mice/group, p = 
0.06) and DiNP (Fig. 6D, n = 8-21 mice/group, p = 0.08) when compared to control. 
 
15 months post-dosing 
Treatment with DEHP and DiNP did not affect time to mating at 15 months post-dosing (Fig. 
7A, n = 8-15 mice/group).  At this time point, the natural and steep decline in fertility of CD-1 
mice at this age made it difficult to collect data and perform statistical analysis for this breeding 
trial.  However, the percent of females who produced pups was able to be statistically analyzed, 
and treatment with DEHP and DiNP did not affect the overall ability of females to produce pups 
when compared to control (Fig. 7B, n = 7-17 mice/group).  
 
5.4.4 Effects of DEHP and DiNP on litter outcomes 
12 months post-dosing 
At 12 months post-dosing, 200 µg/kg/day of DEHP significantly decreased litter size in treated 
females when compared to control (Fig. 8A, n = 3-8 mice/group, p ≤ 0.05).  Further, average live 
weight of pups on PND 0 was significantly increased by 200 µg/kg/day DEHP treatment (Fig. 
8B, n = 3-9 mice/group, p ≤ 0.05) and borderline increased by 200 mg/kg/day of DEHP when 
compared to control (Fig. 8B, n = 3-9 mice/group, p = 0.07). However, too few litters were born 
to the 200 mg/kg/day DiNP treatment group that statistical analysis of average live weight of 
pups on PND 0 could not be performed (n = 2 mice).  Interestingly, percent of female pups was 
borderline decreased in the 20 µg/kg/day group DEHP (Fig. 8C, n = 3-7 mice/group, p = 0.07) 
and significantly decreased in the 20 mg/kg/day DEHP and 20 µg/kg/day DiNP treatment groups 




number of litters born at this time point in addition to the inability to confidently sex pups due to 
cannibalization, sample size was too low for statistical analysis of the percent of female pups for 
the 200 mg/kg/day DEHP (n = 2 mice), 100 µg/kg/day DiNP (n = 2 mice), and 200 mg/kg/day 
DiNP groups (n = 1 mouse). 
 
15 months post-dosing 
Because the fertility of the CD-1 mouse naturally takes a sharp decline around this time in the 
life of the mouse, very few litters were born to both treatment and control.  Thus, we were not 
able to assess whether treatment affected litter outcomes for the breeding trial conducted at this 
time point. 
 
5.4.5 Effects of DEHP and DiNP on hormone levels 
12 months post-dosing 
Treatment with DEHP and DiNP did not affect testosterone and progesterone levels at 12 months 
post-dosing (Fig. 9A and 9B, n = 5-12 mice/group).  However, 20 µg/kg/day of DEHP borderline 
decreased levels of estradiol when compared to control (Fig. 9C, n = 5-12 mice/group, p = 0.06), 
and 20 mg/kg/day of DiNP borderline increased levels of FSH when compared to control (Fig. 
10A, n = 5-12 mice/group, p = 0.10).  No doses of DEHP or DiNP affected levels of inhibin B 
when compared to control at this time point (Fig. 10B, n = 4-10 mice/group).   
 
15 months post-dosing 
Treatment with DEHP and DiNP did not affect levels of testosterone and estradiol at 15 months 




200 µg/kg/day of DEHP borderline increased levels of progesterone in treated mice (Fig. 11B, n 
= 4-12 mice/group, p = 0.07).  Further, 20 µg/kg/day of DEHP borderline increased levels of 
FSH when compared to control (Fig. 12A, n = 4-12, p = 0.09).  No doses of DEHP or DiNP 
affected levels of inhibin B at 15 months post-dosing when compared to control (Fig. 12B, n = 4-
10 mice/group). 
 
18 months post-dosing 
Treatment with DEHP and DiNP did not affect progesterone levels when compared to control at 
this time point (Fig. 13B, n = 7-16 mice/group).  In contrast, treatment with 200 mg/kg/day of 
DEHP borderline increased levels of estradiol when compared to control (Fig. 13C, n = 7-16 
mice/group, p = 0.07), and 100 µg/kg/day of DiNP significantly decreased levels of estradiol 
when compared to control (Fig. 13C, n = 7-16 mice/group, p ≤ 0.05).  Further, 100 µg/kg/day of 
DiNP also decreased testosterone levels when compared to control (Fig. 13A, n = 7-16 
mice/group, p ≤ 0.05).  No effects of treatment were observed on levels of FSH when compared 
to control at this time point (Fig. 14A, n = 7-16 mice/group).  In contrast, the 20 mg/kg/day 
DiNP treatment group displayed increased levels of inhibin B when compared to control (Fig. 
14B, n = 7-16 mice/group, p ≤ 0.05).   
 
5.5 Discussion 
This study tested the hypothesis that short-term exposure to DEHP and DiNP during adulthood 
has long lasting consequences on fertility, estrous cyclicity, follicle populations, and circulating 
levels of hormones at time points just before, during, and after the transition into reproductive 




can have negative consequences on fertility up to 9 months post-dosing [11, 22].  The current 
study builds upon existing knowledge by investigating the effects of short-term exposure to 
DEHP and DiNP during adulthood on time points that have not yet been studied, including those 
encompassing reproductive senescence in the mouse.   
 
We observed that DEHP and DiNP disrupted estrous cyclicity at 12 and 15 months post-dosing 
wherein females spent more time in estrus and less time in metestrus/diestrus compared to 
control.  Increased time in spent in estrus has been shown to occur in the aging rodent [24, 25].  
Thus, this could be indicative of accelerated reproductive aging in the treatment groups 
displaying increased time spent in estrus.  Previous studies in our laboratory have shown that 
both DEHP and DiNP have long-lasting effects on cyclicity up to 9 months post-dosing [11, 22].  
In contrast, a study investigating exposure to DEHP during adulthood in mice reported that 
DEHP increased time spent outside of the estrous phase [26].  Further, a different study found 
that rats that were perinatally exposed to DiNP did not display disrupted estrous cycles [27].  
However, the differences observed between these studies and the present study are likely due to 
differences in age at cyclicity monitoring and window of exposure.   
 
At 12 months post-dosing, we found that DiNP decreased the number and the percent of 
primordial follicles and percent of primary follicles as well as increased percent of preantral and 
antral follicles.  Further, DEHP decreased the number and percent of primary follicles and 
decreased the number of preantral follicles.  Of note is the trend that both DEHP and DiNP 
reduced populations of more immature follicle types, such as primordial and primary follicles, 




immature follicle types to more mature follicle types could be indicative of accelerated 
folliculogenesis, a phenomenon observed in a previous study conducted in our laboratory using 
the same dosing paradigm [10].  If not corrected, accelerated folliculogenesis can lead to early 
reproductive senescence.   
 
We also observed reduced total follicle numbers in the mice treated with 20 mg/kg/day of DEHP 
in addition to reduced percent of unhealthy follicle types in both DEHP- and DiNP-treated 
groups.  In contrast, 20 µg/kg/day of DiNP-treated mice displayed an increased percent of 
unhealthy follicle types.  When comparing the total follicle numbers to the numbers of each 
follicle type, the reduction in total follicles observed in the 20 mg/kg/day DEHP treatment group 
can largely be attributed to the lower numbers of primordial and primary follicles when 
compared to control.  Further, we found the reduction in unhealthy follicle types very interesting, 
and we suspect that treatment with DEHP and DiNP has upregulated clearance of unhealthy 
follicles, giving an appearance of fewer unhealthy follicles.  This hypothesis could also explain 
the increase in unhealthy follicles observed in the lower treatment group of DiNP, which may not 
have been a high enough dose to induce clearance of unhealthy follicles.   
 
At 15 months post-dosing, we primarily observed treatment-induced disruptions in preantral and 
antral numbers and percentages.  This suggests that DEHP and DiNP altered the rate at which 
these follicles progress from the preantral to antral stage.  The transition from the preantral to 
antral stage is regulated by a variety of hormones such as FSH and genes including Sma- and 




transcription factors (Foxo) family [28].  Thus, it is possible that treatment with DEHP and DiNP 
caused aberrant regulation of the genes or receptors for hormones involved in this transition.   
 
At 18 months post-dosing, only some doses of DiNP affected follicle numbers and percentages.  
We observed DiNP-induced increases in the number and percent of primordial follicles and 
disruption of antral follicle numbers and percentages.  Interestingly, we observed contrasting 
effects between the 20 µg/kg/day and 100 µg/kg/day doses of DiNP on antral follicle numbers, 
with 20 µg/kg/day decreasing and 100 µg/kg/day increasing antral follicle numbers.  This non-
monotonic dose response is common with endocrine disrupting chemicals [29] and highlights the 
importance of the investigation of the mechanisms through which these chemicals act.  The 
DiNP-induced increase in primordial follicles is particularly perplexing because previous in vitro 
and in vivo studies in our laboratory have shown that phthalates can accelerate primordial follicle 
recruitment [10, 30].  However, a previous study conducted in our laboratory has shown that 
exposure to a phthalate mixture can reduce atresia in antral follicles cultured in vitro [31].  
Because females are born with a finite number of primordial follicles, an increase in primordial 
follicle numbers can only be explained by less atresia or less recruitment to the next stages of 
growth.  The lack of increased numbers or percentages of primary follicles suggests that the 
increase observed in primordial follicle numbers is likely due to less atresia in the primordial 
follicle pool as opposed to increased primordial follicle recruitment.  It is possible that DiNP is 
acting through a similar mechanism as seen in this previous study that observed reduced atresia.  
Thus, future studies should investigate the mechanisms through which DiNP may regulate 





At 12 months post-dosing, we observed that DEHP and DiNP increased pregnancy loss and 
overall decreased the ability of treated females to produce offspring in multiple treatment groups 
when compared to control.  The reductions in the fertility of the 20 µg/kg/day treatment groups 
for both DEHP and DiNP observed in the present study have been observed in a previous study 
in our laboratory that examined fertility at 3 months post-dosing [22], indicating these effects can 
arise at multiple time points throughout the life of the exposed individual.  Further, these 
treatment groups both exhibited increased time spent in estrus is a marker of reproductive aging 
[25].  Thus, the combination of reduced fertility and increased time spent in estrus suggest the 
onset of reproductive senescence is occurring earlier in these treatment groups.  Although few 
studies have investigated the late-life consequences of exposure to DEHP and DiNP during 
adulthood, previous studies have found that DEHP exposure during adulthood or through 
transgenerational exposure can impact markers of reproductive aging in mice [11, 12, 32].  
Further, epidemiological evidence shows associations between phthalate exposure and early age 
at menopause [33].  Additionally, phthalate exposure has also been associated with increased 
pregnancy loss in women [34], and some animal studies have found that DEHP exposure 
disrupts placental growth and development, possibly providing insufficient support for the fetus 
[35, 36].   
 
In terms of pup outcomes, we found that at 12 months post-dosing, DEHP and DiNP decreased 
the percent of female pups and that DEHP alone decreased litter size and increased average live 
weight of pups when compared to control.  One study has shown that DEHP can interfere with 
receptivity of the uterine lining to implantation [37], which could explain the reduced litter size 




observed previously at earlier time points closer to the exposure window [22].  Although the 
decrease in litter size in the 200 µg/kg/day DEHP group may have led to decreased intrauterine 
growth restriction and subsequently, larger pups, this does not explain the increase in average 
live weight in the 200 mg/kg/day DEHP group.  DEHP has been shown to have obesogenic 
properties, potentially through activation of peroxisome proliferator-activated receptor (PPAR) 
activation [38, 39].  Thus, it is possible DEHP increased the adiposity of the pups, leading to 
increased weight at birth.  These results contrast with some epidemiological findings that 
phthalate exposure is associated with reduced weight at birth [40, 41], but some studies have 
found inverse results [42]. 
 
The alteration in percent of female pups born was surprising due to the pre-conception dosing 
paradigm of the study.  However, sex ratio was altered in a previous study using the same dosing 
paradigm conducted in our laboratory at 9 months post-dosing [22].  In that previous study, we 
postulated that the difference in sex ratio may be due to treatment affecting hormones and, 
subsequently, sperm selection as the sperm traversed the female reproductive tract.  However, we 
did not observe correlations between hormones and alterations in sex ratio in the current study, 
suggesting this is not the mechanism through which DEHP and DiNP alter sex ratio.  Previous 
studies have shown that maternal age and condition can affect sex ratio of offspring [43-45]; 
thus, it is possible that treatment may lead to altered sex ratios by altering aspects not detectable 
through methods used in this study. 
 
Overall, the effects of treatment on hormone levels were limited. However, alterations in 




dosing.  This indicates that hormones may be affected throughout the life of the exposed 
individual.  Indeed, the most striking effects on hormones observed in this study were observed 
at 18 months post-dosing, wherein the 100 µg/kg/day DiNP treatment group exhibited reduced 
levels of both estradiol and testosterone.  Interestingly, this same treatment group had increased 
number of antral follicles, indicating that reducing the antral follicle population is not necessary 
to reduce the levels of sex steroid hormones.  It is likely that either the function of the antral 
follicles has been disrupted or that metabolism of these hormones is occurring at a faster rate 
than production when compared to control.  The other effect seen in hormones at 18 months 
post-dosing was an increase in inhibin B levels in the 20 mg/kg/day DiNP treatment group when 
compared to control.  We find this result surprising because inhibin B is a marker of ovarian 
reserve, and we observed no changes in any follicle types for this group at this time point.  Thus, 
we suspect that this increase in inhibin B is not due to an increase in the ovarian reserve and that 
it may reflect disruptions in the metabolism or production of inhibin B itself.   
 
We find the lack of correlation between the breeding outcomes and hormonal and follicle count 
data perplexing because a lack of fecundity can often be explained by disruptions to follicular 
populations or hormones. It is possible that the observed disruptions in fertility may be based in 
the uterus and not in the ovary or the production of ovarian hormones.  Thus, future studies 
should investigate the effects of DEHP and DiNP on uterine function, especially as it concerns 
the support of pregnancy in light of the increased pregnancy loss observed in this study.   
 
We also find the contrast between the hormone and follicle population data interesting.  The lack 




suggests that the answer may lie in alterations of metabolism or production of these hormones 
and not the absolute follicle numbers.  Previous studies in our research group have shown that 
phthalates can alter expression of a variety of steroidogenic enzymes present within the ovary 
[31, 46].  Thus, it is possible that DEHP and DiNP cause altered expression or activity of the 
steroidogenic enzymes present in the ovary. 
 
In conclusion, this study found that short-term exposure during adulthood has long-lasting 
consequences on estrous cyclicity, ovarian follicle populations, fertility, and hormones in the 
female mouse.  The effects of DEHP and DiNP observed in this study occurred a year or longer 
after cessation of exposure, thus, future studies should investigate the mechanisms through which 
















5.6 Figures and Legends 
Figure 5.1 Effects of DEHP and DiNP on estrous cyclicity at 12 and 15 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  
Females were vaginally lavaged daily for 14 days to assess cyclicity at 12 months post-dosing (n 
= 9-22 mice/group) and 15 months post-dosing (8-20 mice/group).  Statistical significance (p ≤ 
0.05) is denoted with an asterisk (*).  Data are represented as means ± standard error.  Borderline 







Figure 5.2  Effects of DEHP and DiNP on ovarian follicle populations at 12 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months following completion of the dosing period, females were euthanized and ovaries were 
collected and histologically evaluated for raw follicle numbers (n = 3-12 mice/group) (A), 
percent of follicles (n = 3-12 mice/group) (B), percent of unhealthy follicles (n = 3-12 
mice/group) (C), and total number of follicles (n = 3-12 mice/group) (D).  Statistical significance 
(p ≤ 0.05) is denoted with an asterisk (*).  Data are represented as means ± standard error.  





Figure 5.3 Effects of DEHP and DiNP on ovarian follicle populations at 15 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
15 months following completion of the dosing period, females were euthanized and ovaries were 
collected and histologically evaluated for raw follicle numbers (n = 4-11 mice/group) (A), 
percent of follicles (n = 4-11 mice/group) (B), percent of unhealthy follicles (n = 4-11 
mice/group) (C), and total number of follicles (n = 4-11 mice/group) (D).  Statistical significance 
(p ≤ 0.05) is denoted with an asterisk (*).  Data are represented as means ± standard error.  




Figure 5.4 Effects of DEHP and DiNP on ovarian follicle populations at 18 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
18 months following completion of the dosing period, females were euthanized and ovaries were 
collected and histologically evaluated for raw follicle numbers (n = 4-12 mice/group) (A), 
percent of follicles (n = 4-12 mice/group) (B), percent of unhealthy follicles (n = 4-12 
mice/group) (C), and total number of follicles (n = 4-12 mice/group) (D).  Statistical significance 
(p ≤ 0.05) is denoted with an asterisk (*).  Data are represented as means ± standard error.  





Figure 5.5 Effects of DEHP and DiNP on time to mating and gestation length at 12 months 
post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months post-dosing, females were paired with an untreated male mouse directly after 
completion of the estrous cyclicity monitoring period.  Females were checked every morning and 
afternoon for the presence of a copulatory plug.  If a copulatory plug was observed or if 14 days 
had elapsed, the female was put into a new clean cage.  If a female presented with a copulatory 
plug the day immediately after introduction of the male, the time to mating was considered 1 day 
(n = 9-19 mice/group) (A).  The day the copulatory plug was observed was considered day 0.5 of 
gestation (n = 4-13 mice/group) (B).  Females were checked morning and afternoon starting a 
week before the expected delivery date of the litter.  Statistical significance (p ≤ 0.05) is denoted 
with an asterisk (*).  Data are represented as means ± standard error.  Borderline statistical 




Figure 5.6 Effects of DEHP and DiNP on fertility indices at 12 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months following the completion of the dosing period, breeding trials were conducted by 
pairing females with untreated male mice.  The mating index (n = 9-21 mice/group) (A) is the 
number of females who presented with a copulatory plug divided by the total number of females 
in the group and multiplied by 100.  The fertility index (n = 8-20 mice/group) (B) is the number 
of females who became pregnant divided by the number of females who presented with a 
copulatory plug and multiplied by 100.  The gestational index (n = 6-16 mice/group) (C) is the 
number of females who gave birth divided by the number of females who became pregnant and 
multiplied by 100.  Females who gave birth (n = 8-21 mice/group) (D) is the number of females 
who gave birth divided by the total number of females in the group and multiplied by 100.  
Statistical significance (p ≤ 0.05) is denoted with an asterisk (*).  Data are represented as 





Figure 5.7 Effects of DEHP and DiNP on time to mating and overall fertility at 15 months 
post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
15 months post-dosing, females were paired with an untreated male mouse directly after 
completion of the estrous cyclicity monitoring period.  Females were checked every morning and 
afternoon for the presence of a copulatory plug.  If a copulatory plug was observed or if 14 days 
had elapsed, the female was put into a new clean cage.  If a female presented with a copulatory 
plug the day immediately after introduction of the male, the time to mating was considered 1 day 
(n = 8-15 mice/group) (A).   Females who gave birth (n = 7-17 mice/group) (B) was calculated as 
the number of females who gave birth divided by the total number of females in the group and 
multiplied by 100.  Statistical significance (p ≤ 0.05) is denoted with an asterisk (*).  Data are 
represented as means ± standard error (A) and percentages (B).  Borderline statistical 




Figure 5.8 Effects of DEHP and DiNP on litter outcomes at 12 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months following completion of dosing, females were paired with untreated male CD-1 mice 
for breeding trials.  If females delivered pups, litter size on PND 0 was determined (n = 3-8 
mice/group) (A), average weight of all live pups on PND 0 was measured (n = 3-9 mice/group) 
(B), and the percent of female pups was measured (n = 3-7 mice/group) (C).  However, some 
groups lacked proper sample size to analyze outcomes, including average live weight for 200 
mg/kg/day DiNP (n = 2 mice) and percent female pups for 200 mg/kg/day DEHP (n = 2 mice), 
100 µg/kg/day DiNP (n = 2 mice), and 200 mg/kg/day DiNP (n=1).  Statistical significance (p ≤ 
0.05) is denoted with an asterisk (*).  Data are represented as means ± standard error.  Borderline 





Figure 5.9 Effects of DEHP and DiNP on levels of sex steroid hormones at 12 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected for analysis of testosterone (n = 5-12 mice/group) (A), progesterone (n = 5-12 
mice/group) (B), and estradiol (n = 5-12 mice/group) (C) via enzyme-linked immunosorbent 
assay (ELISA).  Data are represented as means ± standard error.  Borderline statistical 






Figure 5.10 Effects of DEHP and DiNP on levels of follicle stimulating hormone and inhibin 
B at 12 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
12 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected.  Sera samples were shipped to the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core for analysis of follicle stimulating hormone 
(FSH) (n = 5-12 mice/group) (A) and inhibin B (n = 4-10 mice/group) (B) via radioimmunoassay 
(RIA).  Data are represented as means ± standard error.  Borderline statistical significance (0.05 










Figure 5.11 Effects of DEHP and DiNP on levels of sex steroid hormones at 15 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
15 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected for analysis of testosterone (n = 4-12 mice/group) (A), progesterone (n = 4-12 
mice/group) (B), and estradiol (n = 4-12 mice/group) (C) via enzyme-linked immunosorbent 
assay (ELISA).  Data are represented as means ± standard error.  Borderline statistical 






Figure 5.12 Effects of DEHP and DiNP on levels of follicle stimulating hormone and inhibin 
B at 15 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
15 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected.  Sera samples were shipped to the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core for analysis of follicle stimulating hormone 
(FSH) (n = 4-12 mice/group) (A) and inhibin B (n = 4-10 mice/group) (B) via radioimmunoassay 
(RIA).  Data are represented as means ± standard error.  Borderline statistical significance (0.05 










Figure 5.13 Effects of DEHP and DiNP on levels of sex steroid hormones at 18 months post-
dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
18 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected for analysis of testosterone (n = 7-16 mice/group) (A), progesterone (n = 7-16 
mice/group) (B), and estradiol (n = 7-16 mice/group) (C) via enzyme-linked immunosorbent 
assay (ELISA).  Statistical significance (p ≤ 0.05) is denoted with an asterisk (*). Data are 
represented as means ± standard error.  Borderline statistical significance (0.05 < p ≤ 0.10) is 





Figure 5.14 Effects of DEHP and DiNP on levels of follicle stimulating hormone and inhibin 
B at 18 months post-dosing 
Female CD-1 mice were orally dosed at age 39-40 days for 10 days with either vehicle control 
(corn oil), DEHP (20µg/kg/day – 200 mg/kg/day), or DiNP (20µg/kg/day – 200 mg/kg/day).  At 
18 months following completion of dosing, mice were euthanized in the diestrous stage and sera 
were collected.  Sera samples were shipped to the University of Virginia Center for Research in 
Reproduction Ligand Assay and Analysis Core for analysis of follicle stimulating hormone 
(FSH) (n = 7-16 mice/group) (A) and inhibin B (n = 7-16 mice/group) (B) via radioimmunoassay 
(RIA).  Statistical significance (p ≤ 0.05) is denoted with an asterisk (*).  Data are represented as 
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Summary, Conclusions, and Future Directions 
 
6.1 Summary, Conclusions, and Future Directions 
The goal of my doctoral dissertation work was to investigate the short-term and long-term 
reproductive consequences of 10 days of exposure to DEHP or DiNP during adulthood in 
females.  Phthalates are a class of chemicals commonly utilized as plasticizers and stabilizers in a 
wide variety of consumer goods [1, 2].  Due to this widespread use, humans are exposed to 
phthalates on a daily basis.  DEHP is a particularly prominent member of the phthalate group, 
with several million pounds being produced within the U.S. every year [3].  Of concern is that 
DEHP has been shown to have endocrine disrupting capabilities in females [4-7].  Further, 
DEHP is commonly substituted with other chemicals which often lack adequate studies to 
determine their safety in terms of female reproductive toxicity.  One common DEHP 
replacement is DiNP.  Very few studies have investigated the reproductive toxicity of DiNP, but 
the few studies that have been conducted show that DiNP may be capable of endocrine 
disruption [8-10].  Thus, the safety of DiNP and, subsequently, its adequacy as a viable 
replacement for DEHP are equivocal.  Compounding this concern is an overall lack of 
information on the effects of exposure to either DEHP or DiNP on female reproduction using an 
exposure window during adulthood.  Very few studies have investigated the effects of exposure 
during this time frame and how the exposure may affect the exposed female throughout her life.  
To fill this gap in knowledge, my doctoral dissertation work investigated the effects of short-




timepoints following completion of dosing.  The timepoints in my study ranged from 
immediately post-dosing to 18 months post-dosing.  Collectively, my studies show that short-
term exposure to DEHP and DiNP has long-term consequences on hormones, ovarian follicles, 
and various aspects of female fertility in mice. 
 
In Chapter 3, I tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood affects estrous cyclicity and fertility during the prime reproductive life of the CD-1 
mouse.  Specifically, I investigated timepoints immediately post-dosing and 3 and 9 months 
post-dosing.  I found that 20 µg/kg/day of DEHP or DiNP decreased the ability of females to 
become pregnant at 3 months post-dosing.  Further, I found that multiple doses of DiNP 
disrupted estrous cyclicity at 3 months post-dosing and 100 µg/kg/day DiNP disrupted cyclicity 
at 9 months post-dosing.  Results in Chapter 4 of my dissertation suggest that the reduction in 
fertility observed at the 3 months post-dosing breeding trial is not due to treatment-induced 
changes in follicle populations or circulating hormone levels.  Because the decrease in fertility 
observed at 3 months post-dosing is largely attributable to the decrease in the ability of females 
to become pregnant, it is possible that DEHP and DiNP disrupted the implantation process or 
loss of pregnancy at an early enough stage that we were unable to determine if the female had 
become pregnant at all.  Thus, future studies should investigate the effects of DEHP and DiNP 
on the uterus and implantation at 3 months post-dosing.   
 
In Chapter 3, I also tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood affects litter outcomes.  I observed that multiple doses of DEHP and DiNP caused 




exposure paradigm used in this study resulted in an alteration in the sex ratio of pups.  Further, 
disruptions in sex ratios persisted as shown in Chapter 5.  Results from Chapter 4 again suggest 
that this shift in sex ratio is not due to an alteration in hormone levels.  Interestingly, studies have 
shown that maternal age and health can have influence on the sex of the offspring [11-13].  Thus, 
future studies should investigate the mechanism through which preconception exposure to DEHP 
and DiNP affects the sex ratio. 
 
In Chapter 4, I tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood affect ovarian follicle populations and circulating hormone levels during the prime 
reproductive life of the CD-1 mouse.  Specifically, I investigated timepoints immediately post-
dosing and 3, 6, and 9 months post-dosing.  I found that multiple doses of DEHP and DiNP 
caused significant disruption to hormones and follicle populations at all tested timepoints.  
Interestingly, I found a somewhat inverse relationship with phthalate-induced effects on follicle 
populations and hormones.  Specifically, follicles were more disrupted at timepoints other than 
immediately post-dosing, but multiple doses of DEHP and DiNP disrupted almost every 
hormone assayed immediately post-dosing, with effects tapering off as timepoints progressed.  
Because the antral follicle is the primary source of sex steroid hormones in females, I expected 
follicle numbers, specifically those of antral follicles, to correlate with hormone levels, but this 
was not the case.  Thus, it is likely that DEHP and DiNP acted through disruption of production 
or metabolism of sex steroid hormones.  Therefore, future studies should investigate the function 
of the antral follicle by examining the expression levels of key sex steroid hormones within the 




regulate folliculogenesis to shed light on the mechanisms through which DEHP and DiNP affect 
follicle numbers. 
 
In Chapter 5, I tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood affects fertility and litter outcomes during the late- life of the CD-1 mouse.  
Specifically, I performed breeding trials at 12 and 15 months post-dosing.  I found that DEHP 
and DiNP decreased percent of female pups born at 12 months post-dosing.  The alteration in sex 
ratio of pups was surprising but not unprecedented, as this was a result that I observed in my 
research in Chapter 3, and again I found no correlation between sex steroid hormones and sex 
ratio.  Some studies have suggested that maternal age and body condition can affect sex ratio of 
offspring [11-13].  Thus, future studies should investigate how DEHP and DiNP may affect the 
bodily health of the dam or how DEHP and DiNP may affect aging in general.   
 
In Chapter 5, I also tested the hypothesis that short-term exposure to DEHP or DiNP during 
adulthood affects ovarian follicle populations and circulating hormone levels during the late- life 
of the CD-1 mouse.  Specifically, I investigated timepoints 12, 15, and 18 months post-dosing.  I 
found that both DEHP and DiNP disrupted follicle numbers and percentages and hormone levels 
at several timepoints.  Interestingly, the most drastic changes in hormones occurred at 18 months 
post-dosing where I observed 100 µg/kg/day of DiNP decreased estradiol and testosterone 
compared to control.  In contrast, multiple doses of DEHP and DiNP led to disruption of ovarian 
follicles at almost every timepoint.  This coincides with results in Chapter 4 wherein disruptions 
in follicle numbers and percentages did not always correlate with hormone levels.  Similarly to 




DiNP directly affecting the absolute number of antral follicles.  It is likely that DEHP and DiNP 
are dysregulating the production or metabolism of the sex steroid hormones.  For example, it is 
possible DEHP and DiNP may be altering the expression or activity of the steroidogenic 
enzymes present in the antral follicle.  Thus, future studies should investigate how DEHP and 
DiNP are affecting levels of circulating hormones, and further, future studies should investigate 
what possible mechanisms short-term exposures may act through to impart the observed long-
lasting effects 
 
In Chapter 5, I also tested the hypothesis that short-term exposure to DEHP and DiNP during 
adulthood affects fertility at 12 and 15 months post-dosing.  I observed that multiple doses of 
DEHP and DiNP increased pregnancy loss and that 20 µg/kg/day of DEHP and DiNP decreased 
overall fertility compared to control.  I did not observe any correlation changes between 
treatment groups that experienced pregnancy loss and changes in progesterone, a hormone 
critical for maintenance of pregnancy.  However, mice that contributed hormone data were non-
pregnant and collected during the diestrous stage of the estrous cycle.  Thus, it is possible that 
deficiencies in the production of progesterone may be to blame and such deficiencies may not be 
detectable in non-pregnant mice.  Future studies should investigate the function of the corpus 
luteum during pregnancy at 12 months post-dosing to determine if DEHP and DiNP may affect 
hormone production and, subsequently, support of pregnancy. 
 
In Chapter 5, I also tested the hypothesis that short-term exposure to DEHP and DiNP during 
adulthood accelerate reproductive aging.  I observed that 20 µg/kg/day of DEHP increased the 




estrous cyclicity and decrease in fertility described above are indicative of potential early 
reproductive aging, as females who enter reproductive senescence experience prolonged time in 
the estrous stage of the cycle in addition to becoming less fertile [14, 15].  In agreement, a 
previous study in our laboratory found that 10 days of exposure to DEHP during adulthood 
increased markers of reproductive aging [16].  With my studies and a past study showing 
increased markers of reproductive aging due to exposure to DEHP and DiNP, it is imperative 
that future studies investigate other markers of reproductive aging, such as increased 
inflammation and fibrosis to fully understand how DEHP and DiNP may be accelerating 
reproductive aging [17, 18]. 
 
Overall, my doctoral dissertation work shows that short-term exposure to DEHP and DiNP 
during adulthood disrupts a variety of aspects of female reproduction throughout the natural life 
of the exposed female.  Specifically, 10 days of exposure to DEHP or DiNP decreased fertility at 
multiple timepoints, altered estrous cyclicity at all timepoints, altered sex ratio of pups born at 
multiple timepoints, disrupted ovarian folliculogenesis at all timepoints, and disrupted circulating 
hormones at all timepoints.  My research provides important information on how short-term 
exposure during adulthood, a time frame often thought to not be critical or sensitive, affects 
fertility parameters of the exposed individual for the rest of their life.  Further, my studies add 
crucial information to the scant body of literature concerning the reproductive toxicity of DiNP.  
Moreover, my research utilizes environmentally relevant doses for both DEHP and DiNP, 
heightening the relevance and importance of my findings.  This work is important to public 
health because humans are exposed to phthalates on a daily basis, and proper reproductive 




generating more knowledge on the deleterious effects of phthalate exposure is critical for a more 
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Hormone Variability and Hot Flash Experience: Results from the Midlife Women’s Health 
Study2 
A.1 Abstract 
Objective: Hot flashes, common during midlife, are believed to be related to hormonal changes. 
However, hormonal fluctuations and the incidence of hot flashes has not been studied. The 
objective of this study is to determine hormone measurement summaries that best explain hot 
flash incidence in midlife women. 
 
Methods: Data were from a cohort study of 798 midlife women over 1 to 7 years. Women were 
asked to provide 4 weekly blood samples annually and complete a survey detailing life history, 
ongoing behaviors, and menopausal symptoms. Estradiol, progesterone, and testosterone levels 
were measured from serum samples at each visit. Annual summary variables of each hormone 
consisted of median, mean, maximum, minimum, variance, and range. Association of these 
values with hot flash outcomes (incidence, severity, and frequency) was assessed using 
multivariable logistic regression and Bayesian Network analysis, controlling for smoking history 
and menopausal status. 
 
Results: For most outcomes, the best-fit logistic regression model included progesterone 
variability; an increase in progesterone variance or range was correlated with a decrease in the 
 
 
2. Reprinted with permission from Chiang C., Flaws J. A., Subchronic Exposure to Di(2-ethylhexyl) Phthalate and 
Diisononyl Phthalate During Adulthood Has Immediate and Long-Term Reproductive Consequences in Female 





 frequency and severity of hot flashes. In the Bayesian Network model, the maximum estradiol 
value was negatively correlated with many outcomes. The relationships between progesterone 
variability, maximum estradiol, maximum progesterone, and hot flashes outcomes indicate that 
the effects of progesterone variance on hot flashes outcomes are likely mediated through 
progesterone’s relationship with maximum estradiol. 
 
Conclusions: These results indicate that variability of progesterone, as opposed to mean values, 
should also be used as an indicator for risk of hot flashes in midlife women. 
 
A.2 Introduction 
A future direction of my doctoral dissertation work is to investigate the associations between 
phthalates and hormones in mid-life women.  However, it is important to first characterize 
associations between hormone fluctuations and trends and quality of life outcomes.  
Investigating how hormones levels can affect quality of life will allow for analysis on how 
phthalates, through impacting hormone levels, can affect quality of life. 
 
One significant factor in the quality of life of perimenopausal women is the experience of 
vasomotor symptoms (hot flashes) [1]. Up to 87% of perimenopausal women experience hot 
flashes, and these symptoms are associated with significant costs due to treatment (prescription, 
over-the-counter, alternative, and dietary), physician visits, laboratory testing, and loss of 
productivity; hormone therapy alone has been estimated to cost between $357 and $474 per 





The reasons that perimenopausal women experience hot flashes (HF) are unclear; no single 
factor has been consistently identified as playing a major role [3]. Many studies have shown the 
relationship between HFs and the mean levels of hormones, particularly estrogen withdrawal [1]. 
However, it is generally believed that decreases in estrogen levels are the primary reason for HFs 
[4] as the menopausal transition is a time of fluctuations in hormones and estrogen 
supplementation has been the most effective treatment [5]. No previous studies have considered 
the effect of hormonal fluctuations on HFs.  
 
The objective of this study is to determine the hormone measures that best describe the HF 
experience in a cohort study of midlife women. These include estradiol, progesterone, and 
testosterone, measured as the mean, median, maximum, minimum, and variance. 
 
A.3 Materials and Methods 
All participants gave written informed consent according to procedures approved by the 
University of Illinois and Johns Hopkins University Institutional Review Boards, which 
approved this research.  The study design for the parent study is described in detail elsewhere 
[6]. Briefly, a cohort study of HFs among women 45-54 years of age was conducted starting in 
2006 among residents of Baltimore and its surrounding counties.  Women were recruited by mail 
and were included if they were in the target age range, had intact ovaries and uteri, and were pre- 
or perimenopausal.  Exclusion criteria consisted of pregnancy, a history of cancer, exogenous 
female hormone or herbal/plant substance, and no menstrual periods within the past year.  
Participants made a baseline clinic visit, which included serum collection and completion of a 




providing serum samples at each visit. After the baseline year, participants returned annually to 
complete a questionnaire, repeating all previous questions about hot flashes and smoking, and 
providing the 4 weekly serum samples as before. Blood samples were stored until measurement 
of hormone levels as described below.  
 
The questionnaire asked if women had experienced HFs in the last year, in the last 30 days, and 
the severity and frequency of the majority of their HFs at the time of the visit. With regards to 
severity, descriptions were: mild (sensation of heat without sweating), moderate (sensation of 
heat with sweating), or severe (sensation of heat with sweating that disrupts usual activity). For 
this analysis, severity was also dichotomized into “moderate or severe” versus “none or mild”. 
With regards to frequency, descriptions were: every hour, every 2-5 hours, every 6-11 hours, 
every 12-23 hours, 1-2 days per week, 3-4 days per week, 5-6 days per week, 2-3 days per 
month, 1 day per month, less than 1 day per month, or never. For this analysis, frequency was 
categorized into “daily”, “weekly”, “monthly”, and “never” and dichotomized into “daily or 
weekly” versus “monthly or less”. Although self-report of HFs was not validated in this study 
against an objective measurement, self-report of HFs has been accepted as a valid measure by 
both the National Institute on Aging and the FDA [7, 8]. The questionnaire also asked women to 
report if they currently smoked, formerly smoked, or never smoked, as well as their age. 
Menopause status was defined as follows: premenopausal women were those who experienced 
their last menstrual period within the past 3 months and reported 11 or more periods within the 
past year; perimenopausal women were those who experienced 1) their last menstrual period 




past 3 months and experienced 10 or fewer periods within the past year; postmenopausal women 
were those women who had not experienced a menstrual period within the past year. 
 
Hormone Variability 
Serum samples extracted from the collected blood samples were used to measure estradiol, 
testosterone, and progesterone levels in each sample using commercially available, previously 
validated enzyme-linked immunosorbent assay (ELISA) kits (DRG, Springfield, New Jersey, 
USA) [9-12]. The minimum detection limits and intra-assay coefficients of variation were as 
follows: estradiol 9.714 pg/ml; testosterone 0.083 ng/ml; and progesterone 0.045 ng/ml.  The 
average inter-assay coefficient of variation for all assays was less than 5%. In the case of values 
lower than the detection limits for the assay, we used the limit of detection as the hormone value; 
of samples used for this analysis, 11/560 progesterone values were below the limit of detection, 
whereas no estradiol or testosterone levels were below the limit of detection. Each sample was 
measured in duplicate within the same assay.  All estradiol values greater than 500 pg/ml (n=22), 
progesterone values greater than 40 ng/ml (n=1), and testosterone values greater than 10 ng/ml 
(n=7) were assumed to be laboratory error and removed from the data set.   
 
Across each woman in each year, the following summary variables were calculated for each 
hormone: mean, median, maximum, minimum, range, and variance. All values were log10 








The relationship between each summary value (mean, median, maximum, minimum, range, and 
variance) of each hormone (estradiol, progesterone, and testosterone) and each hot flash 
measurement was assessed using logistic regression (any in the last year, moderate/severe, 
weekly/daily, and in the last 30 days) or ordinal logistic regression (severity and frequency), with 
random effects to account for the year of the study and the individual. 
 
Multivariable Analysis 
The best fit multivariable model for each outcome was fit using receiver-operator characteristic 
(ROC)-based forward model selection, controlling for menopausal status and with and without 
the potential confounder of smoking history included in the model. Briefly, the model was fit 
with each of the potential variables added separately, and the area under the curve (AUC) of the 
ROC for each model was calculated. The model with the highest AUC was selected for that 
round, and the process was repeated additively until no additions produced a higher AUC. 
 
Bayesian Network Analysis 
Using data from the baseline visit, a Bayesian Network was fit for the variable nodes of hot 
flashes in the last year; hot flashes in the last 30 days; moderate/severe hot flashes; weekly/daily 
hot flashes; mean, maximum, minimum, and variance of all hormones; age; and smoking status. 
Smoking status was divided into two variables: ever vs. never smoked, and current smokers vs. 
not currently smoking. Menopausal status was divided into premenopausal vs. perimenopausal; 
there were no postmenopausal women at baseline. Hormone summary levels were not allowed to 




summary values. The number of parents for any variable was limited to 3. HFs in the last 30 days 
was forced to be a child to hot flashes in the last year. Best-fit models were plotted to include all 
parental nodes to the outcomes. Vectors were plotted with the coefficient of the statistical 
relationship between the parent and child node. For categorical variables, these relationships are 
based on a logistic regression model. For continuous variables, these relationships are based on a 
linear regression model. 
 
Model Fitting 
Logistic regression models were fit using the lme4 package13 in R 3.4.2 [14]. Ordinal logistic 
regression models were fit using the multgee package [15] in R 3.4.2 [14]. The AUC of the ROC 
curve for the model predictions was calculated using the pROC package [16] for logistic 
regression models and the HandTill2001 package [17] for ordinal logistic regression models. 




The number of samples available to analyze for each of the hormones measured (estradiol, 
progesterone, and testosterone) are shown in Table 1. The distribution of the summary variables 
relative to HF experience is shown in Figure 1. Individuals providing only one sample in a year 








All summary variables for estrogen and progesterone were significantly associated with all 
outcomes (p<0.001 for all comparisons), with increases in any summary variable associated with 
decreases in the probability of any output (data not shown). The range of testosterone values was 
only significantly associated with the two outcomes measuring severity (p=0.029 for the ordinal 
outcome and p=0.005 for the dichotomous outcome, data not shown). All other summary 
variables for testosterone were significantly associated with all outcomes (p<0.05), with 
increases in any summary variable associated with decreases in the probability of any output 
(data not shown). 
 
Multivariable Analysis 
The results of the multivariable logistic analysis are shown in Tables 2-5.  Smoking status was 
correlated with several HF outcomes.  Specifically, never smoking and former smoking was 
correlated with a decrease in HF frequency, HF severity, experiencing HFs in the last year, and 
experiencing HFs in the last 30 days when compared to current smokers (Tables 2-5).  
Menopausal status was correlated with all measured HF outcomes.  Pre-menopausal status was 
negatively correlated with all HF outcomes, whereas post-menopausal status was positively 
correlated with all HF outcomes when compared to peri-menopausal status (Tables 2-5).  








Bayesian Network Analysis 
The result of the Bayesian Network analysis are shown in Figure 2.  Variables that were not 
correlated with HF outcomes are not shown.  Smoking was associated with probability of any 
HFs.  Higher probability of any HFs was associated with lower maximum estradiol as well as 
menopausal status.  The relationship between maximum progesterone and frequency of HFs was 
mediated through maximum estradiol levels, which were negatively associated with experiencing 
any HFs.  Menopausal status was associated with hormonal outcomes as well as HF outcomes.  
The relationship menopausal status shares with HF outcomes was partially mediated by the 
negative association between maximum estradiol and probability of any HFs, while the 
relationship between menopausal status and the frequency of hot flashes was partially mediated 
by the negative association between maximum progesterone and the frequency of HFs. 
 
A.5 Discussion 
Our results found that progesterone variance was the most important hormonal measurement in 
terms of HF experience.  Specifically, when controlling for menopausal status and smoking 
history, an increase in progesterone variance was associated with a decrease in frequency and 
severity of HFs.  Using a multivariate machine learning approach, most HF outcomes were 
ultimately explained by the variance of progesterone, history of smoking, and menopausal status. 
 
Previous analyses of these data [19-22] and similar studies [3, 9] have found associations 
between mean hormone levels and HF experience, but this study shows that the predictive ability 
of the models was maximized by using summary values more related to variability. It is known 




transition [23], but to our knowledge, this is the first analysis to show that the variability of 
progesterone is highly associated with HF symptoms. Progesterone has long been suspected to 
play a role in vasomotor symptoms, as progesterone receptors have been found in the 
hypothalamus and progesterone can alter gene expression within serotonin neurons [24]. 
Progesterone therapy is known to reduce vasomotor symptoms, and may improve the efficacy of 
low-dose estrogen therapy [5].  It is possible that the associations we found between 
progesterone variability and decreased HF symptoms may be explained by the variance of 
progesterone throughout the menstrual cycle, indicating that these women with increased 
progesterone variability and, subsequently, decreased HF symptoms, may still be experiencing 
full menstrual cycles.  The menstrual cycle is commonly divided into the follicular phase and the 
luteal phase [25].  In the follicular phase, follicles within the ovary begin to mature and a 
dominant follicle arises and stimulates the preovulatory luteinizing hormone (LH) surge, leading 
to ovulation and release of the oocyte from the follicle.  Following ovulation, the corpus luteum 
(CL) is formed and the luteal phase begins.  During this time, the CL produces large of amounts 
of progesterone as well as estradiol.  Progesterone and estradiol production both decline with the 
degeneration of the CL and the beginning of the new follicular phase, whereas estradiol will 
slowly begin to rise again with the growth of the dominant follicle.  Because estradiol is present 
in both the follicular and the luteal phase in addition to the preovulatory estradiol spike being 
relatively brief, it is perhaps not surprising that maximum estradiol, as opposed to variance of 
estradiol, was associated with reduced HF symptoms in women who donated samples once a 
week for four weeks.  In contrast, progesterone is produced in very low quantities in the 
follicular phase and very high quantities in the luteal phase, possibly leading to samples  over the 




experiencing more severe HF symptoms) having more variable readings of progesterone.  Thus, 
it is possible that variance of progesterone in addition to measurements of maximum estradiol 
and maximum progesterone can be used as an indicator of cycling status in midlife women and, 
therefore, a predictor of their risk of experiencing HFs. 
 
Many possible summary variables were associated with many possible HF-related outcomes in 
this study, which raised a potential for false association due to multiple testing. However, some 
models found an association with the variance of progesterone, which indicates that this measure 
is associated with the experience of HFs. In addition, the Bayesian Network approach, which is 
designed to allow the discovery of complex relationships with many factors, found that the 
connection between hormone values and HF experience was limited to a few summary variables: 
progesterone variance, maximum progesterone, and maximum estradiol. 
 
Many of the hormone variables were highly correlated, which could lead to multicollinearity in 
model fitting. However, the forward-stepping model selection procedure allowed for addition of 
the variables most improving the predictive ability of the model; highly correlated variables 
would not be likely to improve the model prediction. 
 
The findings of this study indicate that one hormone measurement, or summarizing multiple 
hormone measurements by averaging them, is not the best way to predict HF experience. Given 
that there is evidence that hormone fluctuations are also important predictors of depressive 
symptoms during menopause [26], measurement of hormones in studies of perimenopausal 




A.6 Tables, Figures, and Legends 
Table A.1a Number of woman-year combinations providing multiple samples analyzed for 
hormone levels  
 Number of samples provided 
 1 2 3 4 
Estrogen 38 242 336 1579 
Progesterone 37 241 324 1592 























Table A.1b Description of women in data analyzed 
Variable Level 
No Hot Flashes  Hot Flashes  
number % number % 
Frequency none 1011 0.49 0 0 
monthly 0 0 387 0.19 
weekly 0 0 294 0.14 
daily 0 0 317 0.15 
Severity  none 1011 0.49 0 0 
mild 0 0 387 0.19 
moderate 0 0 587 0.28 
severe 0 0 82 0.04 
Hot Flashes in the last 30 days no 1011 0.49 152 0.07 
yes 0 0 894 0.43 
Smoking status Current  67 0.03 136 0.07 
Former  338 0.16 425 0.2 
Never  606 0.29 507 0.24 
Menopause status peri 257 0.12 559 0.27 
post 50 0.02 225 0.11 
pre 704 0.34 284 0.14 
  mean s.d. mean s.d. 
Estrogen  median 1.71 0.3 1.52 0.33 
mean 1.76 0.29 1.55 0.33 
max 1.94 0.34 1.69 0.39 
min 1.47 0.32 1.33 0.31 
variance 2.65 1.2 1.8 1.63 
range 1.53 0.96 1.04 1.26 
Progesterone  median -0.13 0.62 -0.58 0.6 
mean 0.09 0.63 -0.45 0.67 
max 0.41 0.74 -0.24 0.8 
min -0.77 0.45 -0.94 0.4 
variance 0.08 1.59 -1.31 1.71 
range 0.21 1.04 -0.6 1.15 
Testosterone  median -0.49 0.3 -0.52 0.28 
mean -0.48 0.3 -0.51 0.28 
max -0.39 0.29 -0.43 0.27 
min -0.59 0.33 -0.62 0.3 
variance -2.29 0.54 -2.34 0.51 






Table A.2 Multivariable results for hot flashes in the last year. Area under the ROC curve 
= 0.802  
OR Estimate Std. 
Error 
z value Pr(>|z|) 
Former smoker 0.68 (0.47, 0.98) -0.39 0.19 -2.09 3.66E-02 
Never smoker 0.44 (0.31, 0.62) -0.83 0.18 -4.58 4.76E-06 
Post-menopause 2.12 (1.49, 3.03) 0.75 0.18 4.15 3.29E-05 
Pre-menopause 0.18 (0.14, 0.22) -1.71 0.11 -15.30 7.09E-53 
 
Table A.3 Multivariable results for hot flashes in the last 30 days. Area under the ROC 
curve = 0.797  
OR Estimate 
Std. 
Error z value Pr(>|z|) 
Former smoker 0.57 (0.4, 0.82) -0.56 0.18 -3.06 0.0022 
Never smoker 0.39 (0.27, 0.55) -0.94 0.18 -5.29 1.25E-07 
Post-menopause 2.61 (1.86, 3.66) 0.96 0.17 5.58 2.42E-08 
Pre-menopause 0.21 (0.16, 0.26) -1.58 0.11 -14.14 2.21E-45 
 
Table A.4 Multivariable results for hot flash severity. Area under the ROC curve = 0.505  
OR Estimate Std. 
Error 
z value Pr(>|z|) 
Former smoker 0.6 (0.448 - 0.814) 0.504 0.152 3.316 0.001 
Never smoker 0.37 (0.275 - 0.489) 1.002 0.146 6.85 <0.001 
Post-menopause 1.28 (1.001 - 1.645) -0.249 0.127 -1.965 0.049 
Pre-menopause 0.31 (0.244 - 0.386) 1.18 0.116 10.132 <0.001 
Variance of Progesterone 0.82 (0.772 - 0.877) 0.195 0.032 6.005 <0.001 
 
Table A.5 Multivariable results for hot flash frequency. Area under the ROC curve = 0.508  
OR Estimate Std. 
Error 
z value Pr(>|z|) 
Former smoker 0.57 (0.42, 0.77) 0.57 0.16 3.58 <0.001 
Never smoker 0.44 (0.32, 0.59) 0.83 0.16 5.27 <0.001 
Post-menopause 1.48 (1.13, 1.95) -0.39 0.14 -2.8 0.01 
Pre-menopause 0.26 (0.21, 0.33) 1.35 0.12 11.7 <0.001 
Variance of Progesterone 0.82 (0.74, 0.91) 0.2 0.05 3.89 <0.001 
Minimum Progesterone 0.81 (0.58, 1.12) 0.21 0.17 1.29 0.2 






Figure A.1 Sex steroid hormone distributions between women who do and do not 



















Distribution of parameter values among women experiencing (blue, right) or not (purple, left) 
hot flashes in the last year.  Values are shown as log-transformed.  Bars indicate the median 




Figure A.2 Bayesian Network for hot flash experience.   
 
Black/solid lines are outcomes, red/dotted lines are progesterone, blue/dashed lines are estradiol, 
and purple/dash-dot lines are the potential confounders smoking history and menopausal status.  
Lines leading into progesterone and estradiol boxes are coefficients from linear regression 
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